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“It’s not that I’m so smart, it’s just that I stay with problems longer.”
Albert Einstein
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Electroconvulsive therapy (ECT) is an effective treatment in patients with acute and chronic 
psychiatric disorders resistant to psychotropic medications or need urgent control of their 
symptoms. Worldwide, it has been estimated that about one million patients receive ECT 
annually.1,2 The aim of ECT is to induce a therapeutic tonic seizure with the minimum required 
energy, tailored to the condition of each patient. ECT has evolved into a widely recognized 
treatment modality in the practice of psychiatry. 
While the efficacy ECT is mainly inherent to the biological alterations in brain through the 
induced therapeutic seizure, ECT procedural safety is pivotal to the outcome of treatment 
such that optimizing the procedural safety will improve the efficacy of the therapy outcome. An 
effective ECT procedure requires a good knowledge of anesthetic principles, understanding 
of the interaction between anesthetic drugs and seizure activity, the effect of anesthetic 
drugs on the ECT response and the clinical pharmacologic effects of the drugs used to 
attenuate the side effects related to ECT, and an awareness of the physiologic responses 
to the electrical stimulus. Additionally, it has been shown that some anesthetic drugs could 
augment the response to treatment or affect the quality of seizure that might be associated 
with short or long term efficacy of ECT.
Pharmacogenetics is the science to investigate an individual’s sensitivity and response 
to a variety of drugs or the outcome after therapeutic intervention via studying genetic 
variations and gene-gene interactions.3 Clinical insights into pharmacogenetics of ECT and 
understanding the biological mechanism of ECT not only improves its safety and efficacy in 
the patients, but also helps to develop alternative and more effective therapeutic agents in 
psychiatric disorders. This required knowledge also includes the adjunctive medications that 
might augment the response to treatment and can help to improve the efficacy of treatment in 
patients who do not respond to antidepressants or other psychotropic medication. 
Therefore, the aim of this dissertation is to investigate the “safety and efficacy” of ECT, the 
two integrated aspects of this therapy procedure and how conducting investigations on 
these two indispensable precepts might lead to improving the quality of ECT outcome for 
treatment of indicated disease. To achieve this objective, we firstly explore the literature on 
the history of ECT application as a therapeutic procedure for psychiatric disorders and how 
the anesthetics, particularly invention of neuromuscular blocking agents (NMBAs) for ECT, 
improved the safety of this procedure (chapter two). Anesthesia for ECT includes the use of 
an induction agent and short acting muscle relaxant such as succinylcholine to minimize the 
amount of muscle contraction that occurs with the seizure. Accordingly, in chapter two, we 
also provide a comprehensive review on the neuromuscular blocking agent usage in ECT, 
their applied doses and potential side effects. Furthermore, we attempt to find supportive 




mainly been used for ECT due to its rapid onset time and short duration of action. 4
In chapter three, a crossover randomized trial is designed to compare the commonly used 
muscle relaxant i.e. succinylcholine with rocuronium during the ECT and define the optimal 
doses that could predict the acceptable seizure induced muscle activity.  The optimal doses 
for rocuronium and succinylcholine are defined and recovery time indices are explored. This 
research is distinguished as the first study, which identifies the optimal (minimal effective) 
doses of mostly used neuromuscular blockers in ECT using objective assessment by 
neuromuscular monitoring. The main objective of this investigation is providing a clinical 
guidance for clinicians in applying the minimal dose of succinylcholine or rcocuronium that 
could result in an optimized seizure activity during ECT. 
Increasing our knowledge on pharmacology of succinylcholine and other nondepolarizing 
NMBAs in different conditions, i.e. simultaneous measurement of their plasma concentrations or 
a surrogate measure (pharmacokinetics) and neuromuscular blockade (pharmacodynamics) 
during ECT could help in increasing the safety of NMBA application or even the search for 
a new alternative NMBA.  Pharmacokinetic–pharmacodynamic models help in measuring 
the drug effect and the relation between blood concentration and the target organ under the 
effect of drug. In chapter four and as a follow-up study on the chapter three, we conduct a 
PK-PD study to provide a quantitative model to describe the kinetics and the dynamics of 
succinylcholine chloride and rocuronium after the different bolus doses applied for inducing 
muscle relaxation in patients underwent ECT.  
As earlier mentioned, inherent genetic differences and neurobiological alterations could be 
of high importance in response to ECT.  In chapter five, we explore the past and current 
knowledge of pharmacogenetics in electroconvulsive therapy and adjunctive medications 
whose applications might augment the response to ECT and present the evidence of 
pharmacogenetics role in patients with psychiatric disorders undergone ECT. The safety of 
the procedure has two aspects: (i) safety of medications used during ECT (ii) side effects 
of ECT procedures e.g. cognitive disorders. In addition to reviewing these two aspects 
from pharmacogenetics perspective, we will also explore the functional genomics, gene 
polymorphisms and biological brain transmitters might play role in the effectiveness of ECT.
In spite of the availability of multiple pharmacologic classes of antidepressants (ADs) 
and their sequenced trials using available guidelines for depression treatment, majority of 
patients with unipolar or bipolar depressive disorders fail to achieve complete remission. 5 
The enzyme cytochrome P450 2D6 (CYP2D6) plays an important role in the pharmacokinetics 
of many ADs (i.e. SSRIs and TCAs). Consequently, The CYP2D6 gene could be a prominent 
contributor to interindividual drug response variability and predicted phenotype of enzymes 
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i.e. poor metabolizer (PM), intermediate metabolizer (IM), extensive metabolizer (EM) and 
ultrarapid metabolizer (UM).6 In chapter six, we investigate the accumulation of aberrant 
CYP2D6 genotypes and predicted metabolizer phenotypes (UM, IM, and PM) potentially 
affecting the antidepressant treatment response in depressive patients indicated for ECT 
compared to patients with single episode of depression.  
Anesthesiological care during ECT differs from the usual anesthesiological management for 
surgical patients 7,8 and a short acting hypnotic is used along with muscle relaxant. The ideal 
hypnotic agent for ECT has a short half-life, does not influence seizure duration and quality, 
and guarantees the patient’s hemodynamic stability. Propofol has the shortest half-life of all 
the available hypnotic agents that makes it as the first choice hypnotic agent for induction of 
anesthesia for ECT. 9 Compared with methohexital, another hypnotic agent for ECT, propofol 
is associated with improved hemodynamic stability and an earlier return of cognitive function 
after ECT, though it might decrease the duration of seizure. 10 Although few side effects have 
reported after infusion of this hypnotic, it has increasingly been administered for general 
anesthesia and short procedures such as ECT in recent years. Therefore, clinicians should 
be attentive to any probable new side effect of propofol. The potential adverse effect of any 
drug could be due to either chemical structure of the drug (medication side effect) or an 
interaction with another drug (interaction side effect).  In chapter seven, we investigate a 
new potential interaction side effect of propofol based on a series of reported occurrences 
of severe hypotension after induction with propofol in patients who had received rifampin 
for prophylaxis of infection for spinal surgery. We would like to focus on this not previously 
reported severe hypotension after induction with propofol in comparison to induction with 
other anesthetics and explore the literature for evidences that could support this observation.
In recent years, there has been substantial increase in the number of noninvasive and 
short procedural interventions that shorten patients’ duration of stay at health care facilities. 
Consequently, healthcare practitioners are faced with a larger number of patients requiring 
procedural sedation. Effective sedation and analgesia during procedures not only provides 
relief of suffering, but also frequently facilitates the successful and timely completion of the 
procedure. However, any of the agents used for sedation and/or analgesia may result in 
adverse effects. 11 It has been reported that postoperative hemodynamic severe adverse 
events (PHASE), i.e. severe bradycardia and hypotension, can occur during recovery from 
spinal anesthesia. Incidence, contributing factors, and consequences of PHASE are unclear. 
In chapter eight, we aim to evaluate the incidence of PHASE, contributing factors and the 
impact on post anesthesia care unit (PACU) length of stay. Finally, in chapter nine, we will 
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ABSTRACT 
Electroconvulsive therapy (ECT) is the transcutaneous application of small electrical stimuli to 
the brain to induce generalized seizures for the treatment of selected psychiatric disorders. 
The clinical indications for ECT as an effective therapeutic modality have been considerably 
expanded since its introduction. Anaesthesia and neuromuscular blocking agents (NMBAs) 
are required to ensure patients’ safety during ECT. The optimal dose of muscle relaxant 
for ECT reduces muscle contractions without inducing complete paralysis. Slight residual 
motor convulsive activity is helpful in ascertaining that a seizure has occurred, while total 
paralysis prolongs the procedure unnecessarily. Suxamethonium is commonly used but 
nondepolarizing NMBAs are indicated in patients with certain comorbidities. In this review 
we summarize current concepts of NMBA management for ECT. 




Electroconvulsive therapy (ECT) is a well-established psychiatric treatment; in which 
generalized seizures are induced by transcutaneous electrical stimuli to the brain. The aim 
of ECT is to induce seizure with the minimum required energy, tailored to the condition of 
each patient, to treat specific psychiatric disorders such as major depressive or cyclothymic 
disorders. ECT has evolved into a widely recognized, albeit controversial treatment modality 
in the practice of psychiatry. ECT is currently applied to between 5-10/100,000 persons/
year in Asia and 20-100/100,000 persons/year in the Western Countries.  In the United 
States approximately 4% of annual psychiatric admissions are solely for the purpose of 
ECT, 1 resulting in about 100,000 treatments per year. 2,3 In both the United Kingdom and 
Scandinavia, ECT appears to be declining in popularity, 4 and in other European countries 
its use remains highly variable. 5 As an example, ECT use is falling in Italy, but increasing in 
the Netherlands. 5 The reason for these differences in the application of ECT is not clear, but 
financial considerations may be a contributing factor. 6
ECT owes its current acceptance to modern anaesthesia. Prior to the introduction of general 
anaesthesia, violent tonic-clonic convulsions associated with ECT could result in injuries 
such as limb fractures and compression fractures of vertebral bodies. The introduction of 
anaesthesia and neuromuscular transmission blockade to mitigate the tonic-clonic motor 
activity provided an effective means to reduce the physical and physiological trauma 
associated with uncontrolled tetanic muscle contractions. 
Historical Perspective 
Convulsive therapy for treatment of psychiatric disorders predates the use of electricity and 
the field of modern anaesthesiology. In the 1500s, the Swiss physician Paracelsus induced 
seizures by administering camphor by mouth to treat psychiatric illness. 7  The first report 
of the use of seizure induction to treat mania, using camphor was published in 1785. 7  
Meduna advanced it based on the fact that patients with schizophrenia often improved when 
spontaneous epileptic seizures developed. 8 He induced convulsions in a patient in 1934 by 
injecting a solution of oleum camphoratum, which although successful, was subsequently 
replaced by metrazol. The result of metrazol therapy in schizophrenic patients was reported 
in 1935. In 1939, Bennett reported several cases of spontaneous fractures, which occurred 
during convulsions induced by metrazol. 8  He used Curare to modify metrazol-induced 
convulsive therapy. 9 The introduction of electric shock therapy by Bini and Cerletti (Italy) in 
1939 10 provided added impetus for the use of neuromuscular blockade. Bennett’s technique 
of using curare to block neuromuscular transmission greatly reduced the incidence of 
fractures and dislocations due to contraction of skeletal muscles. 11,12 Electrical induction of 
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seizures soon replaced metrazol therapy because it was safer and had fewer adverse side 
effects. 13 The introduction of suxamethonium as a synthetic alternative to curare in 1951 led 
to the more widespread use of “modified” contemporary ECT. 11 
Contemporary use of ECT
ECT has become an increasingly important treatment for therapy-resistant major depression, 
which has a prevalence ranging between 3% in Japan to 17% in the US. In general, 
approximately 70 percent of all patients with major depressive disorder achieve remission 
with pharmacotherapy. 14  Patients who fail one or more adequate medication trials have a 
diminished but substantial rate of response to ECT. 15,16 ECT is highly effective in the elderly, 
perhaps even more so than the younger age groups.17,18 ECT may also be used to treat 
bipolar disorder, mania and catatonia, neuroleptic malignant syndrome, Parkinson’s disease, 
refractory epilepsy, Tourette syndrome and refractory obsessive compulsive disorder. 19,20
The therapeutic tonic seizure that is induced by ECT usually lasts 10-15 seconds, and is 
followed by a clonic phase lasting 30-50 seconds, with a target seizure activity of more than 
20 seconds. 21 Electroconvulsive therapy is commonly administered 2 or 3 times per week 
during the immediate course of treatment, until either improvement is seen or the treatment is 
deemed unsuccessful. 19  The total number of treatments administered during the short-term 
course of ECT varies, and is based on the presence or severity of cognitive side effects, as 
well as the efficacy of the treatment and evidence for clinical improvement. 
Electroconvulsive Therapy and Neuromuscular Blocking Agents (NMBAs)
Bone fractures and dislocations have been reported when ECT treatments are performed 
without appropriate muscle paralysis. 22-24  Consequently, neuromuscular blockers are 
required to minimize the convulsive motor activity, in order to prevent fractures and physical 
injury during the seizure, 25-27 which is especially important in patients with osteoporosis or a 
history of spinal injury. 25,26 The aims of neuromuscular blocking for ECT could be summarized 
as:  (1) Reduction of motor activity (with accurately assessed paralysis) to avoid injury, (2) 
Minimal interference with seizure activity, and (3) Prompt recovery of spontaneous ventilation 
without residual paralysis.
It is important to await the induction of general anaesthesia before neuromuscular blocking 
agents are administered. Although a relatively “light level” of anaesthesia is preferred (the 
procedure is not painful) to avoid prolonged emergence, the anaesthetic regimen should 
provide loss of response to vigorous stimulation while controlling the cardiovascular 
responses and autonomic arousal. 7,19 Cardiovascular responses consist of a brief initial 
increase in parasympathetic activity, followed by sympathetic response.  In certain patients 
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the sequence described may result in bradycardia (or even sinus pause) followed by 
tachycardia, dysrhythmia, and hypertension. 28 If not properly controlled, the haemodynamic 
response to ECT can induce myocardial ischemia and even infarction, as well as transient 
neurologic ischemic deficits, intracerebral hemorrhages, and cortical blindness. However, 
adequate monitoring and therapy of hypertension and tachycardia with short-acting drugs 
enables ECT to be used even in patients with a variety of severe cardiovascular impairments. 
29
Based on its rapid onset, short duration of action, and rapid recovery,30,31 suxamethonium 
is considered the NMBA of choice for ECT. Small doses of nondepolarizing NMBAs such 
as mivacurium and rocuronium are alternatives that may be used 19,28, but the prolonged 
effects of nondepolarizing NMBAs need to be adequately reversed before emergence from 
anaesthesia. Moreover, the sensitivity to the effects of these NMBAs is highly variable, even in 
patients with no known risk factors or complicating neuromuscular disorders. As an example, 
the coefficient of variation for the 50% effective dose (ED50) of rocuronium is > 25%. 32 Thus, 
even in a relatively small cohort of patients the ED50 may vary from 0.09 mg.kg-1 to as high 
as 0.25 mg.kg-1 (even higher in the absence of inhalational anaesthetics). Therefore, it is 
prudent to monitor the effects of nondepolarizing NMBAs during ECT. 
Although 50% twitch depression is suggested to provide optimal conditions for endotracheal 
intubation, 33,34 this level of blockade may be insufficient to mitigate the excessive muscle 
contractions during ECT. A twitch depression of 11-25% was reported appropriate in one 
study 35, but the optimal level of neuromuscular blockade for ECT remains largely unknown. 
Future studies are warranted to systematically examine ECT quality and outcome with 
different levels of neuromuscular blockade, and to test if a twitch depression of 50% is also 
adequate for ECT. 
Suxamethonium (Succinylcholine) 
The mean dose of suxamethonium producing 95% blockade (ED95) at the adductor pollicis 
muscle is 0.3 to 0.35 mg.kg-1.  The onset of skeletal muscle paralysis is achieved 30 to 60 
seconds after administration of suxamethonium, and usually lasts between 5 to 10 min (5 min 
at the dose of 0.5 mg.kg-1 and 10 min at the dose of 1 mg.kg-1, assessed as 90% recovery 
from neuromuscular blockade). 36 Although a single best dose of suxamethonium has not 
been identified for ECT, 0.5 mg.kg-1 to 1 mg.kg-1 is often used based on previous experience 
of anaesthesia providers and defined interindividual variability of its effects. 1,27,36-45 Reducing 
the dose of suxamethonium from 1.0 to 0.60 mg.kg-1 shortens the duration of neuromuscular 
effect at the adductor pollicis with 1.5-2 min. The extent to which this dose reduction affects 
the duration of neuromuscular blockade at the diaphragm, laryngeal adductors, or the upper 
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airway muscles in the ECT setting has not been studied. When complete neuromuscular 
block is important, however, doses of 1.0 to 1.5 mg.kg-1 are generally appropriate.46 During 
the first ECT session, it has been recommended that a higher dose (1 mg.kg-1) should be 
used 38,44, after which the suxamethonium dose can be adjusted based on the individual 
patient’s amount of motor activity. 47 The time until full recovery is dose-dependent and 
reaches 10 to 12 min after a dose of 1 mg.kg-1. 48  Using larger doses can lead to a complete 
absence of motor activity, which might impede monitoring of seizure adequacy. 
Suxamethonium has many side effects, compelling the clinician to perform a risk-benefit 
analysis for individual patients prior to its administration. One of the most deleterious side 
effects of suxamethonium is hyperkalaemia leading to cardiovascular instability in susceptible 
patients. Several recent reports implicate distinct pathologic states that predispose a 
patient to suxamethonium-induced hyperkalaemia. 49-54  A common and important risk factor 
is prolonged immobilization, 55 especially in elderly patients. Concomitant presence of 
pathologic conditions that up-regulate the acetylcholine receptors (e.g. meningitis) can lead 
to a more rapid and profound increase in serum potassium levels after suxamethonium. 56 
Other important side effects include bradycardia, 57 neuroleptic malignant syndrome (NMS) 
and malignant hyperthermia (MH). 36,57  Suxamethonium should, therefore, be avoided in 
any patient with a risk for severe hyperkalaemia 56 or with a history of, or susceptibility to 
NMS, MH, or catatonic schizophrenia. 58,59
Irrespective of the choice of the anaesthetic technique, previous studies 60-63 have shown 
that ECT may produce asystole at any point during the course of a series of treatments. 
Conversely, even if haemodynamically significant bradyarrhythmias or asystole occur during 
one treatment, subsequent ECTs may be safely conducted if pertinent risk factors are 
eliminated (e.g. vagal tone or high potassium levels). 63
Nondepolarizing Neuromuscular Blocking Agents
In contrast to suxamethonium, nondepolarizing NMBAs, used to achieve muscle relaxation 
for ECT treatment do not pose risk of side effects related to muscle fasciculation and 
cholinergic activation, or the potential to cause hyperkalaemia or malignant hyperthermia. 
The down-side of these NMBAs relates to their relatively long duration of action, typically 
beyond the time required for an ECT procedure, even when intermediate-acting NMBA are 
used. Also, there is wide variability in the sensitivity to the effects of these NMBAs, requiring 
that high doses be administered initially to reliably obtain neuromuscular blockade.  The time 
to onset of effect is also variable between agents (see below) and need to be considered. 
Accordingly, adequate neuromuscular transmission monitoring is recommended to titrate 
the effect of these NMBAs, and pharmacological reversal is usually required.




A nondepolarizing NMBA with a relatively short duration of action, mivacurium has been used 
as an alternative to suxamethonium for ECT treatment. 38,49,64-69 Savarese and collaborates 
showed that 0.08 mg.kg-1 of mivacurium (its ED95) is less effective than 0.5 mg.kg-1 
suxamethonium in blocking the neuromuscular transmission, when applied 120 seconds 
and 30 seconds before ECT, respectively. 70  Fredman and colleagues conducted a dose-
effect study of mivacurium (0.12 to 0.2 mg.kg-1) in a patient with susceptibility to neuroleptic 
malignant syndrome and history of prolonged bed-rest, and found that only 0.2 mg.kg-1 of 
mivacurium given 3 min before ECT was associated with effective muscle relaxation during 
ECT-induced seizure. The recommended dose of 0.15 mg.kg-1, or any of the doses smaller 
than 0.2 mg.kg-1, did not effectively mitigate the tonic-clonic response to ECT.  28,38 Although 
mivacurium can cause a significant histamine release and occasional hypotension,27,71 the 
authors reported no haemodynamic instability or clinical signs of histamin release. 38 A similar 
dose (0.15-0.25 mg.kg-1) appears to be sufficient for ECT in patients with myasthenia gravis, 
as was reported by Gitlin. 67 Others have reported optimal neuromuscular blockade with 
0.12-0.16 mg.kg-1 (in a patient with neuroleptic malignant syndrome) 59 or 0.15-0.25 mg.kg-1 
(patients with or without myasthenia gravis). 67 Based on data from three patients with major 
comorbidities (severe osteoporosis, amyotrophic lateral sclerosis, and bradycardia), Janis 
and colleagues recommended the use of 0.16 or 0.2 mg.kg-1 for ECT treatment. 66 A smaller 
dose (0.11 mg.kg-1) was also reported to adequately blunt ECT-induced muscular contraction 
in a patient with post-polio syndrome with high risk of severe respiratory sequelae and 
neuromuscular dysfunction. 69 Mivacurium has been used as a substitute for suxamethonium 
to avoid (potential) adverse effects like hyperkalaemia or bradycardia. 64,65,68 (Table 2) Of 
note, mivacurium is also metabolised by pseudocholinesterase, and a prolonged effect is, 
therefore, expected in patients with pseudocholinesterase deficiency. Mivacurium usage in 
the United States has declined rapidly in favour of alternative agents that are perceived to 
offer a more rapid onset of action and a safer cardiovascular profile. I t is more commonly 
used in Europe, in particular in the United Kingdom. 
Atracurium and Cisatracurium 
The dose of atracurium to effectively modify the tonic-clonic convulsions and prevent 
excessive muscle contractions during ECT was reported to be 0.5 mg.kg-1 (2.5 times its 
ED95), given 2-3 min prior to the treatment.52 35 Given the profound neuromuscular blockade 
and the prolonged duration of action associated with this relatively high dose, nevertheless, 
Lui and colleagues examined if 0.3 mg.kg-1 also provides adequate neuromuscular blockade 
for ECT. The authors found that 0.3 mg.kg-1 was sufficient to keep the T1 blockade at 11-
25%, whereas 0.5 mg.kg-1 maintained T1 blockade at 0-10% throughout the ECT. As was 
expected, the time to recovery to a T4 ratio of 0.5 was longer following 0.5 mg.kg-1 compared 
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with 0.3 mg.kg-1 of atracurium (9.2 ± 0.8 minutes vs. 4.3 ± 0.4 minutes). 35 Therefore, the 
authors recommended that the lower dose (0.3 mg.kg-1) be used for ECT to reduce the 
risk for prolonged neuromuscular blockade and to ascertain the occurrence of generalized 
seizures, as indicated by peripheral muscle activity at the time of electrographic seizures. 
In another report, 10-15 mg of atracurium was compared to 2-5 mg of suxamethonium in a 
64 kg patient with atypical pseudocholinesterase. 72 The dose to produce 90 % first twitch 
blockade was reported as 15 and 2.5 mg for atracurium and suxamethonium, respectively. A 
dose of 0.5 mg.kg-1 of atracurium has been used in other reports in patients with cholinesterase 
deficiency or burn injury. 52,73 Because of the short duration of ECT relative to the duration of 
action of atracurium, reversal of neuromuscular blockade with a cholinesterase inhibitor is 
usually recommended. 27   
Cisatracurium, a stereoisomer of atracurium with minimal release of histamine, has largely 
replaced atracurium in clinical practice. At a dose of 0.05 mg.kg-1, the time to 90% of peak 
effect is approximately 4.5 min, and the maximum effect (100%) is not achieved until 7 min 
after its administration. 74  Increasing the dose shortens the time to peak effect, but results 
in a long duration of action, which is usually unfavourable in a busy ECT setting. Despite an 
improved pharmacological profile with a reliable elimination, which is independent of renal 
or hepatic function, there are hitherto no clinical reports on the use of cisatracurium for ECT. 
Vecuronium and Rocuronium 
In appropriate doses, rocuronium has a speed of onset only marginally slower than that of 
suxamethonium, making it an appropriate alternative to suxamethonium for ECT. 75 Williams 
and colleagues employed 0.3 mg.kg-1 of rocuronium in a patient with delayed motor recovery 
caused by suxamethonium during a prior ECT treatment. 76 In a crossover study, Turkkal and 
colleagues compared rocuronium 0.3 mg.kg-1 versus suxamethonium 1 mg.kg-1 administered 
90 seconds before ECT. The authors found similar ECT results in the two groups of subjects, 
with the exception of an increased time until the first spontaneous breath in the rocuronium 
group (9.46 vs. 8.07 min). Of note, the authors did not use quantitative methods to assess the 
neuromuscular transmission, limiting the ability to identify differences in the incidence and 
severity of residual paralysis. 75  
Dodson reported the effects of a 2 mg IV dose of vecuronium in a patient who had developed 
bronchospasm after induction of anaesthesia and administration of 30 mg suxamethonium. 77 
The tonic-clonic response after vecuronium was similar to that after 30 mg of suxamethonium, 
and the authors concluded that 2 mg of vecuronium provides satisfactory neuromuscular 
blockade. Setoyama and colleagues administered vecuronium 0.01 mg.kg-1 followed 
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by a dose of 0.1 mg.kg-1 in three patients with NMS for ECT. They reported a prolonged 
anaesthesia time (38 vs. 19 min) in comparison to patients who received suxamethonium. 78 
Objective safety measures: Monitoring of the NMBA effect 
Monitoring of the neuromuscular transmission during ECT is helpful in titrating the dose of the 
NMBA to the desired relaxation, and confirming its effect. The isolated arm or cuff technique66,75 
can be used to reliably monitor the motor response, particularly if electroencephalography 
(EEG) is not available to confirm the induction of generalized seizure activity. A forearm or leg 
is then isolated from circulation by inflating a blood pressure cuff to above systolic pressure 
after anaesthesia induction, but before NMBA administration. 79 The technique is, however, 
not widely applied, as the available data is inconsistent with respect to its clinical benefit. 80 
While the optimal relaxation level for ECT still needs to be defined in a prospective study, 
sufficient information is available on how to predict adequate recovery. If quantitative NMT 
monitoring (e.g. T1 recovery to 90% 81 or TOF ≥0.9 59,66,68,72 )  is not available, subjective 
methods such as visual and tactile assessment by a nerve stimulator, 82 eye opening, head 
lift, tongue depressor, 75,82,83 and hand grip should be considered (Table 1, 2). 84,85 However, 
recently published data confirms that subjective techniques for assessment of the NMT fail 
to detect mild but clinically significant postoperative residual curarization. 86-99  In fact, even 
very experienced observers are unable to manually detect TOF or double-burst stimulation 
(DBS) fade at TOF ratio of 0.4-0.6 or more. 100-103  Therefore, quantitative measurement of 
the TOF ratio using acceleromyography is increasingly recommended for titrating the dose 
of muscle relaxants and their antagonists, and for detection of residual paralysis. 33,90,96,99,104-
113 Although the incidence of residual paralysis after ECT is unknown, recent data from 
postanaesthesia care units indicates an association between NMBAs and postprocedural 
residual paralysis as well as adverse respiratory events, and provides evidence in support of 
quantitative monitoring of the neuromuscular transmission. 99,114 
Reversal of the effects of nondepolarizing NMBA
Tables 1 and 2 summarize the studies and case reports that compare nondepolarizing NMBAs 
and suxamethonium in ECT treatment. As is evident from these studies and was also outlined 
previously in this review, the use of a nondepolarizing NMBA is often required as a substitute 
for suxamethonium in patients with different comorbidities. Given the relatively prolonged 
duration of action of the nondepolarizing agents, nevertheless, it is often recommended that 
clinicians monitor the neuromuscular transmission, and confirm the return of neuromuscular 
function before emergence from anaesthesia. 94,105,112,115-119 Cholinesterase inhibitors do not 
reverse deep levels of neuromuscular blockade, and may have undesirable autonomic side 
effects. 120 Their effect may also wear off before complete clearance of an NMBA, resulting 
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in recurarization with the risk for adverse respiratory events. 116,121 However, recurarization 
is unlikely after ECT, during which only a single and relatively low dose of an NMBA is 
given. A clinically interesting approach to neuromuscular blockade for ECT is to administer 
rocuronium for rapid onset of action, and to reverse the blockade with sugammadex.81
Potential role of Sugammadex for ECT
Given the limitations of anticholinesterases and the complications associated with residual 
neuromuscular blockade, new reversal agents have been investigated. The ideal reversal 
agent can be given at any time after the administration of a NMBA and completion of ECT, 
and is efficacious irrespective of the degree of neuromuscular blockade. It has ideally a 
rapid onset of action and a minimal side effect profile. 122,123 
Sugammadex is the first of a new class of selective muscle relaxant binding drugs developed 
for the rapid and complete reversal of neuromuscular blockade induced by rocuronium 
and vecuronium. Several studies have reported a predictable dose-response relationship 
with sugammadex for reversal of neuromuscular blockade. 124,125 Published data from 
Duvaldestin and colleagues suggest that 2 mg.kg-1 sugammadex is sufficient to reverse 
rocuronium at a posttetanic count of 1 or 2. It has been extrapolated from these findings 
that doses as low as 1 mg.kg-1 may provide clinically satisfactory reversal of rocuronium 
in <5 minutes once the TOF count has returned to a value of ≥2. 126 Available data from 
multiple other studies104,111,127,128 support this hypothesis. 126  Sugammadex titration, using 
quantitative neuromuscular monitoring, may be a viable approach to optimizing the extent 
of neuromuscular blockade during ECT. Indeed, low-dose sugammadex (0.22 mg.kg-1) 
can reverse a rocuronium-induced neuromuscular blockade at a TOF ratio of 0.5 within 2 
minutes. 129 High-dose sugammadex, on the other hand, can reverse even high degree of 
neuromuscular blockade (T1=0), e.g. after a high dose of rocuronium. 81 Rapid reversal of 
deep blockade with high doses of sugammadex is appealing in a busy ECT setting but it may 
not be cost-effective. An insufficient dose of sugammadex, on the other hand, may result in 
incomplete decurarization, or potentially recurarization if multiple doses of rocuronium have 
been administered. 130 Although the efficiency and safety of the rocuronium-sugammadex 
combination for ECT needs further investigation, available data suggests that sugammadex, 
compared with neostigmine, may provide a safer reversal of moderate neuromuscular 
blockade. Low-dose sugammadex may also be cost-effective for the reversal of moderate or 
profound neuromuscular blockade, provided that the time saving factors reported in recent 
trials are taken into account. 131,132 Despite its use in Europe for many years, the American 
Food and Drug Administration have yet not approved sugammadex for clinical use for safety 
concerns. 










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Neuromuscular blockade has dramatically reduced the incidence of important complications 
such as vertebral fractures and physical injuries related to ECT. With a rapid onset of 
action and short duration of effect, suxamethonium remains the NMBA of choice for ECT. 
However, significant comorbidities may require modification of the anaesthetic regimen and 
avoidance of suxamethonium. Nondepolarizing NMBAs are effective when suxamethonium 
is contraindicated. Clinicians should use quantitative or qualitative assessment of the 
neuromuscular transmission and pharmacological reversal of the neuromuscular blockade 
when nondepolarizing NMBAs are administered. Sugammadex provides rapid and reliable 
reversal of neuromuscular blockade after vecuronium and rocuronium, and the combination 
of steroidal NMBAs and sugammadex may be an attractive alternative to suxamethonium for 
ECT.
Neuromuscular blocking agents for ECTChapter 232 |
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ABSTRACT
Background
Neuromuscular blockade is required to control excessive muscle contractions during 
electroconvulsive therapy (ECT).  In a crossover, assessor-blinded, prospective randomized 
study, we studied the optimal effective dose of succinylcholine and rocuronium for ECT, 
defined as the lowest dose to provide acceptable control of muscle strength during induced 
convulsions. 
Methods
Succinylcholine (0.8 mg.kg-1) or rocuronium (0.4 mg.kg-1) were randomly administered in 
227 ECT sessions to 45 patients. The dose was incrementally increased or decreased by 
10% based on two psychiatrists’ (blinded to treatment) assessment of ‘acceptable’ or ‘not 
acceptable’ control of evoked muscle contractions (sufficient vs. insufficient or excessive 
paralysis). The neuromuscular transmission was monitored quantitatively until full recovery. 
Results
The optimal effective doses of succinylcholine and rocuronium in 50% of patients (OED50) 
were 0.85 mg.kg-1 (95% CI: 0.77-0.94) and 0.41 mg.kg-1 (95% CI: 0.36-0.46), and the 90th 
percentile of the applied optimal doses (OED90) 1.06 mg.kg-1 (95% CI: 1.0-1.27) and 0.57 
mg.kg-1 (95% CI: 0.51-0.62), respectively.  Nadir twitch height for acceptable muscle activity 
was 0% [0-4] and 4% [0-30] (p<0.001), and the time to recovery of the neuromuscular 
transmission after optimized induced seizure 9.7 ± 3.5 and 19.5 ± 5.7 min, respectively. 
The inter-individual variability of the OED50 (coefficient variation) was 1.24-fold greater for 
succinylcholine than rocuronium.
Conclusion
A twitch suppression of more than 90% is needed for control of motor contractions during 
ECT. Succinylcholine doses of 0.85-1.06 mg.kg-1 produce acceptable muscle blockade. 
Rocuronium is a safe alternative if appropriately dosed  (0.41-0.57 mg.kg-1) and monitored.




Electroconvulsive therapy (ECT) is a treatment in which generalized seizures are induced by 
transcutaneous electrical stimuli to the brain to treat specific psychiatric conditions such as 
therapy-resistant depression, catatonia and therapy-resistant schizophrenia. 1, 2 The quality 
and duration of the induced seizure by ECT have been associated with the efficacy of the 
procedure. Anesthetic drugs and neuromuscular blocking agents (NMBAs) are administered 
to ensure patient comfort and safety, but need also be titrated to provide optimal conditions 
for the induced seizure activity during the treatment, while allowing a rapid recovery upon 
its completion.3 Due to its rapid onset and short duration of action, succinylcholine is 
considered the NMBA of choice for ECT.  However, a non-depolarizing NMBA needs to be 
considered in some patients with metabolic, neuromuscular or neurological comorbidities, 
or other contraindications to succinylcholine (e.g. immobilization or pseudocholinesterase 
deficiency).4 Despite the importance of NMBAs to provide favorable conditions for ECT, the 
optimal NMBA dose to achieve acceptable level of muscle contracture using neuromuscular 
blockade without excessive or untoward effects has not previously been identified in a 
prospective randomized fashion and using objective monitoring techniques.5 The aim of this 
study is, therefore, to identify the optimal NMBA doses of two commonly used neuromuscular 
blocking agents (succinylcholine and rocuronium), defined as the lowest dose to provide 
optimized muscle strength modulation during ECT.
MATERIALS AND METHODS
This cross-over randomized controlled, assessor blinded clinical trial was conducted 
in the post-anesthesia care unit at Massachusetts General Hospital in Boston, MA, USA. 
Institutional Review Board approved the study protocol, and written informed consent was 
obtained from all participating patients. 
Patients
Two hundred and twenty-seven ECT sessions were conducted in 45 hospitalized patients 
aged 24-80 years with American Society of Anesthesiologist Class I -III, admitted for a series 
of ECT treatments at a frequency of 3 times per week. The indication for ECT in all enrolled 
patients was major depressive disorder or bipolar disorder, and all patients were taking 
psychotropic medications including antidepressants and antipsychotics, as indicated by 
their psychiatric condition. Only patients within 20% of the ideal body weight were included. 
Exclusion criteria included an age of <18 years, patients with illness or medications known 
to influence neuromuscular transmission, significant renal or liver dysfunction, electrolyte 
abnormalities and pregnant women. 
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Protocol
The flow of patients through the study is depicted in figure 2. Following screening by the 
psychiatrist and anesthesiologist responsible for the clinical treatment of each patient, 
informed consent was obtained and patients were enrolled.  After preoxygenation with 
100% oxygen for 3 minutes through a facemask, anesthesia was induced with propofol (1.2 
mg.kg-1 intravenously over 5 sec). Continuous neuromuscular transmission monitoring was 
applied after stabilization and baseline calibration to establish a control twitch response 
prior to NMBA injection (see below). Succinylcholine (Quelicin®, Hospira Inc., Lake Forest, 
IL) 0.8 (2.67 × ED95) mg.kg-1 or rocuronium-bromide (Zemuron®, Oganon USA Inc) 0.4 
mg.kg-1 (1.33 × ED95) was then administered intravenously over 5 sec via an intravenous 
catheter in the arm contralateral to the side of neuromuscular transmission monitoring, which 
was then flushed with a 10 ml bolus of normal saline. These initial doses were selected as 
the median of applied succinylcholine and rocuronium doses to achieve acceptable ECT 
induced motor activity in pilot study of 10 patients. Ventilation was assisted until recovery of 
normal spontaneous ventilation via a facemask and an Ambu-bag with supplemental 100% 
oxygen. After the peak effect of neuromuscular transmission blockade was established, an 
electrical stimulus at approximately 6x seizure threshold was delivered with right unilateral 
application of electrodes with a MECTA Model SR II apparatus (MECTA Corp., Portland, OR, 
USA). The treating psychiatrists, blinded to the type and dose of the NMBA (see discussion), 
determined the stimulus parameters for the applied ECT (level, dynamic, energy, intensity 
and duration of stimulus) and the subsequent duration of seizure (Table 2).  The duration of 
seizure was monitored by EEG and recorded from EEG activity.
Systolic and diastolic blood pressures (SBP and DBP) were recorded every 3 min and the 
heart rate (HR), and oxygen saturation (SpO2) were monitored and recorded continuously 
throughout the procedure and until full recovery. Temperature was monitored and 
maintained ≥ 35°C. Labetalol (10-50 mg IV) or esmolol (40-80 mg IV) was administered to 
treat hypertension and tachycardia, when necessary. 
After termination of seizure and when appropriate, as determined by the practicing 
anesthesiologist, the rocuronium-induced neuromuscular blockade was reversed with 
neostigmine 50 microgram.kg-1, administered with glycopyrrolate 10 microgram.kg-1. 6 
After return of normal spontaneous breathing, patients were placed in a lateral decubitus 
position. Neuromuscular monitoring was continued until full recovery of the neuromuscular 
blockade was recorded (T1 =100% or TOF ratio of > 0.9 for succinylcholine and rocuronium, 
respectively). 7 




Neuromuscular transmission was monitored using acceleromyography and a TOF-Watch SX® 
monitor (Organon, Roseland, NJ, USA) connected to a laptop computer. Before induction 
of anesthesia, the subject’s arm was taped in a stable and comfortable position, skin was 
cleansed and surface electrodes were placed (3-5 cm apart) over the ulnar nerve at the 
wrist. A hand adaptor (Organon International Inc., Roseland, NJ, USA) was used to fix the 
thumb position to minimize the potential variability in evoked muscle contraction. The TOF-
watch was calibrated by using the standard calibration with default supramaximal stimulation 
(CAL1: 10 sec stimulation current of 50 mA), and ulnar nerve stimulation was resumed with 
single twitch stimulation at 0.1 Hz and continued till observation of less than 5% variation of 
twitch heights for 2-3 min, after which a bolus dose of the NMBA was injected.8 The same 
mode of stimulation was continued until the peak effect of neuromuscular transmission 
blockade was established (first of three consecutive twitches with the same/increasing 
value or ≥ 95% depression of twitch). 8 After completion of the ECT- induced seizure, twitch 
stimulation was continued in patients who had received succinylcholine until a twitch height 
of 100% of control (baseline) with response variation less than 5% for 2 min was recorded.8 
For rocuronium-treated patients the mode of stimulation was changed to TOF-stimulation 
with square wave pulses of 0.2 msec duration delivered at 2 Hz every 15 sec, and continued 
until three consecutive responses with a TOF ratio ≥ 0.9 were recorded. All twitch height 
values during the recovery phase were normalized to final twitch value, and were expressed 
as percentages of control values. 8 
NMBA randomization and crossover 
Patients were randomized to receive either succinylcholine or rocuronium at a standard initial 
dose, as listed above, during their first ECT. During each subsequent ECT treatment (two 
days apart), patients received a 10% higher (if insufficient paralysis) or lower (if sufficient or 
excessive paralysis) dose of the same NMBA until the minimum effective dose that resulted 
in acceptable muscle relaxation (defined as the optimal dose) was identified. When the 
optimal dose of the first NMBA was identified, each patient received the second NMBA 
(i.e. succinylcholine if rocuronium had been administered, and vice versa) for his or her 
subsequent ECT treatments, and the dose was increased or decreased in 10% increments 
according to the same protocol until the minimum acceptable dose for the second NMBA 
was established (Figure 1, study design).
Quality assessment of muscle relaxation
The quality of muscle relaxation during seizure was independently assessed using a 
dichotomous scale of ‘acceptable’ or ‘not acceptable’ by two psychiatrists, who were 
blinded to the dose and type of NMBA. A grading system was used to score the two 
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psychiatrists’ evaluation. Each psychiatrist provided a single score based on defined criteria 
for ‘acceptable’ or ‘not acceptable’ ECT conditions (Table 1). A summed score of more than 
or equal to two was considered as ‘acceptable’ level of induced muscle relaxation. Any 
summed score of less than two was considered as ‘not acceptable’ level of induced muscle 
relaxation. Consequently, NMBA trials were continued until the lowest dose that provided 
acceptable relaxation during induced seizure was identified. 
Outcome Variables
The primary clinical outcome of the study was to define the optimal effective dose (OED) 
of succinylcholine and rocuronium for each subject to achieve acceptable level of muscle 
relaxation, defined as the smallest dose of succinylcholine or rocuronium that resulted 
in adequate muscle relaxation and safe application of ECT in 50% of the cases (OED50). 
We also provide the NMBA dose that resulted in adequate relaxation in 90 and 95% of 
the population (OED90 and OED95) and the nonparametric bootstrap confidence intervals 
for the upper tail distribution of the optimal doses. The measured OED50s of succinylcholine 
and rocuronium and the corresponding T1 suppression for acceptable motor activity during 
ECT are comparable to their ED95s (median dose corresponding to more than 95% twitch 
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Figure 1. Study design
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depression9), i.e. m×ED95 under the conditions studied (ECT). 
The secondary outcome was the duration of the neuromuscular transmission blockade; 
defined as the time to complete recovery from neuromuscular blockade after a single bolus 
dose of the OED50, i.e. return of the twitch height to its baseline if succinylcholine had been 
administered, or TOF ratio ≥ 0.9 if rocuronium was used. All patients were monitored until 
full recovery from neuromuscular blockade (twitch height of 100% or TOF ratio ≥ 0.9 for 
succinylcholine and rocuronium, respectively). 
Additionally, the coefficient of variation (CV), a measure to show the relative variability 
of OEDs in each treatment group (succinylcholine and rocuronium), was calculated and 
compared, as well as the quartile coefficient of dispersion of the OEDs to make comparison 
of dispersion of OEDs within and between the treatment groups.
5 declined to participate
34 subjects randomized to start crossover 




1 Received rocuronium in error
1 Received succinylcholine in error
1 Withdrew consent
2 Did not complete series of ECT
9 Had technical errors (twitch monitoring failure 




31 had Complete and reliable twitch monitoring data 








89 ECT trials with rocuronium
 
Interim data review 
11 additional subjects were enrolled and 
randomized 
(Total N=45) 
39 Patients scheduled for series of ECT 
approached for consent after screening
Figure 2: Schema of the study methods. After screening for eligibility criteria, we enrolled consecutive patients who 
scheduled for series of electroconvulsive therapy after consenting to participate in the study. Only captured data from 
patients who completed the series of treatments with reliable neuromuscular monitoring were used for analysis.
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Table 1. Definitions of conditions and terms for assessing the quality of “acceptable” or “not-acceptable” 
muscle relaxation during ECT induced seizure. Each assessor (psychiatrist) provided a separate score. 




Evidence of electric seizure present from 
EEG monitoring or increase in heart rate, but 
complete absence of clonic movements or 





Sudden/brisk muscle jerks at the stimulus 
delivery in limbs, trunk or neck, or 
subsequently during the seizure presence of 
tonic-clonic movements in one or more limbs 




Freely movable joints from loss of muscle 
tone, absence of a plantar withdrawal 
response, disappearance of deep tendon 
reflexes, disappearance of fasciculation, 
generalized tonic–clonic of more than 15 
sec 
1 (Good) or 2 (Excellent)
Statistical Analysis
Data are presented as mean ± SD or [range] unless otherwise specified. Based on the 
results from previous NMBA dose-repose studies, we considered a minimum samples size 
of 24 to be adequate for the estimation of ED50 with 80% power and with a reasonable 
degree of assurance. 10, 11 In addition, we conducted a power analysis to determine the 
sample size needed for our secondary outcome parameters; the duration of block and time 
to recovery. In our pilot data from10 patients, a 3-min difference in recovery endpoints (100% 
twitch height recovery or TOF ≥0.9 for succinylcholine and rocuronium, respectively) with a 
standard deviation of 5 min was observed. Assuming a normal distribution of the data, we 
calculated a sample size of 31 to achieve 90% power to detect a mean of paired differences 
of 3.0, with a known standard deviation of differences of 5.0 and with a significance level 
(alpha) of 0.05 using a two-sided Wilcoxon test. Accordingly, we concluded that a sample 
size of 31 would provide adequate power for both of our clinical outcome parameters.
All the calculations were performed using “SPSS Statistics for Windows, Version 19.0 
(Armonk, NY: IBM Corp., USA, IBM Corp. 2010)”, “PASS 11 (NCSS, LLC. Kaysville, Utah, 
USA, 2011)” and SigmaPlot 11 (Systat Software, San Jose, CA). R Package ‘MBESS’ was 
used to construct the confidence interval for the CVs of succinylcholine and rocuronium 
OEDs and other applied doses. 12  Normality assumption of the measured variables was 
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Table 2. ECT parameters as well as hemodynamic, acceleromyographic and clinical characteristics of 
subjects after muscle relaxation with succinylcholine or rocuronium under optimized induced seizure 
activity (* significant at p-value cutoff of 0.01)
Variables
Optimized Induced 
Neuromuscular Transmission Mean 
differences






         Pulse width (miliampere)
         Energy (joule)
         Duration (sec)
         Mode (up/down)                         



















Duration of seizure (sec)
        Mean (SD)





-4 (18) 0.003* -0.03 0.85
Nadir preprocedural SpO2 
         Mean (SD)
         Range
92 (4) %
79-99 %
94 (3) % 
85-100 %
-2 (4) 0.011 0.16 0.33
Propofol dose (mg)
         Mean (SD) 100 (28) 107 (29) -7 (33) 0.463 0.16 0.334
Pre-ECT heart rate (per min) 
          Mean (SD)





-1 (17) 0.818 0.46 0.81
Pre-ECT systotlic blood pressure (mmHg) 
         Mean (SD)





+2 (25) 0.655 -1.35 0.412
Pre-ECT diastolic blood pressure (mmHg) 
         Mean (SD)





0.5 (15) 0.845 0.063 0.7
Post-ECT heart rate (per min)
         Mean (SD)





-1.5 (20) 0.647 0.37 0.65
Post-ECT systolic blood pressure (mmHg) 
          Mean (SD)         





-5 (53) 0.564 -0.027 0.87
Post-ECT diastolic blood pressure (mmHg) 
          Mean (SD)





-5 (29) 0.337 0.081 0.62
Nadir T1
        Median, Mode





-4 (7) <0.001* -0.15 0.36
Time to 100% T1 recovery (min)   
       Mean (SD)





-3.5 (5) <0.001* -0.19 0.25
Time to TOF > 0.9 (min) 
       Mean (SD)
       Range
n/a 19.5 (5.7)
8-30
- - - -
Time to first spontaneous breathing (min)
        Mean





-2 (1.5) <0.001* 0.18 0.27
Time to Eye Opening (min)    
       Mean (SD)





-3 (3.3) <0.001* 0.134 0.4
assessed using the Lilliefors test (all p > 0.12 and N=31). Welch’s t-test was conducted to 
compare the measured variables (e.g. recovery time, duration of seizure, and hemodynamic 
Optimal doses of succinylcholine and rocuronium for ECTChapter 350 |
variables etc.) obtained under succinylcholine and recouronium conditions (p > 0.01). 13, 
14 Cohen’s Kappa for inter-rater reliability was used to assess inter-rater reliability between 
the two assessors of motor seizure activity during ECT. The optimal effective dose of NMBA 
(OED) was defined as the lowest dose that provided completion of ECT under acceptable 
conditions. The “optimal” doses obtained from the study patients (31 optimal doses for either 
of treatment groups, succinylcholine or rocuronium) were resampled 10000 times using the 
nonparametric bootstrap method.15 The 25th, 50th (median), 75th, 90th and 95th percentiles 
of these samples and the corresponding 95% and 99% confidence intervals were then 
calculated. 
Covariates included were age, ASA Physical Status, anesthetic dose, and the ECT parameters. 
A p-value < 0.05 (unless otherwise specified) was considered statistically significant and 
reported for a two tailed test. 
RESULTS
Two hundred and twenty-seven ECT treatments in 45 enrolled subjects were recorded. 
Thirty-one subjects completed their series of treatment, generating a total of 187 qualified 
ECTs for data analysis (Figure 1). Four to 8 observations were recorded for each patient with 
both NMBAs. The mean age and body weight of the subjects were 50 ± 8 years [24-80, F/M: 
15/16] and 80 ± 20 kg [49-109], respectively. Median of ASA physical status was II.  There 
were no significant differences between the two groups (treated patients with optimal doses 
of succinylcholine or rocuronium) in baseline values of SpO2, HR, SBP and DBP. The dose of 
propofol used to induce anesthesia was not different in the succinylcholine and rocuronium 
treatment groups (100 ± 28 mg vs. 105 ± 29 mg, p > 0.05) No significant difference was 
observed between the groups in the dose of any medications administered during ECT (e.g. 
esmolol and labetalol). 
Primary Clinical Outcome: Optimal Effective Dose of NMBA dose and onset time
OED50 of succinylcholine and rocuronium were 0.85 mg.kg-1 (95% CI: 0.77-0.94) and 0.41 
mg.kg-1 (95% CI: 0.36-0.46), respectively. The 90th and 95th percentile of optimal doses were 
amounted to 1.06 mg.kg-1 (95% CI: 1.0- 1.27), 1.16 mg.kg-1 (95% CI: 0.8-1.5) for succinylcholine 
and 0.57 mg.kg-1 (95% CI: 0.51-0.62), 0.59 mg.kg-1 (95% CI: 0.56-0.63) for rocuronium, 
respectively. The range of applied optimal doses for succinylcholine and rocuronium were 
[0.46-1.22] mg.kg-1 and [0.26-0.59] mg.kg-1, respectively. Table 3 demonstrates 99% CI of 
the OED percentiles.
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Table 3. 95% and 99% nonparametric bootstrap confidence intervals (CI) of the percentiles of optimal 
effective doses (OED) for succinylcholine and rocuronium.  The intervals calculated using the adjusted 
bootstrap percentile (BCa) method.
Succinylcholine Dose (mg/kg) 95% CI 99% CI
OED25 0.704225 (0.6077-0.7392) (0.5979-0.7834) 
OED50 0.846446 (0.7664-0.9381) (0.7163- 0.9467)  
OED75 1.019541 (0.870-1.087) (0.859-1.103) 
OED90 1.062941 (1.021-1.266) (1.020-1.555) 
OED95 1.163164 (1.085-1.555) (1.064-1.555) 
OED99 1.425879 (1.158-1.555) (1.135-1.555)
Rocuronium
OED25 0.365957 (0.3169-0.3932) (0.3060-0.3952) 
OED50 0.412794 (0.3577-0.4568) (0.3471-0.4669) 
OED75 0.506449 (0.4356-0.5463) (0.4264-0.5512) 
OED90 0.567167 (0.5071-0.6117) (0.5060-0.6117) 
OED95 0.587320 (0.5563-0.6294) (0.5187, 0.6294)  
OED99 0.5996132 (0.5669-0.6294) (0.5571-0.6294)
The CV for the optimal dose of succinylcholine was 1.24-fold greater than that of rocuronium 
(25.7% [CI: 21-29] vs. 20.86% [CI: 20-27]). These values were not different compared 
to the CV of other applied doses for each NMBA (25% [CI: 22-30] and 21% [CI: 18-25] 
for succinylcholine and rocuronium, respectively). The quartile coefficient of dispersion 
succinylcholine OEDs was 1.11 that of rocuronium OEDs (0.185 vs. 0.167).
Acceptable ECT induced seizure contracture was achieved after 1.4 ± 0.5 min and 3.7 ± 
1 min in the succinylcholine and rocuronium groups, respectively (p<0.001). Nadir twitch 
suppression to achieve an acceptable controlled seizure quality (muscle activity) was 0 ± 
2% [0-10, frequency of 0: 92.5%] for succinylcholine and 4 ± 6% [0-30, frequency of 0: 
40%] for rocuronium. A twitch suppression of 0-10% resulted in 100% acceptable muscle 
relaxation after succinylcholine (97.5%: 0-4%, 2.5%: 5-10%). When rocuronium was used, a 
T1 twitch value of 0-10% of baseline resulted in acceptable level of muscle relaxation in 95% 
of cases (60% of these patients had a T1 value of 0-4% baseline, and 35% had T1 of 5-10% 
baseline).
Secondary Clinical Outcome: Time to recovery from neuromuscular blockade 
The time to 90% twitch recovery after succinylcholine was 9.37 ± 3.2 min, while 100 % twitch 
recovery was obtained after 9.7 ± 3.5 (3-20) min (Figure 3). The time to TOF recovery >0.9 
was 19.5 ± 5.7 min after rocuronium (Table 2).
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ECT Parameters, Hemodynamic Variables and Ancillary Data
No clinically significant differences were identified in the recorded EEG parameters or seizure 
quality when adequate neuromuscular blockade was obtained with rocuronium instead of 
succinylcholine. ECT parameters including pulse width, energy, frequency and duration 
were similar in both treatment groups (Table 2). No differences in HR, SBP and DBP data 
were observed between or within the succinylcholine and rocuronium groups. Nadir SpO2, 
defined as the lowest recorded periprocedural oxygen saturation, were 94 ± 3% [85-100] 
and 92 ± 4% [79-99] for rocuronium and succinylcholine, respectively (p> 0.05). 
The inter-rater reliability for the raters was found to be Kappa = 0.862 (p <0.001), 95% CI 
(0.801- 0.923). Duration of motor seizure activity following succinylcholine and rocuronium 
amounted to 27 ± 14 and 31 ± 11 sec, respectively (p<0.001, Table 2). 
DISCUSSION
The findings reported herein indicate that near-complete twitch suppression is required for 
optimal neuromuscular blockade during ECT. The time to achieve acceptable neuromuscular 
blockade was increased by approximately 2.3 min when rocuronium was used, resulting in a 
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Figure 3. Time course of single twitch height (percent baseline) after injection of succinylcholine or rocuronium (Means 
± SE) in optimized ECT-induced seizure quality.  * P value<0.05 A. Onset of action and suppression of twitch height B. 
Recovery of twitch height 
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Optimal Dose of Succinylcholine and Time to Onset of Maximal Effect
Although a single best dose of succinylcholine for ECT has yet not been identified in the 
literature, doses between 0.5–1 mg.kg-1 are often used based on anecdotal reports and 
previous experience of anesthesia providers. 5, 16-18 Consistent with the report from Murali and 
his colleagues,19 our data suggest that succinylcholine doses close to 1 mg.kg-1 may provide 
acceptable ECT conditions and also highlight the importance to avoid early application 
of ECT after the administration of succinylcholine (<1.4 min, time to onset of acceptable 
relaxation), even in the absence of a twitch response to nerve stimulation. This observation 
is also consistent with previous finding by Beale and colleagues20 that the muscle response 
to ulnar nerve stimulation can be extinguished long before cessation of muscle fasciculation, 
and suggests that the time to onset of adequate relaxation for ECT is longer than the 
traditional 60 sec that is used for rapid sequence intubation (1 mg.kg-1of succinylcholine, 3.5 
× ED95). 21-23 This difference in time to obtain acceptable ECT conditions as compared to that 
for endotracheal intubation may be attributed to a difference in sensitivity to succinylcholine 
in different muscle groups (e.g. oropharynx versus extremities), but can also indicate that a 
deeper neuromuscular blockade is needed for acceptable ECT conditions as compared to 
endotracheal intubation. Kopman et al.24 showed that the speed of onset of succinylcholine 
might be dependent on rapid plasma clearance such that in patients with normal plasma 
cholinesterase activity, following an ED95 dose of succinylcholine time to peak effect (95% 
twitch depression) occurs in less than 2 min (109 sec ± 15).  
The 90th percentile of the optimal effective dose of 1.06 mg.kg-1 (≈3.5 × ED95) succinylcholine 
in our study and an induced twitch height suppression of 0-4% for acceptable motor seizure 
modification are in line with findings by Murali and his colleagues, who recommended a dose 
of 1.0 mg.kg-1 and twitch suppression to 0-5% of baseline.19 The 95th percentile of optimal 
dose of succinylcholine (1.17 mg.kg-1) has also been used in other clincal trials (1.2 mg.kg-1). 
25-28 
Duration of Paralysis and Time to Recovery after Succinylcholine
The time required for 90% twitch recovery (9.4 min) after optimal dose of succinylcholine 
is comparable with the reported recovery time by others after a single dose of 1 mg.kg-1 
(9.3 min). 29, 30 Similarly, the time required for 100% twitch recovery (9.7 min) in our study 
is similar to that in previously published pharmacokinetic studies of this NMBA (10 minutes 
after applying the dose of 1.0 mg.kg-1). 31, 32 Accordingly, our data suggest that the seizure-
induced release of acetylcholine into the neuromuscular junction does not significantly alter 
the duration of succinylcholine-induced neuromuscular blockade. 
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Rocuronium as an Alternative to Succinylcholine during ECT
Rocuronium is increasingly employed as an alternative to succinylcholine for neuromuscular 
blockade during ECT, primarily in the elderly and patients with cardiovascular and neurological 
comorbidities. Immobilized patients and elderly or those who have suffered a stroke are 
particularly susceptible to succinylcholine-induced hyperkalemia due to depolarization 
of upregulated nicotinic (neuronal) alpha-7 acetylcholine receptors. 5  On the other hand, 
ECT is highly effective and is increasingly applied in the elderly and those with increased 
incidence of prolonged immobilization and higher risk of hyperkalemia. 5  Nondepolarizing 
NMBAs do not cause hyperkalemia and can be given to these patients and those with 
susceptibility to malignant hyperthermia or contraindications to succinylcholine, but are often 
avoided because of their relatively long duration of action, typically exceeding the ECT time. 
Moreover, there is a significant variability in the sensitivity and the time needed to obtain 
appropriate neuromuscular blockade after non-depolarizing NMBAs. This might explain why 
higher doses are often chosen to reliably obtain neuromuscular blockade for ECT, with the 
consequence of potentially inducing a prolonged paralysis and recovery. 
Currently, rocuronium is given as a single bolus of 0.3 to 0.6 mg.kg-1 prior to ECT treatment.5 
Doses beyond 0.4 mg.kg-1, for ECT, have been used in combination with the reversal agent 
sugammadex, a selective relaxant-binding agent (currently not available in the USA), which 
has also been used to reverse profound rocuronium-induced neuromuscular blockade in 
adult surgical patients. 5 Its rapid effect on rocuronium-induced neuromuscular blockade 
yields recovery times that are comparable to that of succinylcholine during ECT. 5  Our study 
confirms that even in absence of this selective reversal agent, in patients with contraindications 
to the use of succinylcholine 3, the rocuronium-neostigmine combination can provide a safe 
and relatively time-effective alternative to succinylcholine. 
Optimal Dose of Rocuronium and Time to Onset of Maximal Effect
The OED90 in our study (0.57 mg.kg-1 ≈ 2 × ED95) is comparable to the dose that has 
previously been reported to induce > 95% block in 98% of subjects. 33, 34 The time needed 
to achieve acceptable conditions for ECT is also consistent with previous studies, with a 
twitch suppression to 10% baseline after 2.9 ± 1.0 min and 0% after 3.7 ± 1.0 min. The 
time from NMBA injection to acceptable ECT conditions is hence approximately 2.3 minutes 
longer with rocuronium as compared to succinylcholine. As the anesthetic agents affect the 
duration of the ECT-induced convulsions, clinicians should consider this difference in time 
from anesthesia induction to ECT application with rocuronium versus succinylcholine, and 
adjust the dose and timing of their hypnotic agents accordingly.
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Duration of Paralysis and Time to Recovery after Rocuronium
Bevan and colleagues35 reported the time to 90% recovery of the first twitch (T1 90) to be 
more than 10 min. Consistent with their data, our study showed that a twitch value of 90% 
was obtained after 12 min. However, in the former study, the TOF ratio of 0.9 was achieved 
28 min after rocuronium-induced paralysis (0.45 mg.kg-1). In our study, a TOF ratio of 0.9 was 
recorded after 19.5 min, which is comparable with a recovery time of 21 ± 4 min reported by 
Fuchs-Buder and colleagues 36 (after rocuronium 0.4 mg.kg-1) and 19.4 ± 5.1 min by Lederer 
et al.37 (rocuronium 0.4 mg.kg-1).
ECT Quality and Seizure Duration after Rocuronium versus Succinylcholine 
Using subjective tools to assess the recovery from neuromuscular blockade, Turkal et al.38 
reported that motor seizure duration was greater after 0.3 mg.kg-1 rocuronium as compared 
to 1 mg.kg-1 succinylcholine (33 and 24 sec, respectively). Similarly, Hoshi and colleagues 39 
reported longer duration of seizure with rocuronium as compared to succinylcholine. Our data 
is consistent with these previously published studies confirming a small difference in seizure 
duration, which may be attributed to a decline in propofol-induced EEG suppression 40 after 
rocuronium associated with the 2 min delay in achieving appropriate muscle relaxation. As 
there is an association between clinical effectiveness of ECT and the duration of induced 
seizure41, the American Psychiatric Association task force advocates seizure lengths > 
20 sec for effective ECT treatment. 42 This recommendation underscores the importance 
of titrating the dose of the NMBA to achieve an adequate neuromuscular blockade. EEG 
monitoring is also recommended for induced seizure monitoring 43, particularly in patients 
who might need higher doses of an NMBA to achieve acceptable modified seizure. Further 
studies are needed to assess the therapeutic effects of the cumulative seizure time in a 
series of ECTs using optimal doses of these NMBAs. 
Dose Variability with Succinylcholine versus Rocuronium
The observed inter-individual variability for the OEDs of rocuronium and succinylcholine 
is consistent with previously reported studies (coefficient variation of 25%, range: 15-
27% for N>2412).  As compared to rocuronium, succinylcholine showed relatively higher 
inter-individual variability (coefficient variation ratio of 1.24) and dispersion (the quartile 
coefficient dispersion ratio of 1.1) for the applied effective doses that resulted in acceptable 
neuromuscular blockade and controlled ECT induced seizure.  
Inter-individual differences in the expression and activity of butyrylcholinesterase enzyme 
(BChE) is known to be of importance for the metabolism of succinylcholine 31, 44, 45, and may 
explain the observed difference in its dose variability when compared to rocuronium. 30 A 
relatively smaller OED variability for rocuronium might clinically have a greater significance 
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if achieving the optimized induced seizure activity is important to rapidly maximize 
the therapeutic effect of sequential ECTs, particularly if the use of succinylcholine is 
contraindicated. However, if the initial dose of rocuronium (0.4 mg.kg-1) is insufficient and 
increasing doses are required, the duration of the induced neuromuscular blockade is less 
predictable. Longer recovery times that may even extend beyond the duration of the ECT 
should be considered. 29, 46 
Clinical implications
Due to the documented inter-individual variability in the OED50-ECT of succinylcholine, an 
initial dose of 0.85 mg.kg-1 is reasonable for the first ECT session, with dose adjustments in 
0.1 mg.kg-1 increments or decrements, based on the quality of the observed motor seizure 
activity for each individual during subsequent treatments. 
As an alternative and if clinically indicated, we suggest a 0.4 mg.kg-1 bolus of rocuronium as 
the initial dose of the applied NMBA. ECT should be applied after a twitch suppression of 
>90% is documented or, if twitch monitoring is not available, after sufficient time has been 
provided to ensure > 90% peak effect from the administered rocuronium (i.e. 3 min).  If 
excessive or insufficient neuromuscular block is noticed during the induced seizure, dose 
adjustment with 0.05 mg.kg-1 decrements or increments is advisable. After the treatment, the 
rocuronium-induced neuromuscular blockade should be reversed in the regular fashion with 
neostigmine (50 microgram.kg-1). Due to inter-individual variability in the time to recovery, 
particularly if doses in excess of 0.6 mg.kg-1 are administered, quantitative NMT monitoring 
is recommended to evaluate adequate level of relaxation and to ensure sufficient recovery 
of the induced neuromuscular blockade, in order to minimize the risk for adverse respiratory 
events. 5, 47 Clinicians should ensure that all patients stay under close observations by 
appropriately trained personnel, and continue to monitor the neuromuscular function until 
complete recovery of the neuromuscular transmission has been verified (e.g. sustained head 
lift or tongue depressor test). 48
In summary, the presented data shows that a twitch suppression of > 90% is required 
for acceptable neuromuscular blockade during ECT. The time to achieve acceptable 
neuromuscular blockade is increased by approximately 2.3 min when rocuronium is used 
instead of succinylcholine, resulting in an average of 12 min increased procedure time. 
When appropriately dosed and monitored, rocuronium can be a safe alternative NMBA for 
electroconvulsive therapy in patients with contraindications to succinylcholine.
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SUPPLEMENTARY APPENDIX
Bootstrap method for estimation of OED5 confidence intervals (CI) and resam-
pling for evaluating the effect of sample size on estimated confidence limit
The data from of 31 subjects who were evaluated in our randomized crossover trial for 
application of rocuronium and succinylcholine in ECT were used for analysis. This approach 
resulted in 31 minimum effective doses of rocuronium and 31 minimum effective doses of 
succinylcholine resulted in acceptable induced seizures among subjects. Using “boot” 
package in R statistical software, 10000 bootstrap replications, bias corrected 95% and 99% 
confidence intervals (CIs) for the median of the optimal effective doses (OED50) of rocuronium 
and succinylcholine were estimated. Similarly, CIs of 90 and 95 percentiles of the optimal 
effective doses of rocuronium and succinylcholine were calculated (OED90 and OED95).
To confirm that 31 subjects were sufficient to obtain reasonable 95% and 99% confidence 
limits of optimal effective doses of succinylcholine and rocuronium, 10, 15, 20, 25 and 30 
subjects were separately resampled from the optimal effective doses. The above bootstrap 
technique with 10000 replications was performed in each one of the new datasets and 95% 
and 99%confidence limits for the estimates of the OED50 of each dataset were obtained. The 
results for the effects of sample sizes are shown below:
Variable estimate Percentile Number of subjects
Succinylcholine 10 15 20 25 30
OED50 5 0.6305 0.7042 0.7135 0.7163 0.7392
95 1.0195 1.0213 0.9504 0.9467 0.9071
0.1 0.6117 0.7146 0.6991 0.6991 0.7246
0.99 1.0823 1.0195 1.0305 1.0414 0.9553
Rocuronium
OED50 5 0.3329 0.3731 0.3725 0.3674 0.3877
95 0.5463 0.5174 0.4864 0.4746 0.4568
0.1 0.3169 0.3660 0.3572 0.3489 0.3660
0.99 0.5488 0.5507 0.5117 0.5064 0.4669
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ABSTRACT
Background 
Neuromuscular blocking agents (NMBAs) are used during electroconvulsive therapy (ECT) 
to mitigate the induced severe muscle contractures. The objective of this study was to 
analyze the pharmacokinetics-pharmacodynamics (PK-PD) relationship of succinylcholine 
and rocuronium during ECT.
Methods 
The available data on the first twitch height (T1) of 31 patients who underwent ECT as well 
as the corresponding intravenously applied doses of succinylcholine and rocuronium were 
used for the analyses in the study.  The T1% (percentage change from the response to the 
supramaximal stimulus) derived from continuously applied TOF Watch recording to assess 
the minimal effective doses of succinylcholine and rocuronium during ECT. NONMEM 
software was used to construct, evaluate and validate the PKPD models. The PKPD of the 
two NMBAs was described using a two-compartment PK model and effect compartment 
model. The PK-PD parameter estimates required for the simulation of blood concentration 
were abstracted from previously reported studies in the literature.
Results  
The PD model parameter estimates for succinlcholine and rocuronium during ECT were 
ke0= 0.04 min−1 (SEE=0.004) and ke0= 0.17 min-1 (SEE=0.19), respectively. The Ce50 
estimations for these two NMBAs were amounted to 0.7 μg/ml (SEE=0.06) and 1.6 (SEE=0.1), 
respectively. The ke0 for neostigmine was not estimable, however the Ce50 was measured to 
be 0.412 (SEE=0.06).
Conclusion
The estimated PK-PD parameters for succinylcholine and rocuronium during ECT are almost 
comparable to previous PK-PD estimates for these two NMBA. The observed higher Ce50 
for rocuronium might explain faster recovery after ECT from NMB and warrants further 
investigation. 




Neuromuscular blocking agents (NMBAs), known as muscle relaxants, are key medications 
administered to patients undergoing electroconvulsive therapy (ECT). The induced relaxation 
using NMBAs averts ECT patients’ unwanted severe muscular responses that might result in 
physical injuries such as bone fractures and unpleasant experience of the procedure.1 These 
drugs also modify the quality and duration of induced seizure by ECT that has been shown 
to be associated with the efficacy of ECT.  Anesthetic drugs and neuromuscular blocking 
agents (NMBAs) are administered to ensure patient comfort and safety, but need also be 
titrated to provide optimal conditions for the induced seizure activity during the treatment, 
while allowing a rapid recovery upon its completion.2
Succinylcholine (SUX) is a bis-quaternary ammonium compound and depolarizing 
neuromuscular blocking agent, has been extensively used in anesthesia of ECT. In patients 
without plasma cholinesterase deficiency, succinylcholine has the advantage of a rapid 
onset and short duration of action. Therefore, this NMBA is preferred as the main NMBA for 
inducing muscle relaxation during ECT.1 In spite of common use of succinylcholine, there 
are medical conditions that succinylcholine do not serve as a safe NMBA an alternative 
NMBA might be required for the safety of patients.  Succinylcholine is hydrolyzed by plasma 
cholinesterase. 3 Genetic variants of the plasma cholinesterases, low plasma cholinesterase 
activity due to an acquired deficiency (e.g. liver disease, carcinoma, debilitating disease), 
and other factors, among which some remain unknown, may lead to an episode of prolonged 
apnea after succinylcholine. 3 Because of this recognized variation in the activity of plasma 
cholinesterases, large intersubject differences in pharmacokinetic, pharmacodynamic, and 
pharmacokinetic–pharmacodynamics relations are expected. 4
Currently, nondepolarizing NMBAs such as rocuronium bromide are being used as an 
alternative choice for inducing muscle relaxation during ECT. Rocuronium bromide is an 
aminosteroid non-depolarizing neuromuscular blocking agent with a more rapid action than 
other currently available non-depolarizing drugs but with duration of action considerably 
longer than succinylcholine vecuronium. Rocuronium acts by competing for cholinergic 
receptors at the motor endplate. 5
The nondepolarizing NMBAs have longer duration of action and should be used along with 
reversal agents (e.g. neostigmine) to accelerate recovery from neuromuscular blockade 
(NMB) and prevent postoperative residual NMB. The use of anticholinesterases to reverse 
residual neuromuscular block is efficacious only if recovery is already established. Even in 
these circumstances, the full effect of anticholinesterases and recovery takes considerable 
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time to achieve. 6, 7 Neostigmine is a parasympathomimetic which by indirect cholinomimetic 
mechanism inhibits acetylcholinesterase, thereby increasing the concentration of 
acetylcholine in the synaptic cleft.
Hypothetically, the ideal reversal agent can be given at any time after the administration of a 
NMBA and completion of ECT, and is efficacious irrespective of the degree of neuromuscular 
blockade. It has ideally a rapid onset of action and a minimal side effect profile. 6, 7 Similarly, 
an ideal nondepolarizing NMBA could be an agent with short duration of action and 
recovery time with potentially matched with a reversal agent that could be applied at any 
time after achieving the desired level of neuromuscular blockade. The search for the ideal 
nondepolarizing NMBA involves an understanding of the factors that makes succinylcholine 
blockade so evanescent. This entails increasing our knowledge on pharmacology of 
succinylcholine and other nondepolarizing NMBAs, i.e. simultaneous measurement of their 
plasma concentrations or a surrogate measure (pharmacokinetics) and neuromuscular 
blockade (pharmacodynamics). A pharmacokinetic–pharmacodynamic analysis could help 
in measuring the drug effect and the relation between blood concentration and the target 
organ under the effect of drug. 
ECT produces hemodynamic changes, including increase in cardiac output (CO) during 
seizure activity due to sympathetic stimulation and systemic catecholamine surges. 1 Effect 
of cardiac output on pharmacokinetics of has been investigated. To our knowledge there is 
no study in literature to include the pharmacokinetic–pharmacodynamics (PK-PD) relations/
analysis of succinylcholine and an alternative such as rocuronium during ECT. The objective 
of this study was to provide a quantitative model to describe the kinetics and the dynamics of 
succinylcholine chloride and rocuronium after the different bolus doses applied for inducing 
muscle relaxation in patients underwent ECT.  Accordingly, the aims in model development 
were to establish the PK–PD model for succinylcholine and rocuronium induced NMB in 
patients undergoing ECT. The secondary objective was to determine if the in vitro rate of 
degradation recorded by neuromuscular transmission monitoring (NMT) is of predictive 
value for the in vivo elimination rate of succinylcholine and rocuronium in ECT patients.
MATERIALS AND METHODS
This study is a secondary analysis on the crossover randomized controlled, assessor blinded 
clinical trial that was conducted in the post-anesthesia care unit at Massachusetts General 
Hospital in Boston, MA, USA to estimate the optimal doses of rocuronium and succinylcholine 
for ECT. The results of the main study are presented in chapter three of this dissertation. 




Two hundred and twenty-seven ECT sessions were conducted in 45 hospitalized patients 
aged 24-80 years with American Society of Anesthesiologist Class I -III, admitted for a series 
of ECT treatments at a frequency of 3 times per week. The indication for ECT in all enrolled 
patients was major depressive disorder or bipolar disorder, and all patients were taking 
psychotropic medications including antidepressants and antipsychotics, as indicated by 
their psychiatric condition. Only patients within 20% of the ideal body weight were included. 
Exclusion criteria included an age of <18 years, patients with illness or medications known 
to influence neuromuscular transmission, significant renal or liver dysfunction, electrolyte 
abnormalities and pregnant women. 
Protocol
The flow of patients through the study is depicted in figure 1. Following screening by the 
psychiatrist and anesthesiologist responsible for the clinical treatment of each patient, 
informed consent was obtained and patients were enrolled.  After preoxygenation with 
100% oxygen for 3 minutes through a facemask, anesthesia was induced with propofol (1.2 
mg.kg-1 intravenously over 5 sec). Continuous neuromuscular transmission monitoring was 
applied after stabilization and baseline calibration to establish a control twitch response prior 
to NMBA injection (see below). Succinylcholine (Quelicin®, Hospira Inc., Lake Forest, IL) 
0.8 (2.67 × ED95) mg.kg-1 or rocuronium-bromide (Zemuron®, Oganon USA Inc) 0.4 mg.kg-1 
(1.33 × ED95) was then administered intravenously over 5 sec via an intravenous catheter in 
the arm contralateral to the side of neuromuscular transmission monitoring, which was then 
flushed with a 10 ml bolus of normal saline. These initial doses were selected as the median 
of applied succinylcholine and rocuronium doses to achieve acceptable ECT induced 
motor activity in pilot study of 10 patients. Ventilation was assisted until recovery of normal 
spontaneous ventilation via a facemask and an Ambu-bag with supplemental 100% oxygen. 
After the peak effect of neuromuscular transmission blockade was established, an electrical 
stimulus at approximately 6x seizure threshold was delivered with right unilateral application 
of electrodes with a MECTA Model SR II apparatus (MECTA Corp., Portland, OR, USA). The 
treating psychiatrists, blinded to the type and dose of the NMBA determined the stimulus 
parameters for the applied ECT (level, dynamic, energy, intensity and duration of stimulus) 
and the subsequent duration of seizure. Systolic and diastolic blood pressures (SBP and 
DBP) were recorded every 3 min and the heart rate (HR), and oxygen saturation (SpO2) 
were monitored and recorded continuously throughout the procedure and until full recovery. 
Temperature was monitored and maintained ≥ 35°C. Labetalol (10-50 mg IV) or esmolol (40-
80 mg IV) was administered to treat hypertension and tachycardia, when necessary. 
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After termination of seizure and when appropriate, as determined by the practicing 
anesthesiologist, the rocuronium-induced neuromuscular blockade was reversed with 
neostigmine 50 microgram.kg-1, administered with glycopyrrolate 10 microgram.kg-1.8 
After return of normal spontaneous breathing, patients were placed in a lateral decubitus 
position. Neuromuscular monitoring was continued until full recovery of the neuromuscular 
blockade was recorded (T1 =100% or TOF ratio of >0.9 for succinylcholine and rocuronium, 
respectively).9 
Neuromuscular transmission monitoring
Neuromuscular transmission was monitored using acceleromyography and a TOF-Watch SX® 
monitor (Organon, Roseland, NJ, USA) connected to a laptop computer. Before induction 
of anesthesia, the subject’s arm was taped in a stable and comfortable position, skin was 
cleansed and surface electrodes were placed (3-5 cm apart) over the ulnar nerve at the 
wrist. A hand adaptor (Organon International Inc., Roseland, NJ, USA) was used to fix the 
thumb position to minimize the potential variability in evoked muscle contraction. The TOF-
5 declined to participate
34 subjects randomized to start crossover 




1 Received rocuronium in error
1 Received succinylcholine in error
1 Withdrew consent
2 Did not complete series of ECT
9 Had technical errors (twitch monitoring failure 




31 had Complete and reliable twitch monitoring data 








89 ECT trials with rocuronium
 
Interim data review 
11 additional subjects were enrolled and 
randomized 
(Total N=45) 
39 Patients scheduled for series of ECT 
approached for consent after screening
Figure 1. Patient flow through the study
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watch was calibrated by using the standard calibration with default supramaximal stimulation 
(CAL1: 10 sec stimulation current of 50 mA), and ulnar nerve stimulation was resumed with 
single twitch stimulation at 0.1 Hz and continued till observation of less than 5% variation 
of twitch heights for 2-3 min, after which a bolus dose of the NMBA was injected.10 The 
same mode of stimulation was continued until the peak effect of neuromuscular transmission 
blockade was established (first of three consecutive twitches with the same/increasing 
value or ≥ 95% depression of twitch).10 After completion of the ECT- induced seizure, twitch 
stimulation was continued in patients who had received succinylcholine until a twitch height 
of 100% of control (baseline) with response variation less than 5% for 2 min was recorded.10 
For rocuronium-treated patients the mode of stimulation was changed to TOF-stimulation 
with square wave pulses of 0.2 msec duration delivered at 2 Hz every 15 sec, and continued 
until three consecutive responses with a TOF ratio ≥ 0.9 were recorded. All twitch height 
values during the recovery phase were normalized to final twitch value, and were expressed 
as percentages of control values.10 
NMBA randomization and crossover 
Patients were randomized to receive either succinylcholine or rocuronium at a standard initial 
dose, as listed above, during their first ECT. During each subsequent ECT treatment (two 
days apart), patients received a 10% higher (if insufficient paralysis) or lower (if sufficient or 
excessive paralysis) dose of the same NMBA until the minimum effective dose that resulted in 
acceptable muscle relaxation (defined as the individual optimal dose) was identified. When 
the optimal dose of the first NMBA was identified, each patient received the second NMBA 
(i.e. succinylcholine if rocuronium had been administered, and vice versa) for his or her 
subsequent ECT treatments, and the dose was increased or decreased in 10% increments 
according to the same protocol until the minimum acceptable dose for the second NMBA 
was established.
Quality assessment of muscle relaxation
The quality of muscle relaxation during seizure was independently assessed using a 
dichotomous scale of ‘acceptable’ or ‘not acceptable’ by two psychiatrists, who were blinded 
to the dose and type of NMBA. A grading system was used to score the two psychiatrists’ 
evaluation. Each psychiatrist provided a single score based on defined criteria for ‘acceptable’ 
or ‘not acceptable’ ECT conditions (Table 1, chapter three). A summed score of more than 
or equal to two was considered as ‘acceptable’ level of induced muscle relaxation. Any 
summed score of less than two was considered as ‘not acceptable’ level of induced muscle 
relaxation. Consequently, NMBA trials were continued until the lowest dose that provided 
acceptable relaxation during induced seizure was identified. 
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Outcome variables for PK-PD analysis
The primary clinical outcome of the main study (chapter three) was to define the optimal 
effective dose (OED) of succinylcholine and rocuronium for each subject to achieve 
acceptable level of muscle relaxation, defined as the smallest dose of succinylcholine or 
rocuronium that resulted in adequate muscle relaxation and safe application of ECT in 50% 
of the cases (OED50). 
The secondary outcome of main study was the duration of the neuromuscular transmission 
blockade, defined as the time to complete recovery from neuromuscular blockade after a 
single bolus dose of the OED50, i.e. return of the first twitch height to its baseline for both if 
succinylcholine and succinylcholine and additional measure of TOF ratio ≥ 0.9 if rocuronium 
was used. To evaluate the secondary outcome of the primary analysis, all patients were 
monitored until full recovery from neuromuscular blockade (twitch height of 100% or TOF 
ratio ≥ 0.9 for succinylcholine and rocuronium, respectively). Using this data and for 
pharmacokinetic–pharmacodynamics (PK–PD) analysis in this study, we extracted all the 
measured first twitched (T1s) changes during the NMBA onset of action and recovery from 
the induced neuromuscular blockade (NMB), corresponding to the applied doses (both 
optimal and suboptimal doses).  Accordingly, we generated two data sets for PK-PD analysis 
including the T1 changes in response to all the applied succinylcholine and rocuronium 
doses, respectively. Additionally, the measured OED50s of succinylcholine (0.85 mg/kg) and 
rocuronium (0.41 mg/kg) and the corresponding T1 suppression for acceptable motor activity 
during ECT were used to compare the onset of action and recovery times for succinylcholine, 
rocuronium and rocuronium plus neostigmine. 
The primary objective of this study was to provide a quantitative model to describe the 
PK-PD relationship of succinylcholine chloride and rocuronium applied doses in patients 
undergoing ECT. The secondary objective was to determine if the in vitro rate of degradation 
(T1) is of predictive value for the in vivo elimination rate of succinylcholine and rocuronium 
in the patient that underwent ECT procedure. Subsequent aims in model development were 
to establish the PK–PD model for rocuronium-induced NMB and its reversal by neostigmine.
Statistical analysis
The data were analyzed using the statistical package NONMEM, Version 7.3.0 (Icon 
Development Solutions, Hanover MD, USA). Pharmacodynamic parameters were assumed 
to be log-normally distributed across the population. Residual error was assumed to be 
normally distributed, but the dependent variable was constrained to lie within the interval 
(0,100). The Laplacian approximation was used for the estimation method. 11 The generalized 
additive model (GAM) procedure was used to identify covariates. 12 The GAM procedure 
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is a multiple nonlinear regression analysis of the empirical Bayes estimates for each of the 
pharmacodynamic parameters and the available covariates. 12 To assess goodness−of−fit, 
the coefficient of determination (R^2, figure 2) was calculated for every occasion and was 
used as a measure of the goodness of fit of the regression model (figure 2A and B).
Pharmacodynamic modeling
The pharmacokinetic models were coupled to an inhibitory sigmoid Emax model via a 
blood−effect−site concentration half−life t1/2ke0 (t1/2ke0: the half time of equilibration between 
drug concentration in the blood and drug effect; ke0: the effect compartment equilibration 
rate constant). For neostigmine it was assumed that it increases the effect compartment 
concentration at 50% blockage representing (Ce50, the effect-site concentration associated 
with 50% maximal drug effect that often referred as the potency factor) of rocuronium with 
Ce50rocneo (t) = Ce50roc. (1 +  (Ceneo (t) / Ce50nreo) ϒneo).
The concentration in the effect compartment, 
Ce (t) is given by dCe (t) / dt = ke0. (Cb (t) – Ce (t)) where Cb (t) is the blood concentration of 
the NMB agent or the antagonist, and ke0 = log (2) / t1/2ke0. For neostigmine, not all parameters 
were identifiable; and an indirect response model to describe acetylcholinesterase was 
deemed to be unfeasible. Therefore it was assumed that the ke0 of neostigmine was identical 
to the ke0 of rocuronium, and the offset of effect of neostigmine that could not be estimated 
from the data was removed from the model by the following formula: 
dCeneo (t) / dt = ke0roc . Cbneo (t)
The neuromuscular blockade is then given by: 
Effect (t) = 100 / (1 + (Cenmb (t) / Ce50)ϒnmb )
Selection of Pharmacokinetic Parameter Sets
Because in this study no blood samples were taken, the blood concentrations of 
succinylcholine, rocuronium, and neostigmine were simulated using pharmacokinetic data 
from previously reported parameters in the literature.
I. Succinylcholine Study
Succinylcholine pharmacokinetic parameters were taken from Roy et al. 4; the geometric 
means were taken from the first six subject in Table 3 of the reference with exclusion of the 
seventh subject as appeared to be an outlier: V1: 0.00930 L/kg, k10: 3.87, k12: 1.25, k21: 
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1.46 min−1.
II. Rocuronium
The rocuronium pharmacokinetic parameter set was taken from Wierda et al. 13, Table II of 
this reference. Vermeyen et al.’s investigation 14 found this parameter set to be the best for 
rocuronium among the studies that investigated the parameters of interest in the literature.
III. Neostigmine
The neostigmine pharmacokinetic parameters in adults was used as investigated by Fisher 
et al. 15, Table 2 of the reference. These constants were converted to central volume and rate 
constants: V1: 0.0400 L/kg, k10: 0.240, k12: 0.363, k21: 0.140, k13: 0.189, k31: 0.0201 min−1.
RESULTS
Two hundred and twenty-seven ECT treatments in 45 enrolled subjects were recorded. 
Thirty-one subjects who completed their series of treatment and complete monitoring data 
for first twitches were captured, were included in the PK-PD analysis. All the NMBA doses 
that generated acceptable and unacceptable NMB during ECT were considered for PK-PD 
analysis. The mean age and body weight of the subjects were 50 ± 8 years [24-80, F/M: 
15/16] and 80 ± 20 kg [49-109], respectively.
The half-life of transports between the plasma and effect compartments (tl/2ke0) for 
succinylcholine and rocuronium were amounted to 17 min (SEE=1.6) and 3.7 min (SEE=3.7), 
respectively. Accordingly, the ke0 estimates were 0.04 min-1 (SEE=0.004) and 0.19 min-1  
(SEE=0.19) for succinylcholine and rocuronium, respectively.
The estimated Ce50 for succinylcholine and rocuronium were 0.7 μg/ml (SEE=0.06) and 1.6 
(SEE=0.1), respectively. For neostigmine, the constant of ke0 was not estimable, however, 
the Ce50 was estimated to be 0.412 (SEE=0.06). Table 1 (sections A and B) summarizes the 
parameter estimates for both succinylcholine and rocuronium/neostigmine.
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Table 1. Estimated pharmacokinetic parameters for succinylcholine and rocuronium during ECT. Table 
1A and 1B summarizes the measured PK-PD parameters for succinylcholine and rocuronium (reversed 




Estimate SEE W2 SEE
1T1/2ke0 (min) 17.1 1.58 0.261 0.0724
2Ce50 (ug/ml) 0.706 0.0599 0.221 0.05






Estimate SEE W2 SEE
T1/2ke0  (min) 3.67 0.367 0.256 0.0131
Ce50 (ug/ml) 1.59 0.0977 0.0636 0.0128
ϒ 7.54 0.733 0.0875 0.0407
Neostigmine
Ce50 (ug/ml) 0.412 2 0.06 Not 
estimable
ϒ 3.49 0.594 0.444 0.171
SD 12.7 0.792
1. Equilibration half-time
2. Median effective concentration
3. Gamma, determines the steepness of the concentration- effect relationship (the Hill factor describing sigmoidicity 
of the concentration-effect relation)
4. Standard deviation
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SUX ID = 36, R2 = 0.98












ROC ID = 41, R2 = 0.96
Figure 2. The plots demonstrated the examples of generated fits for individuals from data that are selected based on 
the range of R2, lowest, median and highest estimated values for succinylcholine and rocuronium studies)
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Figure 3. A and B: The graph demonstrates the goodness-of-fit plots (observed vs. predicted individual first twitch 
heights) for succinylcholine and rocuronium, respectively.
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Figure 4A and B. The plots demonstrate the population simulation results for the succinylcholine and rocuronium/
neostigmine studies. In the figure A, the doses are assumed to be 0.8 mg/kg and 0.4 mg/kg for succinylcholine and 
rocuronium. These doses are approximately the minimal effective doses that resulted in the acceptable induced 
seizure during ECT in 50% of subjects (OED50). In figure B, these doses are assumed to be 1.1 mg/kg and 0.54 
for succinylcholine and rocuronium, respectively. These doses are 95 percentile of minimal effective doses (OED95) 
resulted in acceptable induced seizure during ECT. 




The half-life of transport between the plasma and effect compartment (t1/2ke0, time for effect site 
concentration to reach to 50% of concentration when the plasma concentration is constant) 
for succinylcholine at adductor pollicis in this study was almost 5 times that of rocuronium. 
Onset time of neuromuscular blocking drugs is determined by the time required for drug 
concentrations at the site of action to reach a critical level, usually that corresponding to 95% 
block. Onset time is longer than time to peak plasma concentrations. The faster equilibration 
between plasma concentrations of succinylcholine (higher t1/2ke0 -> lower ke0) at adductor 
pollicis results in more rapid onset of blockade in adductor pollicis than rocuronium, as 
shown in this study.
Our succinylcholine ke0 estimation in this study is consistent with finding by Roy et al.4
The authors reported the estimate ke0 of 0.058 for succinylcholine. Considering their reported 
standard error estimate (SEE) of 0.026, our measured ke0 of 0.04 is a reasonable measure 
of ke0.  Furthermore our measured Ce50 of succinylcholine “the effect-site concentration 
associated with 50% maximal drug effect” being 0.706 ug/ml ± 0.06, is comparable to the 
Roy et al.’s estimate of this measurement (0.734 ± 0.211).
Plaud et al. 16 investigated the rocuronium neuromuscular blocking effect (a 5-min infusion) 
along with neostigmine for its reversal on twitch height in adductor pollicis and estimated the 
parameters of the  rocuronium pharmacokinetics in relation to pharmacodymics according 
to Sheiner model 17, i.e., the rate constant of transport between the plasma and effect 
compartments (ke0) and the concentration producing 50% block (Ce50). They used a two-
compartmental pharmacokinetic model. These measured estimates in their study were 0.168 
± 0.06 min-1 and 0.823 ± 0.16 ug/ml for ke0 and Ce50. While the estimate of ke0 in our study 
(0.19 ± 0.19 min-1) is comparable to Plaud et al.’s report, the Ce50 estimate in our study is 
two times of the measure (1.6 ± 0.1 ug/ml) by these authors. The effect of increasing cardiac 
output (CO) on the tissue clearance or distribution rate has already been shown, at least when 
tissue uptake is perfusion limited, as is the case with rocuronium. 18 ECT is associated with a 
more prominent sympathomimetic activity and an increase in CO. 19 This fact might explain 
higher estimated rocuronium Ce50 and subsequent the faster recovery times measured by 
T1 measurement in adductor pollicis that were observed in this study and ECT procedure 
as compared to the previous reports. 13, 20 In earlier study presented in chapter three, we 
also reported longer duration of induce seizure in patients who received rocuronium as 
NMBA. Other investigators have reported this observation, as well. 1 This observation might 
be another factor that potentially has affected the concentration of rocuronium in the effect 
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compartment. Our measured ke0 and t1/2ke0 for rocuronium is also consistent with the findings 
by Weirda et al. (0.16 and 3.85 min, respectively).13 Cortinez et al. also measured the ke0 of 
rocuronium using both parametric and non-parametric approaches. In both methods the 
estimated ke0 was similarly 0.19 min-1. 21 However, the measured Ce50 in their study was 0.92 
ug/ml. Kuipers et al. 18 showed that the CO could affect some pharmacokinetics parameters 
and recommended using recirculatory pharmacokinetic model instead of compartmental 
models to include the CO effect, a matter that should be investigated in an appropriately 
designed ECT study.
Similar to other studies that investigated PK-PD parameters of neuromuscular blocking 
agents, we identified higher ke0 and lower EC50 for succinylcholine as compared to 
rocuronium.  The onset time for a neuromuscular blocking agent will clinically vary according 
to factors such as the type of anesthesia, applied dose, type of stimulation for monitoring 
of neuromuscular blockade (single twitch vs. train-of-four response), and the clinical end-
point used for onset time determination (peak effect or fixed degree of twitch depression) 
during neuromuscular monitoring. 22 Due to crossover design of our study, most of these 
factors were the same for both succinylcholine and rocuronium, except the applied doses 
that were increased or decreased to identify the minimal effective dose of each of the NMBA 
for inducing acceptable neuromuscular block during ECT.  
The first order plasma–effect-site equilibration rate constant (ke0) values might vary due 
circulatory factors that may, in turn alter the onset of action of a NMBA. 22  Under identical 
clinical settings in our study for both succinylcholine and rocuronium, the inter-individual 
variations in ke0 could explain the observed differences in the onset times and recovery times 
from both of the neuromuscular blockers.  
The effect of drug potency in the onset of action of a neuromuscular blocking agent has been 
supported by several experimental studies such that there is an inverse relationship between 
onset times and molar potency (ED50) of NMBAs in anaesthetized patients. 23, 24 Consistent 
with other investigations with applied kinetic-dynamic model 25, our pharmacokinetic analysis 
supports the observation in onset of action for succinylcholine and rocuronium and according 
to these two NMBA’s ED50s (figure 4A).
A higher rate constant for equilibration of the effect compartment concentration with plasma 
concentration (ke0) and a rapid clearance after a single bolus dose of succinylcholine 
(recovery from block starts from distribution phase 26) as shown in our study (figure 4A and 
B) has made this drug as the first choice of NMBAs for ECT. The comparison of figures 4A 
and 3B, derived from population analysis using NONMEM shows the increase of the applied 
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doses (ED95) of the succinylcholine (from 0.8 mg/kg ≈2.67 ED95 to 1.1 mg/kg ≈3.67 ED95) 
and rocuronium (from 0.4 mg/kg ≈ 1.33 ED95 to 0.54 mg/kg ≈ 1.8 ED95) decreases the 
onset of actions and increases the recovery times for both NMBAs. However, the difference 
in predicted recovery times decreases for the applied doses of 1.1 mg/kg vs. 0.54 mg/kg 
for succinylcholine and reocuronium/neostigmine, respectively. This observation suggests 
that in subjects in need of higher doses of succinylcholine for inducing NMB during ECT 
(approximately > 1 mg/kg), the recovery times might be comparable to induced NMB using 
rocuronium 0.5-0.6 mg/kg reversed by neostigmine 0.04-0.05 mg/kg. 
There are limitations in interpretation of the results of our study to be considered. We did 
not measure the timely levels of NMBAs in blood after injection and during ECT. Another 
limitation of the study is inability to measure the neogstimine keo, in spite of the fact that we 
estimated neostigmine Ce50 and its effect on the reversal of rocuronium. 
In this study, we identified similar pharmacokinetic-pharmacodynamic parameters (ke0 
and Ce50) for succinylcholine during ECT as previously investigated. For rocuronium the 
estimated ke0 is consistent with others’ finding, while we identified higher Ce50 at adductor 
pollicis that might justify the faster observed recovery from rocuronium induced NMB in this 
study. This observation warrants further investigation for PK-PD investigation of rocurnium 
during ECT in a prospective clinical trial.
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ABSTRACT
Electroconvulsive therapy (ECT) has shown apparent efficacy in treatment of patients with 
depression and other mental illnesses who do not respond to psychotropic medications 
or need urgent control of their symptoms. Pharmacogenetics contributes to an individual’s 
sensitivity and response to a variety of drugs. Clinical insights into pharmacogenetics of 
ECT and adjunctive medications not only improves its safety and efficacy in the indicated 
patients, but can also lead to the identification of novel treatments in psychiatric disorders 
through understanding of potential molecular and biological mechanisms involved. In this 
review, we explore the indications of pharmacogenetics role in safety and efficacy of ECT 
and present the evidence for its role in patients with psychiatric disorders undergoing ECT. 




Due to its apparent effectiveness, electroconvulsive therapy (ECT) was commonly used for 
depressive disorders prior to invention of antidepressants in the 1950s. At the beginning, 
unmodified ECT was agonizing and unsafe, leading to, among others, bone fracture or spine 
injury. However, the advent of anesthetics and muscle relaxants along with newer apparatus 
evolved the “modified ECT to achieve maximum benefits while minimizing the procedural 
side effects related to the applied medication (anesthesia), electrical current or the induced 
seizure. ECT is currently administered with individually adjusted electrical currents under 
surveillance of anesthesiologists who apply anesthetics and muscle relaxants in appropriate 
medical setting. 1 
In spite of all the technical advances that have improved the relative risk of ECT, many 
crucial issues remain unresolved. For example, it is difficult to determine a priori whether 
ECT will be associated with an “adequate” therapeutically effective seizure in each patient. 
2 Genetic variations contribute to the variation of an individual’s response to different class 
of medications or treatment procedures via multiple components. This interface between 
our genetic variations and response to therapeutic interventions, i.e. pharmacogenetics, 
determines the individual response to a specific treatment and affects both patient’s safety 
and efficacy of response to ECT. 
Historically, the role of pharmacogenetics in ECT was primarily related to the safety of ECT 
application and was explored by Kalow. Observation of prolonged apnea after succinylcholine 
administration in some individuals paved the way to the preliminary clinical insights into 
pharmacogenetics. In 1956, Kalow discovered that an alteration in plasma cholinesterase 
level caused induction of longer duration of paralysis by application of succinylcholine to 
ECT patients. This change resulted in extension of duration of succinylcholine action from the 
few minutes to over an hour in the affected individuals. 3, 4 Kalow implied the discovery of the 
presence of genetic effects on drug response. 5, 6 
These studies advanced further research related to pharmacogenetics such that in 1960s 
the process of drug acetylation was discovered and the fact that slow acetylators (poor 
metabolizers) are more prone to side effects related to drug metabolism. 5 Furthermore, by 
application of anesthetics during procedural treatments including ECT, the awareness of 
developing side effects such as acute porphyric event due to thiopentone as well as the 
observed association of the malignant hyperthermia with succinylcholine, drew the attentions 
in the how genetics might influence in the applied pharmacology. 7 
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ECT is the most effective acute treatment for mood disorders, especially treatment-resistant 
Major Depressive Disorder (MDD), and has proven efficacy in other non-depressed 
psychiatric disorders such as schizophrenia. 8-11  Several studies have explored the impact 
of genetics in the neurobiological mechanisms involved in ECT. These studies have also 
aimed to improve the efficacy of ECT by predicting the genotype-phenotype distinction of 
patients undergoing ECT. 2, 12, 13 To our knowledge, no comprehensive literature review has 
been published on this ground. Hence, in this review, we will provide an evidence-based 
approach to the role of pharmacogenetics on safety (drugs used during ECT) and efficacy 
of ECT (potential genes and neurobiological mechanisms), and present evidence of its 
importance in patients with psychiatric disorders who undergo ECT (figure 1).
METHOD
Using a structured approach to identify the source of materials for the review, a systematic 
search was conducted for relevant peer-reviewed articles in PubMed and the Google 
Scholar search engine, using the keywords ‘ECT anesthesia genetics’, ‘ECT safety genetics’, 
‘ECT efficacy genetics’, ‘ECT and genetics’, ‘treatment resistant psychotic disorders ECT 
genetics’, ‘depressive disorders ECT genetics’, ‘psychotic disorders ECT genetics’, ‘ECT 
neurotransmitter genes’, ‘genetics and ECT response’ and ‘adjunctive therapy in ECT and 
genetics’. References of the relevant articles or editorials were also considered for potential 
bibliographic related references to avoid any missing publication. All searches were limited 
to research published in English. Due to paucity of articles on this subject, there was no 
restriction on time of publication. The identified papers were predominantly related to 
depression disorders. For the efficacy of ECT and main focus of this review, we included 
all preclinical and human studies that might explain a direct role of a gene in the efficacy 
of ECT or suggest a genetic effect through neurobiological mechanisms. Accordingly, 34 
publications were identified in investigating the pharmacogenetics in efficacy of ECT; only 19 
articles showed direct investigation on role of pharmacogentics in ECT. The ECT associated 
gene signatures were analyzed using MetaCore™ platform for investigation of their potential 
interactions and common biological network pathways in human brain. 
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PHARMACOGENETICS AND SAFETY OF ECT 
I. Anesthesia adverse events
Abnormalities in butyrylcholinesterase
ECT is a short procedure and demands anesthetics with rapid onset and short duration of 
action. These qualities have made succinylcholine as the neuromuscular blocking agent 
(NMBA) of choice for ECT 1.  The enzyme butyrylcholinesterase (BCHE) hydrolyzes ester 
bonds in succinylcholine. The enzyme is composed of 4 identical subunits of 574 amino 
acids, each containing an active catalytic site. The BCHE1 gene is located on four exons of 
chromosome 3q26.1–3q26.2 (online Mendelian inheritance in Man; OMIM 177400). The gene 
encodes a 602 amino acid protein including a 28 amino acid leader peptide. Genetic variation 
in the BCHE1 gene leads to variant enzyme forms, which affect the substrate behavior, 
resulting in reduced or absence of the enzyme BCHE activity.  BCHE deficiency results in a 
prolonged effect of the ultra-short acting depolarizing muscle relaxant succinylcholine due 
to markedly decrease in plasma cholinesterase activity 14. The variants of BCHE included 
wild type (U), atypical (A, dibucaine resistant), fluoride resistant (F), silent (S) and Kalow 
(K). Besides the normal variant (U), A and K variants are more frequent (A20G and G1615A) 
15. It is noted that the patients with homozygosis or carriers with compound heterozygosity 
remain asymptomatic in the absence of exposure exogenous choline ester-compound such 
as succinylcholine.
In Australian population, out of 65 patients referred for prolonged post-succinlycholine apnea, 
85% of the subjects showed one of mutated variants of BCHE gene including dibucaine 
(Dib; D70G), Sil-1 (G115FS), Flu-1 (T243M), Flu-2 (G390V), and K-variant (A539T), with 74% 
being dibucaine homozygote or heterozygote, 6% rare genotypes, 3% heterozygous fluoride 
allele, and 13% undetermined 16. The Danish Cholinesterase Research Unit (DCRU), in a 20-
year longitudinal study, found abnormal response to succinylcholine in 61.1% of the 1,247 
patients who were visited in the center. Of these 1,247 patients, 28.5% had normal genotype 
and 46.5% were genotypically aberrant. While the recovery time of neuromuscular function in 
patients with one aberrant allele was 15-30 min following a single dose of succinylcholine 1.0-
1.5 mg kg-1, it took 35-45 min for patients with heterozygousity of abnormal allele in two genes 
to recover.  Homozygousity in abnormal allele in atypical gene lengthened the recovery 
time to 90-180 min. Patients with genotypes of AK and AH experienced slightly (20 min) or 
markedly longer duration of action (90 min) of succinylcholine, respectively. 17 Accordingly, 
there are several case reports of succinylcholine induced prolonged apnea in patients 
receiving ECT. 1, 18-20 In a longitudinal study, Mollerup et al. determined the BCHE activity and 
the BCHE genotype of 13 patients who were visited in the DCRU after ECT. 21 The authors 
measured and compared the duration of apnea with normal subjects and found BCHE gene 
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mutations, the K-variant being the most frequent. The duration of succinylcholine action and 
consequently duration of apnea were prolonged (5-15 min) in 11 patients compared with 
controls (3-5.3 min). Consequently, they recommended neuromuscular monitoring during 
the first ECT. 
Malignant hyperthermia
Malignant hyperthermia (MH) is a hypermetabolic response to succinylcholine and potent 
volatile anesthetic gases such as halothane, isoflurane, sevoflurane and desflurane. 
Succinylcholine, the main applied muscle relaxant in ECT, is a far more powerful trigger of 
MH than the volatile agents. 22-24 Experimental studies indicate that the mechanism underlying 
MH is an uncontrolled release of intracellular calcium from skeletal muscle sarcoplasmic 
reticulum (SR).  MH is inherited primarily in an autosomal dominant fashion in humans, which 
might result in the MH prevalence of up to 1: 3000 due to the causal genetic mutation. A more 
complex inheritance pattern might also be observed in the affected individuals. 25 
Approximately 50% of MH related genetic variants have been found in the RYR1 gene on 
chromosome 19, a calcium channel located in the sarcoplasmic reticulum. Most cases 
(70%) carry one of 30 RYR1 mutations. Linkage studies have implicated five other regions, 
with variants identified in calcium channels CACNA2D1 and CACNA1S. While these 
regions account for genetic variants in less than 2% of cases, the causal genetic variant in 
approximately 30% of patients remains unknown. 26, 27 Genetic tests may offer a non-invasive 
diagnostic method with lower morbidity than in vitro muscle contracture tests as the current 
functional gold standard for MH diagnosis; however, genetic testing is unreliable because 
the spectrum of contributing loci and alleles is not yet fully understood. 
The reported incidence of MH during ECT has been less than other procedures requiring 
general anesthesia. It seems more likely that other factors may be responsible for this 
observation. Gornert indicated that MH is triggered in proportion to the total dose of triggering 
agents. 28 Thus, even if MH is triggered by succinylcholine during ECT, the absence of 
continued administration of succinylcholine may abort its more fulminant expression. Indeed, 
the anesthetics used in ECT are almost always ultra-short or short acting barbiturates such 
as methohexital or propofol. Absence of the use of volatile anesthetics in ECT also may 
explain the lack of induction of MH. As was previously stated potent volatile anesthetics that 
are commonly employed in general anesthesia are also strongly linked to precipitation of 
MH. 29
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Neuroleptic malignant syndrome  
NMS is a serious and potentially fatal side effect of antipsychotics, consisting of fever, 
muscle rigidity, delirium and autonomic dysfunction. Underlying mechanism of this side 
effect is still unknown and debated. So far some risk factors have been identified, with 
clinical observations and recent pharmacogenetic research suggesting, though with 
inconsistent findings, correlation between genetic mechanisms and predisposition to NMS. 30 
Polymorphisms of CYP2D6 enzyme through which most psychotropic drugs are metabolized 
and TaqIA DRD2, a target for antipsychotic drugs, has been reported to act as the link 
between pharmacogenetic factors and the potential development of NMS. 30 In spite of 
these genetic links, ECT has been reported to be useful for refractory NMS or improving 
NMS symptoms. 31, 32 Further investigation in an appropriately designed study is warranted 
to investigate the treatment role of ECT in NMS and identify the subset of patients with NMS 
who might benefit from this procedure.
II. Potential neurobiological mechanisms in cognitive side effects of ECT
There are some animal and human preliminary evidences on the role of neurotransmitters/
biological alterations with the adverse cognitive effect of ECT. 33, 34 The investigated systematic 
alterations include cholinergic, endogenous opioid, glucocorticoid and glutaminergic 
systems, which were mostly conducted in animal models. 34-37 Among these, the effects of 
glutaminergic and glucocorticoid compounds have been investigated in human studies. In 
an ECT trial of 10 subjects, using ketamine as anesthetics resulted in less impairment of 
short-term memory than applying etomidate 37. The result is suggestive that the ECT-induced 
cognitive disruption might be mediated by glutamate at N-methyl-d-aspartate receptors. 
Neylan et al. 38, in a two-week ECT-trial of 16 subjects, showed that elevated basal level 
cortisol was associated with greater degree of ECT-induced cognitive impairment. 
Palmio et al., in two separate studies, investigated the acute effect of ECT on the perturbations 
in the amino acid transmitters and the brain biomarkers in blood with potential role in neuronal 
activity and neuronal injury. In TRD-MDD patients who underwent a single ECT session, they 
showed significant changes in the serum levels of glutamate, aspartate, gamma-aminobutyric 
acid (GABA), S-100b protein (S-100b), tryptophan, and some other amino acids in 24 hours. 
39, 40 However, it is important that future studies are designed to better distinguish changes 
in the levels of these biomarkers related to both ECT side effects on brain and therapeutic 
response.
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Pharmacogenetics and the efficacy of ECT
The effect of adjunctive psychotropic drugs on ECT outcome
The current remission rates after ECT appear to have declined. 8, 41 In a meta-analysis to 
investigate the effect of previous pharmacotherapy failure on the efficacy of ECT, the overall 
remission rate was reported to be 48.0% (281 of 585) and 64.9% (242 of 373) for patients 
with and without previous pharmacotherapy failure, respectively. Additionally, patients who 
received previous pharmacotherapy but failed to respond to the treatment, showed reduced 
efficacy of ECT. 42 ECT has shown higher efficacy in conjunction with antidepressants and 
antipsychotics. 43 Accordingly, the understanding of pharmacogenetics of the adjunctive 
drug therapy and more comprehensively pharmacogenomics of such treatments has the 
potential to improve therapeutic outcomes of ECT and individualized drug therapy, while 
avoiding toxic effects and treatment failure. Genetic predictors of antipsychotics have been 
widely studied 44, but fewer evidences are available how these factors might influence their 
role in the outcome ECT.
Some studies provide evidence that the application of the N-methyl-D-aspartate (NMDA) 
receptor antagonist ketamine (0.5 mg/kg) could provide rapid and longer antidepressant 
effects after ECT. 45-50 These studies have suggested the involvement of synaptic plasticity 
and neurotrophic signaling in the mechanism of action of ketamine. The observation of 
mammalian target of rapamycin (mTOR) and Brain-Derived Neurotrophic Factor (BDNF) 
pathway activation by NMDA receptor antagonism has proposed the observed link for the 
antidepressant action of ketamine through the interaction between plasticity-related signally 
pathway. 51
Using ketamine (0.5 mg/kg) been promising in depressive patients prior to ECT. 52, 53 Some 
evidences that ketamine might reduce the effect of ECT on memory has drawn more attentions 
to application of ketamine for ECT. 37  The optimal adjunctive dose range of ketamine, its 
safety and effective duration of action should be further investigated. 
The association between carrier status for the long allele of serotonin transporter gene with 
a better response to serotonin selective reuptake inhibitors (SSRIs) has been of interest. 
Solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 (SLC6A4) 
encodes the serotonin transporter and is located on location 17q11.1–q12. Rasmussen et al. 
retrospectively studied whether the polymorphism of the serotonin transporter gene (5-HTT) 
was associated with differential treatment response in 83 ECT patients treated for depressive 
disorder. 12 No significant association was found between serotonin transporter gene allelic 
status with several characteristics of ECT treatment, such as seizure length or threshold, 
number of treatments in a series, and depression scale ratings. 
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Potential pharmacogenomics (neurobiological mechanisms) in the efficacy of 
ECT
I. Brain Alterations in Acute and chronic ECT response 
As was previously stated, for many non-responsive patients to psychotropic drugs, ECT is 
an efficient rapid intervention. However, the neurobiological mechanisms for the efficacy of 
ECT remain unknown. 
While some of the therapeutic response to ECT is shortly observed after treatment, similar 
to psychotropic drugs, efficacy of ECT increases by repeating treatment. This fact has 
made neurotransmitters and metabolic enzymes of greater interest for investigation of ECT 
response. ECT affects wide range of brain areas, 54, 55 which the potential therapeutic 
effects on these regions may be through structural, and/or biochemical changes.  
Several neurotransmitters have been investigated involvement in association with psychotic 
disorders. Yatham et al. 56 suggested the role of serotonin (5-hydroxytryptamine, 5-HT) 
dysfunction. Using positron emission tomography (PET) study in patients with bipolar 
disorders, they showed antidepressants down regulate 5-HT2 receptors in several cortical 
regions. In a follow-up study in patients who treated with ECT due to refractory response 
to antidepressants, they showed similar effect by ECT in down-regulation of brain 
5-HT2 receptors in the limbic and prefrontal cortical brain areas. 57  Similarly in another study 
by Lanzenberger et al., PET scan showed substantial reduction of 5-HT1A receptor-binding 
potential (BPND) almost across the entire cortex after one ECT, particularly in amygdala and 
anterior cingulate cortex. 58 However in another study, after several ECT, BPND did not 
show consistent result with the former study. 59 
Dopamine neurotransmitter has also been of interest in understanding the refractoriness of 
response to treatment in depressive disorder. Saijo et al. scanned seven MDD patients’ brain 
after 6-7 ECTs using PET to examine the effect treatment on Dopamine D2 receptors. They 
found significant increase in D2 receptors of anterior cingulate of patients who received ECT. 
60 Although these studies shows regulatory role of serotonergic and dopaminergic pathways 
in biological mechanisms involved in response to ECT, it is yet to be discovered how ECT 
cause this alterations.
A few studies on depressive disorders have explored the hypothesis of altered connectivity 
within the white matter (WM) microstructures between the frontal and limbic areas, 61-63 such 
that WM abnormalities relate to depression severity and TRD. 64-67 Accordingly, Lyden et al. 
demonstrated ECT effect on structural plasticity within dorsal fronto-limbic pathways and 
plasticity of WM relation to therapeutic response in depression. 67 It is unknown if there is 
any genetic predisposition to these structural alteration, and future investigation is hence 
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warranted.
II. Potential genes involved in ECT response and the related biological pathways
In 1998, Fochtmann et al. showed that both hippocampal A1-receptor, and cortical and 
striatal NMDA-receptor bindings are associated with the quality of seizure (i.e. duration). 
2Their study suggested that induced ECT-neurobiological mechanisms potentially related to 
some genes, might contribute to the desired therapeutic effect of ECT. 
While genetic pathway alterations by ECT and their association with clinical parameters 
could provide pivotal information, few studies have examined the genetic approaches to 
neurobiology of ECT and the impact of pharmacogenomics on treatment response in ECT 
(Table 1). 68-74 These studies have shown that chronic molecular effects induced by ECT are 
more likely to reveal the mechanisms of its therapeutic effects. 
A. Gene expression signatures 
Studies have suggested that the therapeutic effects of ECT might be due to mechanisms 
involving several amino acid transmitter changes in brain through overexpression of 
their regulatory genes. Altar et al. investigated the effects of single versus repeated 
electroconvulsive seizure (ECS) exposure on gene transcription, in an animal model, to identify 
genes and potential biochemical pathways that are associated with the efficacy of chronic 
ECT. 55 Almost one hundred and twenty hippocampal and frontal genes were differentially 
expressed within distinct pathways (particularly BDNF-MAP kinase) in response to acute 
and chronic ECS. Of those, only nineteen genes showed similar expression in response to 
acute or chronic ECS. Brain-Derived Neurotrophic Factor (BDNF), cyclooxygenase (COX)-2, 
neuronal activity-regulated pentraxin (Narp), and TGFβ-inducible early growth response had 
co-directional changes in both brain regions. They suggested that the genes that increase 
only with chronic ECS are more likely to be associated with efficacy of ECT, including those 
of the BDNF-TRKB-MAP kinase pathway, arachidonic acid pathway, vascular endothelial 
growth factor (VEGF), thyrotropin-releasing hormone (TRH), neuropeptide Y (NPY), and 
regulators of neurogenesis. 55
To address the therapeutic efficacy of ECS, Newton and colleagues examined the expression 
of neutrophins and related signaling pathways in the hippocampus of rats in response to ECS 
using a custom growth factor microarray chip. They reported the regulation of several genes 
that are involved in growth factor and angiogenic-endothelial signaling, including neuritin, 
stem cell factor, VEGF, (VGF), COX-2, and tissue inhibitor of matrix metalloproteinase-1 (TIMP-
1). 75 Some of these, as well as other identified growth factors, including VEGF, fibroblast 
growth factor, and BNDF, have effects on brain neurogenesis and cell proliferation. They also 
examined gene expression in the choroid plexus and found several enriched growth factors 
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in this vascular tissue, which were affected by ECS. Among the identified genes, TIMP-1 and 
COX-2 were highly expressed in both acute and chronic ECS. The authors suggested that 
the simultaneous augmented growth factor signaling with angiogenic process could have an 
important role in the mechanism underlying the therapeutic effect of ECT. 
B. Single gene approach: expression or polymorphism based 
In this approach a prior knowledge or presuppositions on a gene which directly or in directly 
may play a role in neurobiological mechanisms involved in efficacy of ECT response was 
used for investigation. 
DARPP-32
DARPP-32 protein (dopamine- and cyclic-AMP-regulated phosphoprotein of molecular 
weight 32,000) has been of interest due to its phosphorylation regulation by dopamine and 
cAMP in nerve, which might mediate some dopamine effects. 76 DARPP-32 gene down-
regulation has also been implicated in schizopherenic patients. 77 Accordingly, Rosa et al. 
showed that DARPP-32 expressions in striatum and hippocampus of rats increased after five 
ECSs in 48 hours.  However, the effect was fluctuant and transient. 78 
COMT and APOE
Catechol-O-methyltransferase (COMT), a major enzyme in dopamine metabolism in the 
prefrontal cortex has been of interest in response to efficacy of ECT.  Anttila et al. showed 
that COMT high-high genotype carriers would be more common in responders to ECT 
than other genotype carriers. 72 A finding that suggested the lower dopamine levels in the 
prefrontal cortex could be associated with substantially better treatment effects of ECT. 
COMT Val158Met, a functional polymorphism of COMT at codon 158 substantially affected 
the dopaminergic activity such that the Met allele homozygosity resulted in considerable 
reduction of enzymatic activity compared with the Val allele homozygosity. 72 
Domschke et al., in further investigation on val158met COMT, proposed that the impact 
of the SNP on the efficacy of ECT in depressive patients could be gender-specific. They 
also suggested that the val158met carrier might be less pharmacologically responsive to 
antidepressant and could benefit from ECT in their earlier stage of mood disorder. 79
DRD2 and mutual effect with COMT
Huuhka et al. investigated the synergistic effect of two polymorphisms of Dopamine 2 
receptor gene (DRD2) and COMT, C957T (rs6277) and Val158Met (rs4680) in response 
to ECT treatment. The study groups consisted of 118 depressive patients and 383 healthy 
controls. 13 They showed that had MT Met allele and DRD2 T allele had synergistic effect in 
prediction of severity of depression. Furthermore, they found that the patients with TT
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genotype of DRD2 C957T SNP and Met/Met genotype of COMT were less likely to reach 
remission than those with CC genotype of DRD2 C957T and Val/Val genotype of COMT. 
Accordingly, they suggested the combined effect of these polymorphisms might be 
associated with response to ECT. 13 
APOE and RGS4
Huuhka et al. also examined the apolipoprotein E (APOE) well known for its association 
with neurodegenerative diseases as well as RGS4 in prediction of TRD-MDD and found no 
association between APOE and RGS4 polymorphism and response to ECT. 69, 71 This finding 
was, however, not consistent with the only previous study on the association of APOE and 
ECT responders. 68 
DRD3 (DR3)
To follow up on the role of dopamine D receptor gene in efficacy of ECT and evaluate the 
potential impact of dopamine D receptor gene (DRD3) variation on ECT outcome in treatment-
resistant major depression, Dannlowski and colleagues used 10 genetic markers with high 
coverage percentage on DRD3 to investigate the association with response to ECT in 104 
treatment-resistant MDD white patients. They found significant association of rs3732790, 
rs3773679 variants of DRD3 with response to ECT (p=0.02 and 0.03, respectively) and 
rs9817063 SNP with remission (p=0.01) after ECT. They suggested that DRD3 gene variation 
might affect the efficacy of ECT that might potentially be mediated through neurobiological 
pathways of striatal activity. 80
Potential role of pharmacogenetics in patients indicated for ECT
Safety of procedure Efficacy of procedure
Anesthesia adverse events 
CACNA2D1 and CACNA1S, BCHE 
genotype, CYP2D6 and RYR1 
Peri-ECT
NMDA receptor activation  and 
induced pathway
Acute molecular effects of ECT 
(glutamate, aspartate, GABA, 
tryptophan production pathways) 
Prediction of the genotype-
phenotype distinction of patients 
undergoing ECT (CYP2D6 and 
CYP2C19, COMT, DRD2, DRD3)
Post-ECT
Chronic molecular effects of ECT 
(BDNF ,VEGF, NTRK2, CREB-
activated genes, DARPP32) 
Figure 1. Various implications of pharmacogenetics in safety and efficacy of ECT




BDNF is a member of the nerve growth factor family of neurotrophins.  BDNF has been 
shown to exert important functions in neuronal survival, proliferation, and synaptic plasticity 
in the brain. 81-84  There are several biological evidences to support the role of BDNF as a 
central neurotrophic factor in the efficacy of ECT.  These evidences have shown the inductive 
effects of both single and repeated ECT on BDNF secretion in brain that are reflective of 
BDNF changes in serum. 55, 74 Similarly, BDNF levels are shown to decrease in individuals 
with depression and increase following antidepressants; the changes that correlates with the 
severity of the disorder. 55, 85 Accordingly, it has been suggested that BDNF may at least in 
part explain both the acute and chronic potent effects of ECT in depressive disorders. 74, 86
The neurobiological mechanisms of action in ECT have been proposed to be involvement 
in, the induction of BDNF secretion by prolonged increase of both BDNF and TRKB (NTRK2) 
mRNA expression in the hippocampus and entorhinal cortex (EC). 87 However, Taliaz et al. 
suggested that while neuroplastic alterations, as expressed by changes in BDNF expression 
within different brain regions, might be induced by ECT, the antidepressant-like effect of 
ECT in an animal model depends on reduction of the ventral tegmental area (VTA) BDNF 
expression but not on the elevation of hippocampal BDNF expression. 88
In an animal experiment, Segawa and colleagues tried to explain the role BDNF and pro-BDNF 
in acute and chronic ECT treatment. They found that single administration of ECS rapidly 
increased hippocampal levels of pro-BDNF along with levels of prohormone convertase 1 
(PC1) and tissue-plasminogen activator (t-PA). These two proteases are involved in intra- and 
extracellular pro-BDNF processing. 89 Further ECSs resulted increase hippocampal level of 
pro-BDNF as well as mature BDNF level. Taken together, they suggested that while PC1 and 
t-PA could both be involved in pro-BDNF processing connected with acute antidepressant 
effect of ECT, t-PA might play a dominant role following repeated ECS. 89 In their model, 
chronic administration of imipramine significantly increased mature BDNF levels, but not 
pro-BDNF and protease levels, indicating that the therapeutic mechanism of antidepressants 
might differ from that of ECT.
Clinical studies support some of the obtained evidences by pre-clinical studies on BDNF. 
The significant increase in serum levels of BDNF has been detected in patients undergoing 
chronic ECTs. 74 A possible mechanism for this observation has been proposed to be due to 
BDNF gene upregulation mediated by histone H3 and H4 acetylation 90, though in pre-clinical 
setting.  Viikki and colleagues, in a recent study of 119 depressive patients, investigated 
the association between BDNF polymorphism rs11030101 and the efficacy of ECT. Their 
study demonstrated that the TA genotype carriers of rs11030101 were less likely to show 
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improvement in Montgomery-Åsberg Depression Rating Scale (MADRS) and benefit from 
ECT compared with patients with the TT genotype. 91
VEGF, P2RX7 and HTR2A
Viikki et al. also examined the association between the VEGF 2578 C/A polymorphism and 
ECT in of 119 patients with TRD who were treated with ECT and 98 depressive patients 
treated with SSRIs compared to healthy controls. According to their findings, the CC 
genotype of VEGF 2578C/A polymorphism was more common in patients treated with ECT 
and SSRI than in healthy controls (31.1%, 25.5% and 18.7% respectively; p=0.056). The 
VEGF 2578 C/A polymorphism was associated with treatment resistant depression and CC 
genotype was more frequent in patients underwent ECT than in controls (31.1% and 18.7% 
respectively; p=0.015). 92 In the same study groups, they investigated the rs2230912 and 
rs2230912 P2RX7 polymorphisms. Neither of these two P2RX7 SNP was associated with 
either remission after SSRI or ECT. 93 In the same study populations, they investigated the 
improvement of depression using MADRS score after ECT in association with rs7997012 
and rs6311 HTR2A polymorphisms. None of the SNPs were associated with the change in 
MADRS score due to treatment.  However, the interaction between the SNPs and gender 
explained 14% of the variance in MADRS score change. 94
CREB
Fizzled 6 (FZ6) is a seven transmembrane-spanning receptor involved in Wnt signaling. This 
signaling pathway is one of the essential mechanisms in cell proliferation, polarity and fate 
determination during embryonic development and tissue homeostasis. 95, 96 The main signaling 
pathway is activated by FZ/β-catenin, FZ/Ca+2 and FZ/planar cell polarity signaling pathways 
97 and inhibited by Dickkopf (Dkk) family members (e.g. Dkk1 which functions as secreted 
Wnt antagonists by inhibiting Wnt coreceptors LRP5/6). 98 Voleti et al. demonstrated that 
chronic administration of ECS augments the activity of several hippocampal genes through 
the cAMP-response element binding (CREB) such that subsequent effects might lead to the 
effectiveness of chronic ECT. FZ6 was also one of CREB-target genes, which was affected 
by chronic ECS. In their study, viral vector-mediated inhibition of Fzd6 produced anxiety and 
depressive-like effects. 99 Accordingly, the authors suggested that the activation of CREB 
might have regulatory effect on multiple functional pathways such that the therapeutic effect 
of ECS is dependent on a particular set of CREB-activated genes. 99
ACE
The angiotensin I-converting enzyme gene (ACE) has been suggested as a major gene 
affecting affective disorders and their treatment. To compare the effects of the ACE genotype 
distributions and treatment response to ECT in MDD patients, Stewart et al. studied 119 
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treatment-resistant depressive patients who were referred for ECT. All participants were 
genotyped for ACE, and the efficacy of ECT was evaluated using the MADRS. ACE genotype 
was not associated ECT efficacy and did not show a different frequency with healthy controls. 
100
Discussion and future perspective
Our review demonstrates that the knowledge for safe application of ECT treatment of major 
depression and other psychiatric disorders has been improved, at least partly due to the role 
of pharmacogenetics in application of anesthetic agents. Some genes such as CACNA2D1 
and CACNA1S, BCHE and RYR1 are associated with safe practice of anesthesia in ECT. 
While our review demonstrates that at this point, the knowledge of the mechanisms underlying 
the efficacy of ECT has not been thoroughly elucidated, we identified several genes (i.e. 
BDNF, COMT, DDR2, DDR3, CREB, VEGF, COX-2, TRKB and NMDA receptor), which their 
transcriptions might play important role in treatment response to ECT. It is important to identify 
the neural and the molecular pathways related to these that might explain the mediation of 
the behavioral changes by ECT and its timely application.  
An ideal shock treatment produces two sets of acute and chronic neurobiological responses 
that result in a rapid and sustained treatment response for treatment of psychological disorders. 
Accordingly, Altar et al.’s experiment showed that the neurobiological mechanisms during 
ECT substantially differ by chronicity. More importantly they showed that a subset of genes 
would continue to be similarly   expressed in some brain regions by both acute and chronic 
ECT. This fact could be suggestive that efficacy of ECT could be due to some common 
regulatory pathways modulated by the therapeutic stimulus. Investigating the potential brain 
regulatory network pathways among the abstracted genes (BDNF, COMT, DDR2, DDR3, 
CREB, VEGF, COX-2 and TRKB), we identified that all genes or their transmitters are co-
expressed as part of transcriptionally regulatory sub-networks in brain, more prominently in 
the frontal lobe (Figure 2 & 3).  In these sub-regulatory networks, AP-1 transcription including 
CREB demonstrates the most regulatory effects on the network objects. This takes on greater 
significance that effectiveness of ECT is more dependent on treatment response to its 
chronic application. Consistently, Hope et al. 101 showed AP-1 complex had high expression 
by administration of chronic ECT and persisted to be highly expressed by 7 days after the 
last ECT. It has been shown that AP-1 modulation affects many cell processes including 
cell proliferation, differentiation, transformation, neuronal activity and growth factor signaling. 
102, 103 More importantly, it has been suggested that AP-1 could act as an environmental 
biosensor in mediating the linked cellular biological process. 102
There are other factors that might affect the variations in expression levels in brain regions 
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Figure 2. The demonstration of regulatory pathways among BDNF, COMT, DDR2, DDR3, CREB TRKB, and NMDA 
receptor in human brain. AP-1 complex shows the most regulatory effect on the genes of interest. Green arrows 
demonstrate activation and red arrows deactivation. 
Figure 3. The demonstration of regulatory pathways among AP-1 complex, Cox2, and VEGF in human brain.
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and directionality of regional regulatory networks.  For example, there is evidence of 
variations in activity level of BDNF transcripts in different brain regions 88, 104 or other patients’ 
clinical characteristics such as gender might influence some observed gene polymorphisms 
in response to treatment. 94
In spite of all the improved knowledge on the safety of ECT and its proved efficacy in 
treatment of some psychiatric patients unresponsive to medical therapy, ECT is still a physical 
intervention and more cumbersome than medications with higher efficacy.  Accordingly, our 
understanding the acute and chronic molecular, cellular, and behavioral changes by ECT 
will provide a new view to find potential targets for novel psychotropic treatments, particularly 
antidepressants, that are highlighted by the findings such as regional gene induction (e.g. 
BNDF, Cox-2), increased neurogenesis, electrophysiological reactivity, the role of VEGF in 
neurogenesis, 105, 106 and DARPP-32 expression. 78 Some genes and associated pathways 
such as BDNF, TRKB-MAP kinase pathway, NPY, VEGF, arachidonic acid pathway, TRH, 
VEGF, and neurogenesis regulation pathways, which have shown differential expressions 
due to chronic stimulation by ECT, are more probable to have an intermediary role in 
benefiting from the long-term effects of ECT. These evidences along with shared regulatory 
pathways such as AP-1 and CREB could be useful for further investigation to identify novel 
gene targets for treating treatment resistant psychological disease. 
Palfreyman et al. suggest illustrating a “disease signature” and “drug signature” of aberrantly 
expressed genes from comparison of normal controls and patients. 107 In this approach, 
the genes associated with disease will be explored. The comparison of the soptted genes 
with ECT signature genes could identify a set of targets whose alteration might be a better 
predictor of disease and the effect of procedural treatment. Ultimately, such overlapping 
genes could be used to identify drug compounds that show similarity in inducing the gene 
expressions, which consequently mimic the therapeutic response of ECT. This method has 
been applied in animal mode such that 108 several compounds have been investigated to 
identify the one that alter the same eleven genes elevated by ECT or exercise in rat brain. 
Of note, exercise has been favorably compared to antidepressant treatment for treatment of 
mild to moderate depression. 108-110  Such compounds could also be used to augment the 
induced differentially genes expressions by chronic exposure to ECT or by antipsychotics. 55 
Further well-designed longitudinal clinical studies are required to increase our knowledge of 
the mechanisms underlying the efficacy of ECT.  
Pharmacogenetics in ECT and adjunctive medicationsChapter 5102 |
Executive summary
Pharmacogenetics and safety of ECT 
I. Anesthesia adverse events
Abnormalities in butyrylcholinesterase
• BCHE deficiency could result in a prolonged effect of the ultra-short acting depolarizing 
succinylcholine, the muscle relaxant of choice ECT, due to markedly decrease in plasma 
cholinesterase activity. 
• Succinylcholine duration of action is prolonged for the patient with heterozygous for the 
K-variant allele, the most frequent variant.
Malignant hyperthermia
• Approximately 50% of MH related genetic variants have been found in the RYR1 gene 
on chromosome 19. 
• Most cases (70%) harbor one of 30 RYR1 mutations.
• CACNA2D1 and CACNA1S variants account for less than 2% of cases and the causal 
genetic variant in approximately 30% of patients is unknown. 
• The reported incidence of MH during ECT has been less than other procedures requiring 
general anesthesia.
Neuroleptic malignant syndrome 
• CYP2D6 polymorphism, the enzyme through which most psychotropic drugs are 
metabolized and TaqIA DRD2, a target for antipsychotic drugs, has been suggested the 
link between pharmacogenetic factors and the potential development of NMS. 
• In spite of these genetic links, reliable NMS during ECT has been reported.
II. Potential neurobiological mechanisms in cognitive side effects of ECT 
• ECT-induced cognitive disruption might be mediated by glutamate at N-methyl-d-
aspartate receptors.
- Using Ketamine as anesthetics during ECT might result in less impairment  of short-
term memory
• Higher basal level of cortisol might be associated with greater degree of ECT-induced 
cognitive impairment.
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• Acute effect of ECT causes perturbations of several amino acid transmitters and the 
brain biomarkers in blood with might be associated with neuronal activity or potential 
neuronal injury.
Pharmacogenetics and the efficacy of ECT
The effect of adjunctive psychotropic drugs on ECT outcome
• The current remission rates after ECT appear to have declined
- The overall remission rate has been reported to be 48.0% and 64.9% patients with and 
without previous pharmacotherapy failure, respectively.
• ECT has shown higher efficacy in conjunction with antidepressants and antipsychotics
• Application of the N-methyl-D-aspartate (NMDA) receptor antagonist ketamine during 
ECT might augment rapid and longer antidepressant effect of ECT.
- NMDA receptor antagonism could activate mammalian target of rapamycin (mTOR) 
and Brain-Derived Neurotrophic Factor (BDNF) pathways.
Potential pharmacogenomics/neurobiological mechanisms in the efficacy of ECT
I. Brain Alterations in Acute and chronic ECT response 
• ECT affects wide range of brain areas.
• Therapeutic effects on brain regions may be through structural, and/or biochemical 
changes
• ECT could have similar effect like antidepressants in down-regulation of brain 
5-HT2 receptors in the limbic and prefrontal cortical brain areas.
• ECT could augment the increase in Dopamine D2 receptors in some brain areas in 
patients who received ECT.
• ECT might effect on structural plasticity within dorsal fronto-limbic pathways and 
plasticity of WM relation to therapeutic response in depression
II. Potential genes involved in ECT response and the related biological pathways
A. Gene expression signatures 
• Therapeutic effects of ECT might be due to mechanisms involving several amino acid 
transmitter changes in brain through overexpression of their regulatory genes.
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• There are some similarities in ECT induced regional alterations, e.g. hippocampus and 
frontal lobe 
• Several genes such as VEGF, VGF, COX-2 and TIMP-1 involved in growth factor and 
angiogenic-endothelial signaling could be co-expressed by both acute and chronic 
ECT. 
B. Single gene approach: expression or polymorphism based 
• Several individual genes have been investigated in association with ECT efficacy. 
• ECT could transiently increase DARPP-32 expressions in striatum and hippocampus. 
• The combined effect of COMT and DRD2 polymorphisms might be associated with 
response to ECT. COMT high-high genotype carriers would be more common in 
responders to ECT than other genotype carriers.
• DR3 rs3732790, rs3773679 SNPs are associated with remission after ECT. 
• Both single and repeated ECTs increase BDNF secretions in mRNA expression, mostly 
in the hippocampus and entorhinal cortex.
-The BDNF change in brain is reflective of changes in serum
- PC1 and t-PA could both be involved in BDNF expression processing connected with 
acute antidepressant effect of ECT; t-PA might play a dominant role following repeated 
ECS
- TA genotype carriers of rs11030101 was shown to be less likely to show improvement 
in Montgomery-Åsberg Depression Rating Scale (MADRS) and benefit from ECT 
compared  with patients with the TT genotype
• VEGF 2578 CC genotype was observed with more frequent in patients underwent ECT. 
• CREB might have regulatory effect on multiple functional pathways such that the 
therapeutic effect of ECS is dependent on a particular set of CREB-activated genes. 
Discussion and future perspective
• BDNF, COMT, DDR2, DDR3, CREB, VEGF, COX-2, TRKB and NMDA receptor are genes 
that their functions could affect the efficacy of ECT.
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• The potential genes involved in efficacy of the ECT or their transmitters are co-expressed 
as part of transcriptionally regulatory sub-networks.
• In these sub-regulatory networks, AP-1 transcription including CREB could be a major 
regulator of the network objects.
• AP-1 complex has shown high expression by administration of chronic ECT and persists 
to be highly expressed by 7 days after the last ECT.
• The shared regulatory pathways such as AP-1 and CREB could be useful for further 
investigation to identify novel gene targets for treating treatment resistant psychological 
disease. 
• Investigating ECT signature genes as compared to different drug compounds could 
help in identifying medications that might augment the induced differentially gene 
expression by ECT.
• Further well-designed longitudinal clinical studies are required to increase our knowledge 
of the mechanisms underlying the efficacy of ECT
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ABSTRACT
Introduction 
Major depressive disorder (MDD) and bipolar disorder (BD) are common mental disorders. 
According to present guidelines, the effective antidepressant for treatment of MDD and 
BD for each individual patient is identified through trial and error switching in sequential 
treatments. A substantial proportion of depressive patients do not benefit from treatment due 
to ineffectiveness of medication therapy or incurring serious side effects. CYP2D6 variants 
are associated with metabolic profile of antidepressant and have been investigated as a 
determinant contributor in treatment resistant depression (TRD). Hereby, we investigate 
the accumulation of aberrant CYP2D6 genotypes and predicted metabolizer phenotypes 
(UM, IM, and PM) potentially affecting the antidepressants treatment response in depressive 
patients indicated for electroconvulsive therapy (ECT) compared to patients with single 
episode of depression. 
Method
84 Dutch Caucasian subjects with unipolar or bipolar treatment resistance depression who 
underwent ECT were genotyped using Amplichip® CYP450 Genotyping Test for CYP2D6 
and its metabolizer phenotypes. 208 genotyped patients with single episode of unipolar or 
bipolar depression were used as controls to examine differences in prevalence of CYP2D6 
phenotypes. 
Result 
The mean age of ECT cases and subjects with single episode of depression was 62 ± 14 
[range: 27-87, F/M: 46/29] and 49 ± 19 [range: 15-91, F/M: 91/117], respectively. Prevalence 
of CYP2D6 phenotypes (PM, IM, EM and UM) was “5.3%, 38.7%, 56% and 0.0%”for ECT 
patients, and “6.4%, 51%, 42.6% and 0.0%” for depressive patients. The type of depression 
and age (P=0.018 [OR=0.33] and 0.001 [OR=1.05], but not CYP2D6 phenotype were 
associated with the response to treatment. 
Conclusion
The frequencies of genotype-predicted-phenotypes, potentially affecting the treatment 
response (UM, IM and PM), did not show increased frequency in patients who received 
ECT for continuation of depression treatment as compared to patients with single episode 
of depression. Preemptive genotyping for CYP2D6 currently appears to have no clinical 
implications in treatment resistance depressive patients undergoing ECT. Further large-
scale prospective clinical trials are warranted. 




Mood disorders, including major depressive disorder (MDD) and bipolar disorder (BD), are 
common mental disorders and amongst the leading causes of disability worldwide. Currently 
depression is estimated to affect 350 million people 1 and according to the World Health 
Organization (WHO) MDD is the eleventh highest cause of disability-adjusted life years 
(DALYs) worldwide. 2
While options for treatment include psychotherapy, pharmacotherapy and electroconvulsive 
therapy (ECT), in both moderate and severe MDD, as well as in BD, antidepressant agents 
are part of the mainstay of treatment in MDD and can be given in the form of single or 
multiple antidepressants. Patients diagnosed with BD suffer from recurrent depressions 
and manic episodes. Between episodes, many patients have a low mood characterized 
as ‘sub-threshold depression’. In BD, mood stabilizers e.g. lithium are the first choice of 
treatment, and in the case of a bipolar depression, antidepressants may be added to the 
mood stabilizer. Numerous studies in MDD patients show comparable response rates across 
different classes of antidepressants 3. Generally, in patients with insufficient response to 
a certain antidepressant, the drug dosage can be increased, augmenting drugs can be 
prescribed or a switch to another antidepressant can be made after an adequate (duration 
and dosage) trial. 4-6 When multiple treatment steps are required, lower acute remission rates 
and higher relapse rates during the follow-up phase are to be expected 5, 7. In spite of the 
availability of multiple pharmacologic classes of medications and their sequenced trials 
using available guidelines for depression treatment, 50% of patients with major depressive 
disorder (MDD) fail to achieve complete remission. 8  ECT, as a non-pharmacological 
intervention, has been shown a favorable option in such cases of treatment resistant unipolar 
and bipolar depression 9-12 and could be an effective and relatively safe antidepressant 
treatment. ECT may, particularly, be a life saving treatment in the case of severe depression 
with psychotic or catatonic features. However, the level of pharmacoresistance that has to be 
reached until ECT may be applied is not clear. Although ECT is generally only administered 
after several medication trials have failed due to the invasiveness of the treatment including 
hospital admission, repetitive narcoses and possible side effects like cognitive disorders, 
guidelines indicate that ECT is always an option in severe MDD and bipolar depression. 13 
Therefore, the indication for ECT is usually a clinical decision, and ECT patients in general 
reflect the severe range of the depression spectrum. 14 
Treatment related factors, including noncompliance and inadequate antidepressant use 
(duration and dosage), are determinants of treatment failure. 15 Though therapeutic drug 
monitoring for antidepressants is commonly available it is not always routinely applied. Any 
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plasma concentration of antidepressants below or above the therapeutic range may lead 
to ineffectiveness or side effects respectively, which in turn could result in poor response 
to treatment or noncompliance, in both MDD and BD. Consequently, adverse effects are 
common reasons for switching antidepressants, leading to more medication trials and a 
sense of medication “resistance.” Genetic factors are important determinants in the variation 
of treatment response in depression disorders as well contributing to its etiology, course and 
prognosis 16. The enzyme cytochrome P450 2D6 (CYP2D6) plays an important role in the 
pharmacokinetics of many antidepressants. The CYP2D6 gene is extremely polymorphic, 
with over 100 alleles known, explaining part of the observed wide range of variability in 
CYP2D6 catalytic activity among individuals 15 and consequently prominent contributor 
to interindividual drug response. 17-20 The CYP2D6 genotype can be used to predict the 
phenotype of the enzyme, and four distinct phenotypes with increasing metabolic capacity are 
distinguished: poor metabolizer (PM), intermediate metabolizer (IM), extensive metabolizer 
(EM) and ultrarapid metabolizer (UM). 
An evident relation between the phenotypes of the CYP2D6 enzyme and the observed 
blood concentration of several antidepressants exists. 12 Determining an individual’s 
CYP2D6 phenotype, or metabolic status, will help identify those that are likely to benefit 
from modifications to pharmacotherapy. 17 This will improve the patient’s experience and 
compliance with medications, which could decrease the number of trials needed to achieve 
remission and avoiding treatment resistance. Additionally the CYP2D6 polymorphism 
may become more important as the use of different medications in patients with multiple 
comorbidities, particularly in the elders, might increase the risk for drug–drug interactions. 
The purpose of our study is to investigate the prevalence of CYP2D6 phenotypes in depressive 
patients who were indicated for ECT treatment as a rapid acting treatment and compared 
to patients with single episode of depression. Accordingly, we hypothesize that there is 
an accumulation of aberrant CYP2D6 genotypes and consequent CYP2D6 metabolizer 
phenotype(s) in patients undergoing ECT. Furthermore, we would like to investigate if the 
patients’ characteristics such as age and gender might affect of the acquired association of 
phenotypes with patient who underwent ECT. 
METHODS
Study protocol was exempt from obtaining approval by institutional review board of Leiden 
University Medical Centre due to the retrospective character of the study and the fact that 
all ECT patients had been routinely genotyped for CYP2D6 as part of the local ECT protocol. 




84 Dutch Caucasian subjects with unipolar or bipolar depression that received ECT for 
treatment of depression in the Department of Psychiatry at the Leiden University Medical 
Centre (LUMC) from July 2009 to June 2014 were included in the study. All the cases had at 
least one adequate trial of a major class of antidepressant, sensitive to genetic polymorphism 
of CYP2D6, at their current episode of depression and time of ECT trials.  In addition, ECT 
cases had a history of concomitant therapy with several other antidepressants in their current 
or prior episodes and sequenced treatment trials, which satisfied the current unstandardized 
criteria for treatment resistant depression (TRD). 15, 21-27 Patients with bipolar disorder were 
also receiving a mood stabilizer such as lithium. The exclusion criteria were receiving non-
CYP2D6-dependent antidepressants, not having reliable medical record on the current 
medication usage or meeting the inclusion criteria for being on adequate dosage/duration 
of antidepressants. Indications for ECT were failure of response to treatment (mostly due 
to treatment resistance depression or intolerability of treatment adverse effects) in unipolar 
and bipolar depressive patients for severe depression with psychotic features. All the 
medications and medical information of patients were collected from the psychiatric and 
medical histories available on CS-EZIS, the electronic patient record file system of LUMC 
comprised of multiple functional modules for clinicians and researchers.
For the control group, depressive patients (unipolar and bipolar) from mental health clinic 
GGZ Centraal, Amersfoort, the Netherlands were used. Using electronic patient record files 
from January 2006 to June 2014, 480 patients with a history of depressive episodes were 
identified and 208 subjects who had a single episode of unipolar or bipolar depression 
treated with antidepressants and without history of depression recurrence were screened 
as the control group. 
Genotyping, Phenotype and activity score 
Amplichip® CYP450 Genotyping Test (Roche Diagnostic GmBH, D-68298 Mannheim, 
Germany) approved by the U.S. Food and Drug Administration (FDA) was used to detect 
the most common variant alleles of the CYP2D6 gene in the ECT patients. The Amplichip 
performs genotyping of two Cytochrome P450 genes and provides the predictive phenotype 
of the associated enzymatic activities, using DNA purified from human blood. The assay 
distinguishes 29 known polymorphisms in the CYP2D6 gene, including gene duplication 
and gene deletion. Detection of these CYP2D6 polymorphisms results in the identification 
of 33 unique alleles, including seven CYP2D6 gene duplication alleles. Control patients 
were genotyped for CYP2D6 *3, *4, *5, *6, *9, *10, *41 and gene multiplication as described 
previously. 28 Subjects were classified, according to their expected phenotype, into four 
groups of poor (PM), intermediate (IM), extensive (EM) and ultrarapid (UM) metabolizers 
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as follows: patients with two null alleles (*3, *4, *5, *6) were classified as PM, patients with a 
null allele in combination with a deficient (*9, *10, *41) or a functional allele (defined by the 
absence of any of the determined mutations), or with two deficient alleles were classified as 
IM, and patients with a gene duplication (xN) in absence of any of the determined mutations 
were classified as UM. Patients for whom no phenotype could be predicted, due to unknown 
identity of the allele multiplied, were classified as “unknown”. We also used CYP2D6 activity 
score system corresponding to each CYP2D6 metabolizer categorizations. 17 
Adequate antidepressant therapy and treatment response assessment
In patients with unipolar MDD who underwent ECT for their current episode of depression, 
an antidepressant trial lasting at least 4 weeks at an optimal dose of the prescribed 
antidepressant (at least as high as the lowest dose defined as effective in the package insert) 
for the current or the most recent episode of depression was considered as an adequate 
treatment for inclusion in the study. 22-25 For bipolar depression, similar criteria of treatment-
resistance  were used with the provision that failure to respond to antidepressant(s) was 
along with at least one adequate mood stabilizer in the current depressive episode. 29
Patients’ clinical courses (severity of depressive episodes) and response failure to treatment 
were validated by the Montgomery-Åsberg Depression Rating Scale (MADRS) 30 prior to 
ECT trials. The cut-off score of more than 10 was considered as treatment ineffectiveness, 
indicating patients who were not in remission under current antidepressant trial. 13, 31
Statistical analysis
Data are presented as Mean ± SD [range]. All the calculations were performed using “SPSS 
Statistics for Windows, Version 20.0 (Armonk, NY: IBM Corp., USA, IBM Corp. 2010.  
A chi-square test of independence was performed to examine the relation between CYP2D6 
phenotypes with patients who indicated for ECT (cases) and patients with single depressive 
episode (controls). Binary regression, was applied to test if the result of the association of 
CYP2D6 phenotypes with patient groups would be affected by the adjustment of variables of 
age, sex and unipolar vs. bipolar depression. 
RESULTS
After exclusion of eight ECT patients due to exclusion criteria, a total of 76 ECT candidate 
patients meeting the DSM-IV criteria for a unipolar or bipolar depressive episode disorder 
who met the inclusion criteria were assessed. Patients with bipolar disorder had adequate 
mood stabilizer for their current depressive episode resulting in ECT trials as well as an 
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optimal dose and an adequate antidepressant treatment. The mean age of ECT cases and 
subjects with single episode of depression were 62 ±14) [27-87, F/M: 46/29] and 49 ±19 [15-
91, F/M: 91/117], respectively (Table 1).
Table 1. Patients’ clinical characteristics and CYP2D6 phenotype distribution and activity score. 
Age, Mean (SD) [range] 62 (14)[27-87] 49 (19) [15-91]
Sex (F/M)a 46/29 91/117
Unipolar/bipolar depression 64/12 196/12


























aF: female, M: male; bPM: poor metabolizer, IM: intermediate metabolizer, EM: extensive 
metabolizer, UM: ultrarapid metabolizer
Prevalence of CYP2D6 phenotypes and activity score
The prevalence of CYP2D6 phenotypes (PM, IM, EM and UM) was “5.3%, 38.7%, 56% 
and 0.0%” and “6.4%, 51%, 42.6% and 0.0%”for ECT patients and depressive patients 
respectively. The relation between patients groups and CYP2D6 phenotypes (UM excluded 
due to frequency of 0.0%) were not significant  (c2 [df=2, N = 282] = 3.99, P =0.136). Median 
of CYP2D6 activity scores in ECT patients vs. patients with single episode of depression was 
1.5 and 1, respectively.
Adjustment of the association of CYP2D6 phenotype for patients’ characteristics 
A logistic regression analysis was conducted to investigate the association of covariates 
(type of depression [unipolar vs. bipolar], age, sex, CYP2D6 phenotype and activity score) 
with cases that were indicated for the continuation of their treatment using ECT. 
A test of the full model against a constant only model was statistically significant, indicating 
that some covariates included, conditioned on others, were associated with patient groups 
(chi square= 39.12, P<0.001 with df=4). The Wald criterion demonstrated that the type of 
depression and age (P=0.018 and P= 0.001, respectively), but not the CYP2D6 phenotype 
(PM/EM, P=0.29), were associated with receiving ECT. Sex and activity score neither 
were significant contributor to the outcome of treatment (P=0.57 and P=0.174). Odds ratio 
(OR) values of age and unipolar depression were 1.05, 0.33, respectively (Table 2). After 
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adjustment for age, gender, and type of depression, CYP2D6 phenotype IM compared to EM 
was associated with patients who were treated with ECT (OR=0.53, P=0.03).
Table 2. Adjusted frequencies of CYP2D6 phenotypes and activity score by type of depression (unipolar 
vs. bipolar), age and sex. a
Age 1.05 1.03-1.06 25.1 <0.001*
Unipolar/bipolar depression 0.33 0.13-0.83 5.6 0.018*















Low (0-0.5)/High (1-2) 0.55 0.21-1.12 1.87 0.17
aF: female, M: male; bPM: poor metabolizer, IM: intermediate metabolizer, EM: extensive metabolizer)
Table 3. Frequencies of CYP2D6 alleles and the predicted CYP2D6 phenotypes in patients indicated for 
ECT due to antidepressant treatment failure.
*4/*4Xn 0 PM 1
*1/*1 2.0 EM 14
*1/*2 2.0 EM 9
*1/*9 1.5 EM 5
*1/*35 1.5 EM 4
*1/*41 1.5 EM 7
*2/*41 1.5 EM 4
*1/*3 1.0 IM 1
*1/*4 1.0 IM 10
*1/*5 1.0 IM 3
*2/*3 1.0 IM 1
*2/*4 1.0 IM 3
*2/*5 1.0 IM 1
*2/*9 1.0 IM 1
*4/*35 1.0 IM 3
*5/*35 1.0 IM 1
*5/*41 1.0 IM 1
*6/*41 1.0 IM 1
*9/*41 1.0 IM 2
*4/*9 0.5 IM 1
*3/*5 0 PM 1
*4/*4 0 PM 2




This study investigated the frequency of the recognized CYP2D6 phenotypes among patients 
who had single episode of depression or indicated for ECT due to non-response to treatment 
for unipolar or bipolar depression or adverse effects to antidepressants. Frequency of UM, 
IM and PM CYP2D6 phenotypes were not associated with failure of antidepressant treatment 
response, i.e. patients who underwent ECT for their continuation of treatment. In another 
study, Haber et al.’s demonstrated that Hungarian patients with difficult-to-treat depression 
(N=55) did not exhibit an increased frequency of aberrant CYP2D6 phenotypes 32 compared 
to the healthy subjects’ CYP2D6 phenotypes. In our study, the observed allele frequency of 
UM was 0.0% as opposed to the previously reported frequency of 0.01 in Dutch population 
(prevalence of 4.5%). 33 Prevalence of CYP2D6 PMs has been estimated to be 5.5%-9% 34-36 
in healthy Dutch volunteers. Consistent with these estimations, the prevalence of PMs in ECT 
patients and patients with single episode of depression were 5.3% and 6.4%, respectively. 
The frequencies of IMs in both ECT patients and those with single episode disorders of 
depression were higher than healthy subjects, 36 such that, after adjustment for other factors, 
the odds of patients with depression eventually treated by ECT was lower, if they had CYP2D6 
IM phenotypes. 
Several studies 37 have demonstrated that poor CYP2D6 metabolizers have a higher incidence 
of adverse effects when taking CYP2D6-dependent antidepressants and more risk of TRD. 38-
42 Laika et al 43 reported that intermediate CYP2D6 metabolizer status on therapeutic outcome 
in 365 psychiatric in-patients treated with neuroleptics or antidepressants was associated 
with delay onset of response to treatment and increased length of hospitalization for patients 
receiving CYP2D6-dependent drugs. They also reported that patients with CYP2D6 IM 
phenotypes receiving CYP2D6-dependent drug doses above the population median had 
more side effects after 4 weeks than extensive metabolizers. However, an almost equal 
number of studies did not find significant evidence to support previously mentioned studies 
on the effect of IMs and PMs over EMs related to occurrence of nonresponse in psychiatric 
patients treated with antidepressants. 44-48 
Similarly, several studies have reported an association between ultra-rapid CYP2D6 
metabolizer status and diminished response to antidepressants, 41, 49, 50 but no association 
was shown in a larger retrospective study. 51 Of note, most these studies are in different 
population witch represent different allele frequencies of CYP2D6 phenotype. 33 Despite 
of the equivocal evidences, the current recommendations for standard doses gives 
consideration for extreme phenotypes of PMs and UMs. It has been suggested that standard 
drug dose may not result in therapeutic plasma levels for UMs and may increase the risk 
of an adverse drug reaction and consequent therapeutic failure in PMs. 33, 41, 52-54 Therefore, 
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it is proposed that lack of response in EMs (and UMs) could be overcome with the dose 
escalation of antidepressants, while a compound switch might be more promising in PMs to 
avoid unresponsiveness to treatment or drug adverse effects. 55 As such, prior knowledge 
of CYP2D6 metabolizer phenotypes and therapeutic monitoring might reduce the risk of 
non-responsiveness to the CYP2D6-dependent antidepressants 56 and indication of ECT, 
at least at earlier stages of treatment of depression. Nevertheless, a routine application of 
CYP2D6 genotyping prior to treatment is under debate and our study is not conclusive for 
such recommendation.
This study further sought to identify possible effect of age, gender and type of depression 
in prediction of response treatment. While some studies have shown a better response to 
antidepressants (particularly to SSRIs) among women 57, 58, our data is consistent with Parker 
and et al.’s finding that women did not show a preferential response to SSRI medication 
59. The failure of gender to be associated with the depression recurrence has also been
investigated in larger, epidemiological samples and a multicenter trial. 60, 61 Future studies 
should consider investigation in potential differences of metabolic ratio among CYP2D6 
phenotypes between women and men 35 in response to antidepressants. 
The influence of age of onset on outcome in antidepressant trials is controversial 62. Our 
data shows that patients who indicated for applying ECT for the treatment of resistant 
and recurrent depression were older than patients with single episode of depression. In a 
long-term randomized clinical trial study by Frank et al. 63, no such association was found. 
However, previous observations showed that both early onset of depression (<40 years old) 
and late onset (>50 years old) are associated with a higher risk of depression recurrence. 
These conflicting results might be explained by the fact that late-onset data have been 
obtained in clinical populations 64, 65, as compared to early onset of depression and higher 
risk of recurrence in a nonclinical population 66. Giles and colleagues showed that only age 
at onset was significant in predicting a recurrent episode. 67 Lewinsohn and colleagues 68 
also demonstrated that a later age of first episode of depression was associated to faster 
recurrence. 
Additionally, our data suggests that patients with bipolar depression might have higher risk of 
receiving ECT as treatment for bipolar depression than those with unipolar depression (odds 
ratio of 3.0). Relevantly, Ghaemi and colleagues 69 studied the outcomes of antidepressant 
trials for 41 patients with bipolar depression and 37 with unipolar depression matched by 
age and sex distribution. They found short-term nonresponse was more frequent in bipolar 
(51.3%) than unipolar (31.6%) depression. Furthermore Forty et al. 70 compared some clinical 
features of depression including course of recurrences in a large sample of in a large sample 
of individuals with major depressive disorder (N=593) and bipolar disorder (N=443). They 
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found the number of depressive episodes was higher in patients with bipolar depression 
(P=0.006). 
Considering the controversial results of the previously performed studies in how much 
of variability in response to treatment and its outcome might be related to other clinical 
characteristics of patients or how these factors might affect the metabolizing capacity of 
antipsychotic drugs, further investigation is required to delineate the relative importance of 
these confounded variables when predicting the response to treatment of depression. 
Our results were drawn from a relatively small set of patients included in a retrospective 
case-control study and consequently should be interpreted with consideration for the 
limitations of the study and its design. The major issue for this study and similar ones is the 
sample size. The frequencies of UMs and PMs might be altogether 10-20% of population. 
Our study was powered to capture a potential medium effect size of 0.2 in at least one of 
the CYP2D6 phenotypes (N=282, df=3, effect size=0.2 at α=0.05 and β=0.20); however, it is 
probable that the effect size of the association of CYP2D6 phenotypes of poor and ultrarapid 
metabolizers is small and less than 0.2. Accordingly, a large sample size (N≈1000 for df=2 or 
3, effect size of 0.1 at α=0.05 and β=0.20) is required to capture substantial number of these 
CYP2D6 phenotypes and their effect size of interest for clinical studies. In addition, most 
patients had undergone repeated treatment trials with different medications, which might 
have caused a heterogeneous sample. This will cause more loss of power for such clinical 
trials with relatively small to medium sample size. 
The unipolar and bipolar depressive patients in our study groups (ECT cases and patients 
with single episode of depression) represent extreme clinical outcomes (phenotypes) 
of depression regardless of type of depression; i.e. one group who had received several 
prior treatments and eventually indicated for ECT and the other with only a single episode 
of depression. It has been recommended that distinction between unipolar and bipolar 
depression would help in initial and optimal management. 70, 71 However, according to 
some biological evidences, it has been suggested that it might be more useful to consider 
conceptualizing bipolar and unipolar depression as the same illness with the presentation 
of its clinical features in continuum, particularly when it applies to depressive episodes. 30, 72 
In conclusion, no increase in prevalence of genotype-predicted-phenotypes was observed 
among patients who received ECT for continuation of depression treatment as compared to 
patients with single episode of depression. Therefore, preemptive genotyping for CYP2D6 
currently appears to have no clinical implications in depressed patients undergoing ECT. 
Further large-scale prospective clinical trials are warranted.
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ABSTRACT
Rifampin is commonly used in the treatment of tuberculosis and  staphylococcal infections, 
as well as for prevention of infection in cardiac valve and bone surgeries. We report a case 
of profound hypotension after anesthesia induction with propofol in a patient who was treated 
with two 600 mg doses of rifampin for prohylaxis of infection prior to surgery. In a retrospective 
case-control study of 75 patients we confirmed this potentially serious drug-drug interaction, 
showing a significant and prolonged blood pressure reduction after anesthesia induction in 
patients receiving the two agents.




Rifampin is a synthetic derivative of rifamycin B that inhibits bacterial RNA polymerase by 
forming a stable drug-enzyme complex. 1 It remains one of the most effective antimicrobials 
used in the treatment of tuberculosis 2, but it is also used to treat methicillin-resistant as well 
as methicillin-sensitive staphylococcal infections 3, or for prevention of infection in cardiac 
valve and bone surgeries. 4-6  Here, we report a case of profound hypotension after anesthesia 
induction with propofol in a patient who was treated with rifampin. We examined for this 
potentially important drug interaction with a retrospective case-control study of 75 patients.
Case Report
A 64 year old female (weight 88 kg, height 163 cm and BMI=33) presented to our institution 
for an elective posterior decompression of a herniated disk at the L5-S1 level.  She had 
a past medical history significant for lumbar stenosis, symptomatic gastro-esophageal 
reflux disease, hyperlipidemia, osteoporosis, and panic attacks. Her medications were 
atorvastatin (10 mg/day), esomeprazole (40 mg/day), and naproxen (1000 mg/day). She 
also took acetaminophen plus hydrocodone (5-325 mg) as needed for pain, and occasional 
multivitamins. The neurosurgical team prescribed rifampin 600 mg p.o. to be given the night 
before and 2 hours prior to surgery as prophylaxis for infection. The patient had no known 
allergies and described herself as physically active.  She had a stress test performed three 
years previously which showed normal exercise tolerance and no evidence of myocardial 
ischemia. The patient remained NPO for 7 hours after midnight, but she had normal intake 
of food and fluids before that. She was anxious and the pre-induction heart rate was 102 
beats/minute, and BP was 150/90 mmHg. She received 2 mg of midazolam and 150 mcg 
of fentanyl (1.88 mcg/kg), intravenously.  This moderately large premedication caused a 
decrease in anxiety but minimal respiratory and hemodynamic effects. At 7 minutes after 
fentanyl administration, rapid sequence induction was conducted using 200 mg of propofol 
(2.3 mg/kg) and 100 mg of succinylcholine (1.1 mg/kg), and a 7.0 mm endotracheal tube 
was inserted without difficulty. Three minutes after induction of anesthesia and prior to 
placing the patient in the prone position, her blood pressure decreased to 60/30 mmHg, 
and heart rate increased to 112 beats/minute. There was no wheezing or difficulty ventilating 
and no changes in skin color suggestive of an allergic reaction.  Rapid intravenous infusion 
of normal saline was initiated (800 ml/20 min) in addition to phenylephrine continous 
infusion (10 mcg/min) with incremental bolus doses, as needed.  Ten mg of ephedrine 
(two 5 mg doses) and 80 mcg phenylephrine bolus were administered. Despite continued 
infusion of fluid, phenylephrine and ephedrine, her sytolic blood pressure remained 60-70 
mmHg (> 40 mmHg reduction from baseline), although all central and peripheral pulses 
were palpable. Epinephrine was added in 0.04 mg bolus doses in addition to 80 mcg 
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doses of phenylephrine.  After administering two doses of epinephrine (0.08 mg) and three 
more doses of  phenylephrine (240 mcg),  the patient’s blood pressure finally improved to 
92/53 mmHg. (figure 1) Serial EKGs showed no signs of ischemia or dysrhythmia during 
the hypotensive period or afterwards. She remained stable without additional epinephrine, 
although  phenylephrine infusion was required to maintain systolic blood pressure within 
70% of her baseline (90-100 mmHg).  After some discussion, it was decided to proceed with 
the surgery with addition of normal saline infusion (1 L/hr) to her continuous phenylephrine 
infusion.  Approximately 35 minutes after induction, the patient was turned prone without 
hypotension, and surgery was completed without incident.  The patient emerged from 
anesthesia and was extubated without problems. Her postoperative period was uneventful 
and  she was discharged to her home on postoperative day 3 with a satisfactory outcome.
Retrospective data
Rifampin is not frequently administered for infection prophylaxis, but it had been used 
this way for several years by members of our neurosurgical division (MGH) doing spinal 
surgery.  There had been anecdotal descriptions of similar hypotensive episodes by the 
neuroanesthesiologists in our department, and a connection with rifampin had been raised 
as a possibility. After the present dramatic episode occurred, we felt it was important to 



































































































































































   
















































Figure 1.  Blood pressure, heart rate and oxygen saturation curves in the reported patient; including 
administered vasoperessors and fluids in treatment of profound induced hypotension after induction. 
SBP-NI= systolic blood pressure-noninvasive, DBP-NI=diastolic blood pressure-noninvasive
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After institutional review board approval, we reviewed 194 anesthesia records and medical 
charts of patients who had undergone spine surgery under general anesthesia between 
2008 and 2010 in our institution. We randomly selected 25 patients for each of three groups 
that were matched for type of surgery and surgeon:  
1. Patients receiving propofol for induction of anesthesia and preoperative rifampin
prophylaxis, (experimental group).
2. Patients receiving propofol for induction but no rifampin pre-treatment (propofol control).
3. Patients receiving thiopental for induction and preoperative rifampin (thiopental control).
Our prospective power analysis indicated that group sizes of 25 would have 90% power to 
detect a 10 mmHg difference in MAP reduction at a significance level of 0.05 (two-sided 
comparison), assuming a standard deviation of 10 mmHg. 7, 8 The prophylactic dose of 
rifampin was uniformly 600 mg p.o., the night before and on the morning of surgery (usually 
about 2 hours before) in both the propofol and thiopental groups. Patient characteristics 
(sex, age, height, weight, ASA physical status classification, Charlson Comorbidity Index 
(CCI), 9 first and total dose of intravenous anesthetics, total doses of vasopressors, fentanyl 
dose  and volume of administered fluids were recorded. Baseline (time of induction)  and 
post-induction values of systolic, diastolic and mean blood pressure were obtained from the 
electronic anesthesia record system. 
Differences between the groups in sex, age, weight, ASA, and CCI were examined by 
ANOVA for continuous variables and Kruskal–Wallis ANOVA for quantal variables.  Mean 
blood pressure responses were compared by two-way ANOVA for repeated measures. 
Our dependent variable, change in MAP, was normally distributed for the three groups as 
assessed by the Shapiro-Wilk test. There was homogeneity of variance between groups as 
assessed by Levene’s test for equality of error variances. The change in MAP with time was 
analyzed for each of the study groups using a general linear univariate model to account for 
the impact of age, type and dose of anesthetic agent, fentanyl dose prior to induction, ASA 
status, CCI, presence of diabetes and hypertension, weight, location of surgery (cervical vs. 
lumbar), vasopressor doses and amount of fluid administered. 
The significant covariates (duration of hypotension, fluid amount, anesthetic agent, 
presence or absence of rifampin) were examined in a general linear multivariate model. 
In the multivariate analysis, anesthetic agent was an independent predictor of hypotension 
(p<0.001). 
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The induction dose of propofol did not differ between the groups. Patients’ baseline 
characteristics (Table 1) did not significantly influence nadir MAP. We did not find any 
association between preexisting hypertension and hypotensive events using chi square 
and binary logistic regression (p=0.564). Patients receiving rifampin and propofol had a 
significantly greater reduction in their MAP and duration of hypotension than propofol alone 
or thiopental with rifampin (Table 2) despite the fact that they received lower doses of 
fentanyl for induction (250 ± 65 mcg) (Table 1). A post hoc test (Tukey’s Honestly Significant 
Difference [HSD]) also showed a significant difference in nadir MAP (p=0.004) and reduction 
of MAP (p<0.001) in patients with rifampin and propofol vs. propofol alone or thiopental-
rifampin.  The dose of phenylephrine was not normally distributed, and the Kruskal-Wallis 
ANOVA showed a significantly greater dose of phenylephrine in the propofol-rifampin group 
vs. our control groups (p=0.039, Table 2).
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DISCUSSION
This case report and the retrospective data analysis demonstrated that the risk of a 
prolonged hypotensive episode increased almost three-fold when propofol rather than 
thiopental was used for induction in patients who received rifampin.  In 10 of 25 cases, this 
exaggerated hemodynamic response required vigorous treatment with vasopressors and 
fluids,  i.e., hypotension persisted despite more than 2 L Ringer’s lactate (or normal saline) 
as well as repeated doses of vasopressors. The peak hypotension might actually have been 
underestimated, since these patients did not have continuous measurements with an arterial 
line.
In our retrospective data analysis the duration of fluid abstinence did not differ between 
the groups 10, nor did the dose or type of pre-induction anxiolytic agent (midazolam). The 
induction dose of propofol was similar with or without rifampin, and the fentanyl dose was 
lower in the propofol-rifampin group. However, the hemodynamic response was significantly 
greater in the propofol-rifampin group, suggesting a drug-drug interaction as the cause. 
Hemodynamic instability was not seen when rifampin was given with thiopental, indicating 
that the interaction is unique to propofol.  
The mechanism for this interaction was not investigated.  Intravenous administration of 
rifampin alone can induce hypotension by a direct, dose-dependent reduction of vascular 
tone and SVR, 11 and propofol-induced hypotension is largely due to venodilation. 12  However, 
it is not clear if oral administration of rifampin will do the same and whether any such effect 
would be relevant for propofol administration so many hours after the first and second doses. 
Anaphylactic or anaphylactoid reactions caused by the induction agent 13-15, or rifampin 16 
are unlikely, given the lack of hypotension in the control groups. In no case, did the clinicians 
record urticaria or flushing, bronchospasm, or mucosal edema.  One mechanism that is 
suggested to promote hypotension after propofol administration is related to its direct effect 
on venous smooth muscle tone, presumabley through increased endothelial production and 
release of nitric oxide (NO). 17 Rifampin might augment this effect as a result of increased 
NO production by upregulating iNOS mRNA transcription.18 This increase in NO levels has 
only been demonstrated in vitro, but it does occur within 20 hours after exposure to clinically 
relevant concentrations of rifampin (10 to 100 μg/ml).  The serum concentration of rifampin 
after 2 hours following a single 600-mg oral dose was reported to be 8.8-12 mcg/ml 19-21 and 
in another study 15.9 mcg/ml (4), so the NO mechanism is a plausible explanation with the 
antibiotic concentrations likely present in our case.  The serum concentrations of rifampin in 
the latter study dropped from 15.9 ± 6.5  mcg/ml at 2 hr, to 7.1 ± 4.3 at 8 hr, with 1.6 ± 1.6 
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mcg/ml still detectable at 24 h. (4)  This suggests that sufficient rifampin may be present to 
cause drug-drug interactions for a significant period of time after typical oral dosing.   
Rifampin is commonly used for treatment of tuberculosis and less often for prophylaxis of 
staphylococcal infections and nisseria meningitidis infections.  It is rarely used for routine 
preoperative antimicrobial prophylaxis, which could explain why this interaction with propofol 
may not have been appreciated previously. Clinicians should be aware of this potentially 
dangerous interaction and if rifampin is necessary, consider using alternative agents for 
induction of anesthesia. A prospective study is desirable to investigate the mechanism of 
this drug-drug interaction.
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ABSTRACT
Background
Postoperative hemodynamic adverse severe events (PHASE, severe bradycardia and 
hypotension) can occur during recovery from spinal anesthesia. The incidence, contributing 
factors and consequences of PHASE are not well described. 
Methods
232 consecutive patients were included in this prospective observational study. PHASE 
was defined as a combination of heart rate <45 bpm, and systolic blood pressure <70 
mmHg. Correlation analysis was used to identify potential predictors of PHASE and then a 
multivariate logistic regression model was constructed to evaluate independent predictors 
of PHASE. PACU lengths of stay between patients with and without PHASE were compared. 
Results
Fifteen patients presented with severe hypotension (SBP 64.5±10.6 mmHg) and twelve 
patients with severe bradycardia (heart rate of 40±5 bpm), resulting in PHASE in 10 patients. 
PHASE occurred on average 307±82 min after spinal anesthesia with a mean spinal 
anesthesia level of L1 at the time of PHASE. Insertion of spinal anesthesia in the lateral 
position (PHASE: 80%, no PHASE: 34%, p=0.030) and morphine dose (20±12mg versus 9±8 
mg, respectively p=0.011) were found to be independently associated with PHASE.  PHASE 
was associated with a 60-minute increase in median PACU length of stay.
Conclusion
PHASE occurs in about 5% of patients recovering from spinal anesthesia. The average time 
for PHASE onset is 307±82 min. The events are associated with insertion of spinal anesthesia 
in the lateral compared with sitting position, and with postoperative opioid administration. 
PHASE during recovery from spinal anesthesia is associated with significantly increased 
PACU length of stay. 




Hypotension and bradycardia are the most common complications associated with spinal 
anesthesia1, 2, occurring in the intra-operative period due to decreases in systemic vascular 
resistance and central venous pressure from sympathetic block.1  Postoperatively, cases of 
spinal anesthesia associated severe bradycardia have been described to occur up to 5 hours 
after arrival in the Post Anaesthesia Care Unit (PACU).3 To the best of our knowledge, there 
has been limited description of the epidemiology of severe bradycardia and hypotension 
during the recovery from spinal anesthesia. The primary study objectives were to determine 
whether PHASE is associated with increased PACU length of stay.
METHODS
The study was approved by Partners Health Care Institutional Review Board, and conducted 
in the 32-bed PACU of the Massachusetts General Hospital (MGH) in Boston, Massachusetts, 
a teaching hospital that serves as a tertiary care referral center, level-1 trauma center, and 
community hospital for the inner city population of Boston. The PACU staffing model consists 
of an anesthesia resident on site 24 hours a day, a supervising staff intensivist, a respiratory 
therapist and a nurse-staffing ratio of 1 nurse for every two patients.  
Subjects
We included 232 consecutive ASA physical status 1-3 patients undergoing orthopedic lower 
limb surgeries arriving in the PACU after spinal anesthesia. Patients with incomplete data 
sets were excluded from the study and 190 patients with complete data set were included in 
data analysis (Table -1). 
PHASE: A focus group of experienced anesthesiologists and PACU nurses was held to 
develop a definition of severe postoperative hemodynamic events occurring after spinal 
anesthesia. Based on the results of this focus group, PHASE was defined as combination of 
heart rate < 45 bpm, and systolic blood pressure <70 mmHg.
Protocol
Patients were given either 1-2 mg intravenous midazolam as a premedication up to 1 hour 
prior to spinal placement. Patient care was delivered in the usual manner and was not 
altered in any way by the investigator. Board certified staff anesthesiologists supervised all 
anesthetics. In accord with departmental guidelines, all patients were preloaded with 500-
1000 ml of ringers lactate prior to spinal anesthesia, which was followed by slow infusion of 
ringers lactate. Hyperbaric bupivacaine 0.5%, 3.6±1ml (mean and standard deviation) was 
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Gender (male) 49% 47% 42% 40%
Age (years) 67±11 66±8 67 ±7 67±4
Height (inches) 66±7 67±3 68±4 66±4











Cardiovascular risk factors 65% 56% 50% 62%
Beta-blocker taken in the 
morning
32% 6.7% 8.3% 10%
Other anti-hypertensives taken 
in the morning
39% 33% 25% 30%
*ASA physical status classification system
injected into L2-3 or L3-4 interspace with the patient in either sitting or lateral position. Standard 
anesthesia monitoring (electrocardiogram, heart rate, pulse oximetry and oscillometric blood 
pressure) was used continuously throughout the OR portion of care. Immediately after spinal 
placement, patients were positioned horizontally and supine as described in the Clincial 
Prcedures of the Masschusetts General Hospital. 4 Side effects of spinal anesthesia such as 
nausea and vomiting were documented and treated. Patients with blood loss of more than 
20% of blood volume were treated with colloids and RBC transfusions. After surgery, patients 
were transferred to the PACU in the supine position with the head of the bed elevated by 20-
30 degrees. Intravenous morphine or hydromorphone were used to provide postoperative 
analgesia. 
Measurements
Preoperative data collected for patients enrolled in the study were age, weight, height, 
gender and history of medical illness (diabetes mellitus, hypertension, stroke, arrhythmia, 
previous myocardial infarction) and medications use (angiotensin converting enzyme 
inhibitors, adrenergic blockers, calcium antagonists, and diuretics). 
Intraoperative data collected on study patients included blood pressure and heart rate, 
temperature, respiratory rate and oxygen saturation. Severe hypotension was defined as 
systolic blood pressure less than 70 mmHg that required treatment with a vasopressor. 
Severe bradycardia was defined as heart rate <45 beats per minute that required treatment 
with ephedrine or atropine. Total duration of surgery was also recorded.
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On the admission to the PACU, PACU nurses who were not involved in the study documented 
the following data: skin temperature (forehead non-contact infrared thermometry), blood 
pressure, peripheral oxygen saturation, and spread of spinal anesthesia (dermatomal 
level, determined by pin prick). Standard PACU monitoring was then conducted according 
to institutional protocol (blood pressure, heart rate, five-channel EKG, peripheral oxygen 
saturation, Aldrete score). Following admission to the PACU dermatomal level of anesthesia 
was recorded in 15 minutes intervals until full recovery from spinal anesthesia. All patients 
were closely monitored in the PACU for the occurrence of PHASE which was documented 
in the patient’s chart and was treated by the PACU attending physician and/or resident, as 
appropriate. The decision about PACU readiness was made by the PACU nurse and the 
PACU resident. According to Departmental guidelines, patients were considered ready for 
discharge after adequate pain control was achieved, they were cardiopulmonary stable, and 
their sensory residual spinal anesthesia level was below S1. PACU length of stay was defined 
as the time from PACU admission until PACU discharge readiness. PACU length of stay was 
recorded by the PACU charge nurse not involved in this study.
Statistical Analyses  
Sample size estimation for the study was based on the study hypothesis that PHASE 
prolongs the PACU length of stay. We used the reports of Ponhold3 and Butterly 5 to calculate 
the required sample size. Based on the report of Ponhold3, describing post operative 
bradycardia , we expected a PHASE incidence of  five to ten percent. We recently reported 
on the association of postoperative complications and PACU length of stay. 5 Based on 
these data, we estimated that PHASE might be associated with a 60-minute difference in 
PACU length of stay with a standard deviation of 60 minutes. Accordingly, we expected that 
a sample size of 190 patients would provide a 90% power to detect an effect of PHASE on 
PACU length of stay (alpha-error: 5 per cent).
Data analysis was performed using the statistics program SPSS (V 12.0, SPSS Inc., Chicago, 
Ill). Demographic data are presented as mean ± standard deviation for continuous variables 
and as frequencies and percentages for discrete variables. The dichotomous variable 
PHASE defined as a combination of heart rate <45 bpm, and arterial blood pressure <70 
mmHg, was used as the primary endpoint. The Mann-Whitney U test was used to compare 
the PACU length of stay in patients with and without PHASE.  
The study objectives were to:  determine whether PHASE is associated with increased PACU 
length of stay. Before start of the study we performed a comprehensive literature review. 
We also held focus group with experienced anesthesiologists and PACU nurses to discuss 
potential causes of PHASE. A priori, we identified three categories of variables potentially 
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associated with PHASE: 1) patient associated factors including basic demographics, 
comorbidities, and ASA physical status 2) intraoperative factors, 3) effects of treatment in 
the PACU.   
Chi square analysis was used to examine the association between PHASE and categorical 
variables while the t and Mann-Whitney U tests were used to compare normally and non-
normally distributed continuous variables respectively between the PHASE and non-PHASE 
groups. Variables that we considered a-priori to be potential preoperative, intraoperative 
and postoperative predictors of PHASE included: gender, age, height, weight, preoperative 
heart rate, preoperative systolic blood pressure, preoperative diastolic blood pressure, 
preoperative EKG abnormality, preoperative conduction disorder, preoperative use of beta 
blocker, use of other antihypertensives, patient in lateral position during spinal bupivacaine 
injection, bupivacaine dose, negative fluid balance, use of vasopressors in OR, use of 
ephedrine in OR, use of intravenous opioids in OR, episode of bradycardia in OR, PACU heart 
rate, PACU blood pressure systolic, thoracic level of spinal anesthesia at PACU admission, 
use of IV narcotics in PACU, long-acting opioid dose (morphine equivalents – assumption: 
one milligram of hydromorphone is equal to 6 mg of morphine), and IV administration of 
antiemetics in the PACU.
Backward stepwise multiple regression analysis was then used to investigate independent 
factors with a significant association to PHASE within a multivariate model. Variables with 
the strongest significant contribution (p <0.05) were regarded as the independent factors 




Initial blood pressure was significantly higher in patients with severe hypotension when 
compared to patients with no events (table 2).  A significantly higher proportion of PHASE 
patients compared with patients without hemodynamic events (80% versus 20%, p<0.05) 
received spinal anesthesia in lateral position. There was no significant difference in terms 
of dose of bupivacaine used in spinal anesthesia and relation between the occurrence of 
intraoperative bradycardia and hypotension with that of severe bradycardia and hypotension 
postoperatively. 
Postoperative course
Variables measured in the PACU are presented in Table 3.
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Heart rate prior to 
induction (bpm)
74±11 71±11 66±11* 69±13
Systolic blood 
pressure prior to 
induction (mmHg)
137±19 130± 21 144± 9 149±16* 
Diastolic blood 
pressure prior to 
induction (mmHg)














17.5±4.5mg 18 ±1.5mg 18.5± 2.5mg 18.5±1.5mg 
Intraoperative 
vasopressor 
73% 67% 50% 50% 
Intraoperative 
bradycardia
0 0 8.3% 0 
Intraoperative 
antiemetics 
37% 46% 25% 30% 
Intraoperative 
opioids 
73% 80% 83% 80% 
* P<0.05 vs. patients without PHASE 










68±13 65±12 60±10* 62±9.6
Systolic blood pressure 
at admission
119±18 100±26* 110±31 103±29*
Cranial spread of spinal 










IV Narcotics in PACU 80% 87% 100% 100%
Morphine equivalent 
dose  (mg)
9±8 mg 18±12 mg* 19±12 mg* 20±12mg* 
PACU length of stay 210±108 360± 270* 312±312* 350±318*
Time from spinal 
placement to event 
304±94. 300±79 307±82
Heart rate (during 
event)
50.22±18.55 40±5 41±5 
Systolic blood pressure 
during event
64.5±10.6 69.31±16.27 62±8 





<T12-4 (33%)   
>L1-4 (33%)
L5-S4: 4 (33%)
<T12-3—30%    
>L1-4 (40%)
L5-S4: 3 (30%)
* P<0.05 vs. patients with no events.
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232 consecutive patients were prospectively  assessed 
after spinal anaesthesia
42 patients, excluded 
(incomplete data set)
190 patients, included in final analysis
12 patients with 
sever bradycardia
15 patients with 
sever hypotension
10 patients with sever bradycardia and 
hypotension (primary end-point)
173 patients without significant 
hemodynamic events














































Figure 2. A and B. Incidences and severity of PHASE components
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During the observation period in the PACU, all patients had oxygen saturation >95% without 
oxygen mask. Fifteen patients presented with severe hypotension (SBP 64.5±10.6 mmHg) 
and twelve patients with severe bradycardia (heart rate of 40±5 bpm) (figure 2A). Ten 
patients presented with PHASE, both severe hypotension and bradycardia in the PACU, the 
main endpoint of our study. Accordingly, the incidence of severe adverse hemodynamic 
events was 5.2%. Mean time to occurrence of PHASE was 307±82 min. Median residual level 
of spinal anesthesia at PACU admission was L1, without differences between patients with 
and without PHASE.
In the univariate analysis, the following variables were associated with PHASE: Thoracic level 
of spinal anesthesia at PACU admission (p<0.0001), morphine equivalent dose (p=0.006), 
total intraoperative fluids (p=0.031), preoperative heart rate (p=0.046), intraoperative 
vasopressor treatment (p=0.015), and lateral versus sitting position (p=0.038). 
Multivariate analysis
To identify independent predictors of PHASE, a backward stepwise regression analysis was 
performed, which initially included the variable found to be associated with PHASE in the 
univariate analysis: position during insertion of spinal anesthesia (sitting versus lateral flat), 
preoperative heart rate, intraoperative vasopressors treatment, as well as opioid dose used 
in PACU. Insertion of spinal anesthesia in the lateral position (event group: 80%, no-event 
group: 34%, p=0.030) as well as morphine dose (20±12mg versus 9±8 mg, respectively 


























No PHASE PHASE 
Figure 3. Effects of severe PHASE on PACU length of stay
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event. None of the patients who developed PHASE required cardiopulmonary resuscitation; 
however all were treated with either atropine, and/or ephedrine.
Effects of severe PHASE on PACU length of stay 
PACU length of stay was significantly longer in patients with adverse severe hemodynamic 
events (median 240 min, IQR 75 min) compared with patients with no adverse hemodynamic 
events (180 min, IQR 120, p=0.233;figure 3). 
DISCUSSION
PHASE occurred in 5% of the patients recovering from spinal anesthesia and was associated 
with a prolonged PACU length of stay. The combination of bradycardia and hypotension 
causing hemodynamic instability make PHASE a potential life-threatening event. Identifying 
factors associated with PHASE might help to decrease the incidence.
In our study, the patient’s position during spinal placement, as well as the postoperative 
opioid dose, were independent predictors of PHASE.
Factors contributing to development of hypotension early after spinal anesthesia placement 
have been well documented. 6,7 Acute hemodynamic effects of spinal anesthesia may be 
explained by sympatholysis, resulting in three major hemodynamic effects: decrease in 
venous return (in turn influenced by posture, bleeding and inferior vena cava compression), 
vasodilatation and decreased cardiac output.8
Bradycardia regularly occurs in patients with higher levels of sympathetic block involving the 
cardiac accelerator fibers (T1-T4), but this effect was most likely not relevant in our patients. 
In our patients, the median cranial margin for blockade was L1 and it was substantially lower 
by the time PHASE occurred (lower lumbar level in 70% of our PHASE patients). Therefore, 
even though the uppermost level of spinal anesthesia measured by temperature elevation 
is up to 6 levels higher compared to the upper limit of sensory blockade 9, it is unlikely 
that ongoing blockade of cardiac accelerator fibers that can explain the findings of PHASE 
occurring many hours after placement of spinal anesthesia.  
We speculate that vagal over-activity, potentially due to a combination of visceral stimulation 
and opioid effects might have been contributing. Since abdominal visceral structures, such 
as peritoneum, are innervated by fibers from both limbs of the autonomic nervous system, 
blockade of sympathetic nervous system supply to these organs may result in unopposed 
parasympathetic nervous system activity. When visceral stimulation, e.g., bladder distension, 
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or visceral pain takes place under these circumstances, parasympathetic afferent transmission 
may lead to reflexive vagal efferent effects, unrestrained by sympathetic counterbalancing, 
resulting in bradycardia. 10  
The magnitude of hypotension and bradycardia occurring early after spinal administration of 
local anesthetics should depend on the spread of the sensory block height. In our study, the 
independent predictor was the position in which the spinal anesthesia was inserted, a variable 
that is clearly related to the spread of anesthesia. When using hyperbaric bupivacaine, which 
we did in our study, the onset time to analgesia is shorter in the lateral compared with sitting 
patients, and hypotension occurs more frequently.
Opioid induced bradycardia 11  may also have contributed to PHASE  in part via inhibiting 
the activity of cardiac vagal neurons.12, 13 Furthermore, pre-operative administration of 
opioids has been shown to be an independent risk factor for intraoperative hypotension in 
patients undergoing spinal anesthesia.14 Therefore, we speculate based on our data that the 
combination of residual (lumbar) neuraxial block and opioid effects contributed to PHASE in 
our patients. In our study PHASE was associated with lateral positioning during administration 
of spinal anesthesia was associated with PHASE.  Based on this finding, lateral positioning 
during placement of spinal anesthesia might be avoided especially in patients with other 
identified risk factors for PHASE.    
The 6.3% incidence of bradycardia found in the PACU during recovery from spinal anesthesia 
is similar to the incidence reported by Ponhold and co-workers3 despite slightly different 
definitions Ponhold defined bradycardia as heart rate lower than 50 bpm, whereas we used 
a 45 bpm cut-off point, which we believed to be more clinically meaningful. 
The time of occurrence of PHASE was similar to the report of Ponhold and Vincenzi. These 
authors reported the latest occurrence of severe bradycardia 320 min after admission to 
the PACU. Similarly we observed PHASE 455 min after admission to the PACU. This late 
occurrence of PHASE makes decisions regarding discharge from the PACU very difficult. 
The practice guidelines for postoperative care by the American Society of Anesthesiologist’s 
Task Force on Post Anesthetic Care 15 provide little guidance on the best timing for discharge 
of patient after spinal anesthesia. It states “Patients should be observed until they are no 
longer at increased risk for cardio-respiratory depression. A mandatory minimum stay should 
not be required. Discharge criteria should be designed to minimize the risk of central nervous 
system or cardio-respiratory depression after discharge”. After spinal anesthesia patients are 
often discharged from the PACU after recovery for motor and sensory function. The concept 
of orthostatic stability as discharge criteria was introduced by Alexander et al 16 and later 
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confirmed by Knoerl et al. 17  These authors reported that using orthostatic blood pressure 
testing instead of return of motor sensory function could decrease the PACU length of stay to 
62 min. While we did not perform orthostatic blood pressure testing it is clinically important 
that PHASE occurred on average 300 min after placement of spinal anesthesia even in the 
absence of profound motor block. We conclude based on our data that patients should 
optimally not be discharged from the PACU until full recovery of sensory and motor function 
has been documented. Further studies are required to define and test optimal clinical criteria 
for safe transfer of patients from the PACU.                  
Severe bradycardia and hypotension can become a life threatening events. None of 
our patients developed cardiopulmonary arrest; however all required a combination of 
vasopressors and chronotropic agents. It can be speculated that only the vigilance and early 
intervention of the PACU staff averted more catastrophic outcomes. Based on the results of 
this study, our PACU staff now receives periodic refresher training regarding the occurrence 
and treatment of PHASE in patients’ post-spinal anesthesia.   
PHASE was associated with a significant increase in PACU length of stay. The magnitude 
of the effects of PHASE on PACU length of stay is economically meaningful only under the 
condition that an institution conducts a high volume of spinal anesthesia. 
This was a single center study in an academic tertiary care center, which limits the ability 
to generalize the findings to different settings. The study was designed as a prospective 
observational study, which limits the ability to control variables of the study. The intraoperative 
course including spinal anesthetic was not controlled. It is therefore possible that other 
factors may influence the occurrence of PHASE. Finally the study’s sample size and low 
incidence of PHASE may have limited our ability to identify risk factors for PHASE especially 
their contribution in the multivariate analysis.
CONCLUSION 
In summary, we found that PHASE occurs in 5% of the patients recovering from spinal 
anesthesia, and is associated with a prolonged PACU length of stay. In our patients, the 
patient’s position during spinal insertion, as well as the postoperative opioid dose, was 
independent predictors of PHASE.  Further studies are required to define and test optimal 
clinical criteria for safe transfer of patients after spinal anesthesia.                  
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Electroconvulsive therapy (ECT) is the transcutaneous application of small electrical stimuli to 
the brain to produce generalized seizure for the treatment of selected psychiatric disorders, 
typically. ECT owes its current acceptance to modern anesthesia. Indeed, a cornerstone of 
the periprocedural management of patients receiving ECT is the proper selection and use of 
anesthetic drugs and techniques tailored to mitigate the associated physiological response 
and potential complications, without interfering with its beneficial effects. 1 A combination 
of a short acting induction agent (e.g. propofol), neuromuscular blocking agent (i.e. 
succinylcholine) and hemodynamic monitoring under supervision of anesthesiologist and 
in collaboration with psychiatrists has favorably yielded more safety for this short treatment 
procedure. Furthermore, anesthesia medications applied during ECT could augment the 
response to induced seizure (e.g. the NMDA receptor antagonist ketamine) as well as 
increasing the safety of the procedure.
Safety of ECT increases the efficacy of therapy and provides fulfillment of a series of required 
treatments resulting in longer treatment effect of ECT. Over the decades many efforts have 
been made to reduce the special risks in ECT. As a result, the safety and efficacy of ECT has 
been improved and its indications have been relatively defined to increase the efficiency of 
outcome of therapy.
While there has been considerable improvement in safety features, further investigation have 
been done to promote both the safety and efficacy of the treatment. These investigations 
take on greater significance by considering that some aspects of ECT safety (e.g. memory 
and cognitive effects) could partly be inherent to unknown induced biological mechanisms 
correlating with transmitters involved in the outcome of treatment (efficacy). However, this 
correlation is not the same in all patients suggesting a more prominent role of pharmacogenetics 
in ECT. Neurotransmitters such as dopamine, norepinephrine, and serotonin systems are 
more involved with depression. These neurotransmitter systems along with multitude of 
other neurochemicals such as endorphins, enkephalins and prolactin, GABA, glutamate and 
acetylcholine play role in the behavioral manifestations of other psychiatric illnesses. Yet 
it is unknown which induced neurobiological system(s) by ECT stimulation might be more 
involved with impairment of memory than efficacy treatment response.
Accordingly, in this dissertation we investigated several important aspects of safety and 
efficacy of ECT from looking into the current literature to conducting clinical research studies. 
We attempted to contribute to the existing literature and clinical principals in application of 
ECT and understanding of the role of pharmacogenetics in ECT. 
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Neuromuscular blockers in ECT and optimal seizure activity (safety improves 
efficacy)
Neuromuscular blocking agents (NMBAs) dramatically revolutionized the practice of 
anesthesia during procedural treatments, particularly in ECT. Neuromuscular transmission 
blockade mitigates the tonic-clonic motor activity during ECT sessions and provides an 
effective mean to reduce the physical and psychological trauma associated with uncontrolled 
tetanic muscle contractions. 
Anesthetic drugs and neuromuscular blocking agents (NMBAs) are administered to ensure 
patient comfort and safety, but need also be titrated to provide optimal conditions for the 
induced seizure activity during the treatment, while allowing a rapid recovery upon its 
completion. 2 As an ideal neuromuscular blocker, what is needed is an agent that is rapidly 
acting, non-cumulative, independent of renal or hepatic function for its elimination, easily 
and rapidly reversed and free from side effects. While waiting for new muscle relaxants 
to be developed, we need to opt for optimization of available NMBAs and improvement 
of neuromuscular transmission (NMT) monitoring. In order to optimize the dose of NMBAs, 
important pharmacological characteristics of each agent have to be considered, including 
its potency, speed of onset, duration of action and the muscle-dependent effects. This 
optimization takes on greater significance as it has been shown that the quality and duration 
of the induced seizure by ECT is associated with the efficacy of the procedure. 2
In chapter two of this dissertation we reviewed the current applied neuromuscular blocking 
agents in ECT. We showed that succinylcholine, due to the short onset time and duration of 
action is the first choice for ECT procedure, however, all the currently available NMB agents 
have their own limitations and the quest continues for an ideal drug. There were some points 
to be considered for the application of succinylcholine.  The recommended dose range 
of succinylcholine during ECT had been reported to be 0.5-1.5 mg/kg that is a relatively 
large range of dose and no clinical guideline for the application of succinylcholine during 
ECT was identified. 3-6 Furthermore, there are some clinical indications, which application 
of succinylcholine could be contraindicated or using an alternative is recommended, e.g. 
elderly patients with risk of hyperkalemia and long length of stay in hospital. 7 The individual 
and variability in response to succinylcholine and other NMB agents is also another point of 
consideration. 8, 9  Owing to these factors, and based on the systematic review conducted 
in chapter two, we conclusively suggested seeking an alternative such as rocuronium to 
be applied for ECT in patients with absolute or relative contraindication of succinylcholine 
usage. 10, 11 We also showed that similar to succinylcholine, a wide range of rocuronium doses 
for ECT, i.e. 0.3-0.6 mg/kg has been administered for ECT and no clinical guideline has been 
recommended for rocuronium application in ECT.  Doses beyond 0.4 mg.kg-1, for ECT, have 
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been used in combination with the reversal agent sugammadex, a selective relaxant-binding 
agent (currently not available in the USA) that has also been used to reverse profound 
rocuronium-induced neuromuscular blockade in adult surgical patients.3 Rocuronium and 
succinylcholine had satisfactorily been compared for other clinical indications such as rapid-
sequence induction of anesthesia and the required dose, onset times and clinical duration of 
actions had been defined. 12, 13
In pursuit of our suggestion, we designed a randomized crossover clinical trial (chapter 
three) and investigated the optimal doses of succinylcholine and rocuronium for ECT and 
compare their clinical significance. Consistent with the report from Murali and his colleagues 
14, our acquired data suggest that succinylcholine doses closer to one mg.kg-1 may provide 
acceptable ECT conditions and also highlight the importance to avoid early application of 
ECT after the administration of succinylcholine, i.e. less than 1.4 min even in the absence of 
a twitch response to nerve stimulation. The 1 mg.kg-1 dose is the 90th percentile of optimal 
effective dose equal to 3.5 × ED95 of succinylcholine. Furthermore, in our study an induced 
twitch height suppression of almost null (0-4%) for acceptable motor seizure modification 
are in line with findings by Murali and his colleagues, who recommended a dose of 1.0 
mg.kg-1 and twitch suppression to 0-5% of baseline.14 This dose has also been applied for 
rapid sequence intubation (1 mg.kg-1of succinylcholine, 3.5 × ED95). 15-17 However our study 
suggests longer time to achieve adequate muscle relaxation for ECT is required (60 sec for 
rapid sequence intubation). This observation is also consistent with previous finding by Beale 
and colleagues 18 that the muscle response to ulnar nerve stimulation can be extinguished 
long before cessation of muscle fasciculation. This difference in time to obtain acceptable 
ECT conditions as compared to that for endotracheal intubation may be attributed to a 
difference in sensitivity to succinylcholine in different muscle groups (e.g. oropharynx versus 
extremities), but can also indicate that a deeper neuromuscular blockade is needed for 
acceptable ECT conditions as compared to endotracheal intubation. 
Rocuronium 0.57 mg.kg-1 (≈ 2 × ED95) was the 90th percentile estimated dose to produce 
acceptable level of muscle relaxation. This dose has already shown its efficacy in inducing 
more than > 95% block in almost 98% of subjects.19, 20 The onset time from NMBA injection 
to acceptable ECT conditions is hence approximately 2.3 minutes longer with rocuronium 
as compared to succinylcholine. While we did not identify any difference in major clinical 
characteristics during seizures such as hemodynamic variables or oxygen saturation 
between rocuronium and succinylcholine, the recovery time of recuronium was substantially 
longer than succinylcholine (8 min).  However, rocuronium application showed some other 
qualities not observed by succinylcholine. Consistent with other studies seizure duration 
was longer in patients who received rocuronium as NMB agent. 21 As there is an association 
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between clinical effectiveness of ECT and the duration of induced seizure 22, the American 
Psychiatric Association task force advocates seizure lengths  more than 20 sec for effective 
ECT treatment.23 This recommendation not only underscores the importance of titrating the 
dose of the NMBA to achieve an adequate and optimized neuromuscular blockade, but also 
this quality might be of interest for potential role in the efficacy of ECT in set of treatments (i.e. 
cumulative seizure time). Further clinical investigation is warranted.
In chapter three, we defined the optimal doses of rocuronium and succinylcholine 
and demonstrated that even in absence of this selective reversal agent, in patients with 
contraindications to the use of succinylcholine, 2 the rocuronium-neostigmine combination 
can provide a safe and relatively time-effective alternative to other available non-depolarizing 
NMBAs and reversal agents. Rocuronium is increasingly employed as an alternative to 
succinylcholine for neuromuscular blockade during ECT, primarily in the elderly and patients 
with cardiovascular and neurological comorbidities. On the other hand, ECT is highly effective 
and is increasingly applied in the elderly and those with increased incidence of prolonged 
immobilization, prone to higher risk of hyperkalemia. 3 Nondepolarizing NMBAs do not cause 
hyperkalemia and can be given to these patients and those with susceptibility to malignant 
hyperthermia or contraindications to succinylcholine, but are often avoided because of their 
relatively long duration of action, typically exceeding the ECT time. Our study demonstrated 
that even in absence of selective reversal agents such as sugammadex, in patients with 
contraindications to the use of succinylcholine, 2 the rocuronium-neostigmine combination 
can provide a safe and relatively time-effective alternative to other available non-depolarizing 
NMBAs and reversal agents. 
As compared to rocuronium, succinylcholine showed relatively higher inter-individual 
variability for the applied effective doses that resulted in acceptable neuromuscular blockade 
and controlled ECT induced seizure. This fact reemphasized the role of pharmacogenetics 
in ECT (discussed more in chapter five) and how the variability in expression and activity 
of butyrylcholinesterase enzyme resulting in different observed degradation quality of 
succinylcholine might have caused this observation.  The lower variability in the applied 
rocuronium doses to identify individualized optimal dose might take on greater significance if 
achieving the optimized induced motor activity is required to rapidly maximize the therapeutic 
effect of sequential ECTs, particularly if alternative for succinylcholine is advisable. However 
after initial dose, if increments are required, less predictable and longer recovery time than 
increment of succinylcholine doses should be considered. 24, 25 
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In general, complete paralysis is neither necessary nor desirable since it may be associated 
with prolonged apnea. As previously mentioned, currently, no guideline has been described 
for application of rocuronium during ECT and according to the guidelines of the Nederlandse 
Vereniging voor Psychiatrie (Richtlijnen Nederlandse Vereniging voor Psychiatrie, tweede, 
herziene versie, 2010), succinlycholine 0.5-1 mg/kg is recommended for ECT. This ECT 
guideline also suggests measurement of serum potassium in certain patients i.e. age>60 or 
use of diuretics, digoxin, corticosteroids, laxatives, antihypertensive drugs, decrease renal 
function, hypertension and diabetes, as increased potassium levels are a contra-indication 
for ECT. The guideline does however does not recommend any alternative to succinylcholine, 
if needed.
 In chapter three, we tried to provide some clinical suggestions for clinicians for how to apply 
these two NMB agents. According to our experimental randomized crossover trial for ECT, the 
optimal dose of succinylcholine and rocuronium mostly oscillates by 0.1 mg.kg, up to 0.2 mg/
kg around their optimal effective dose of 50 (OED50-ECT). Therefore we suggest administration 
of OED50 of either of the NMB agents (succinylcholine 0.85 mg.kg-and rocuronium 0.4 
mg.kg-) with dose adjustments based on the quality of the observed motor seizure activity 
for each individual during subsequent treatments. 0.1-0.2 mg.kg-1 increment or decrement 
in the initial dose should be considered if the corresponding motor activity is insufficient or 
excessive, respectively. Due to short duration of action and fastest recovery from induced 
neuromuscular block, succinylcholine is recommended as the first choice with consideration 
of rocuronium as an alternative. Consistently, Bryson et al. recommended the single bolus 
dose of succinylcholine 0.9 mg.kg-1 for ECT, however they observed high variability among 
their subjects the fact that highlights our suggested clinical guideline. 9 To improve the 
perioperative and anesthesia recommendations for ECT provided by the guidelines of 
the Nederlandse Vereniging voor Psychiatrie (Richtlijnen Nederlandse Vereniging voor 
Psychiatrie, tweede, herziene versie, 2010), our data suggest using succinylcholine 0.6-0.8 
mg/kg for those who might have relative risk of hyperkalemia as initial dose and adjustment 
of the dose based on the clinical outcome, i.e. any adverse effect due to hyperkalemia and 
induced level of neuromuscular blockade. For those who have absolute contraindication to 
succinylcholine or if anesthesiologist in care advise so, e.g. elderly at high risk of developing 
hyperkalemia due to immobilization or their medications, we suggest using rocuronium 0.4 
mg/kg as an alternative initial dose with subsequent dose adjustment as needed. We also 
recommended applying neurotransmission monitoring to facilitate inducing the optimal 
seizure activity. Furthermore, quantitative NMT monitoring is highly recommended to evaluate 
adequate level of relaxation and safe recovery of patients undergoing ECT. NMT monitoring 
helps to avoid increased risk of adverse respiratory events and overcome the potential 
inter-individual variability in time to recovery. 3, 26  ECT should be applied after observing 
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stabilized twitch suppression more that 90% or 1.4 or 3 min (succinylcholine and rocuronium, 
respectively) for achieving more than 90% peak effect, if monitoring is not available. In the 
absence of monitoring, clinicians should ensure that patients stay under close observations 
by appropriately trained personnel in using bedside tests such as tongue depressor test 
to assess the adequate recovery of neuromuscular function until complete recovery of the 
neuromuscular transmission. 27 Our study also provided the gourd for a prospective clinical 
trial using the ED50, OED90 and OED95 of succincylcholine and rocuronium to achieve a 
better estimation of EC90 and ED95 of these two neuromuscular blockers for application in 
ECT. 
In the follow-up PK-PD study on the ECT data and in chapter four, we identified similar 
pharmacokinetic-pharmacodynamic parameters (ke0 and Ce50) for succinylcholine during 
ECT as previously investigated. For rocuronium the estimated ke0 is consistent with others’ 
finding, while we identified higher Ce50 at adductor pollicis that might justify the faster 
observed recovery from rocuronium induced NMB in this study. This observation warrants 
further investigation for PK-PD investigation of rocurnium during ECT in a prospective clinical 
trial.
Pharmacogenetics in ECT: From safety to efficacy
Variation of treatment response and adverse effects of treatment are dependent on genetic 
factors. The aim of pharmacogenetics is to help to predict an individual’s drug response 
(prediction of efficacy), unraveling the potential genetic association (mechanisms in 
efficiency of ECT) while minimizing the side effects (improvement of safety).  Investigating 
the effect of treatment on neurotransmitter concentration or receptor function might help in 
better understanding of the mechanism of ECT treatment. However, the addition of functional 
genomics by considering the interactive biological effect of genes as well as their protein 
expressions in response to ECT treatment, may lead to the development of novel and safer 
medications that mimic the effect of ECT. In chapter five, we discussed this point of view for 
safety of ECT and explored the potential interaction of genes that has been investigated in 
association with the efficacy of ECT.  
Earlier in this section, we discussed in chapter three that the inter-individual variability in 
BCHE expression might cause higher variability in applied optimal doses as compared to 
a non-depolarizing NMB agent such as rocuronium with a different metabolic degradation 
pathway.  Polymorphisms could be clinically important when a medication is dependent on 
a polymorphic enzyme for metabolism. In chapter five, we discussed how genetic variation 
in the BCHE1 gene leads to variant enzyme forms, which affects the substrate behavior 
and results in reduced or absence of the enzyme BCHE activity.  This deficiency results in 
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prolonged post-succinlycholine apnea due to markedly decrease in plasma cholinesterase 
activity. 28 While clinicians should be aware of this adverse event, currently routine test due 
to low prevalence of the clinically deficient subjects is not recommended. However, for those 
patients who exhibit prolonged apnea to succinylcholine, it is important to screen other 
family members to determine their risk of atypical serum cholinesterase. From the safety 
perspective of ECT, in this chapter, we also explored other genes such as CACNA2D1 and 
CACNA1S, and RYR1 that are associated with malignant hyperthermia and safe practice 
of anesthesia in ECT. The reported incidence of MH during ECT has been less than other 
procedures requiring general anesthesia, a report that requires further investigation.
The neural and the molecular pathway alterations induced by ECT stimulus might explain 
the mediation of the behavioral changes by this procedural treatment. These alterations are 
both acute and chronic. While the acute neurotransmitter changes cause the rapid response 
to treatment, the duration of therapy outcome is in part dependent on the continuation of at 
least some those acutely induced neurobiological effects. In chapter five, we reviewed the 
evidences that support these neurobiological responses and how the pharmacogenetics or 
pharmacogenomics might contribute in identifying the neural and the biological pathways 
involved in the efficacy of ECT or even safety of ECT (e.g. cognitive side effects) as well 
as predicting the outcome of the therapy. Accordingly, we showed that few studies had 
investigated gene expression signatures (co-expression of several genes) in response to 
ECT stimulus.  Altar et al.’s pre-clinical investigation, on the effects of single versus repeated 
electroconvulsive seizure (ECS) exposure on gene transcription to identify genes and 
potentially associated biochemical pathways with response ECT, was the major study to show 
the overlap of regionally expressed genes in acute and chronic treatments. 29 They showed 
that almost one hundred and twenty hippocampal and frontal genes were differentially 
expressed (e.g. BDNF-MAP kinase) within distinct pathways in response to acute and 
chronic ECS. Of those, only nineteen genes showed similar expression in response to acute 
or chronic ECS. In contrast with this approach of investigation, several other studies used 
a prior knowledge on a gene which directly or in directly may play a role in neurobiological 
mechanisms to investigate their role in efficacy of ECT response. These studies used either 
gene polymorphism to predict the therapeutic outcome of ECT or altered transcriptional 
expression of gene of interest to infer the potentially involved neurobiological pathway. This 
way, we identified several investigated genes in association with response to ECT treatment. 
These genes include BDNF, COMT, DDR2, DDR3, CREB, VEGF, COX-2, TRKB and NMDA 
receptor. Accordingly these genes could be assumed as set genes that their potential co-
expressions in specific regions of brain might contribute to treatment response. We examined 
this hypothesis by building the regulatory network of these genes and test if these genes are 
significantly enriched in a specific region of brain and as part of the known brain functional 
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regulatory networks. Accordingly, we identified our genes of interest to be prominently 
enriched in frontal functional regulatory networks. We also consistent with prior studies 
found that AP-1 transcriptional complex could play an important role in such regulatory 
networks associated with ECT therapeutic responses, particularly the long-term response. 
30 Acquiring such knowledge on the biological mechanisms involved in ECT will provide 
clues to unraveling the neurobiological alterations that are linked to treatment response and 
identification of potential targets for novel psychotropic treatments. This attempt is important 
knowing that ECT is still a physical intervention and more cumbersome than medications 
with higher efficacy. Although all the above conclusions have to be clinically validated in 
further studies, there is no doubt that by improvement of the growing technology of functional 
genomics, large-scale gene and protein expression could provide new insights in how ECT 
might differently help in treatment psychiatric disorders and which neurotransmitters are 
more related to the efficacy of treatments. Such detailed knowledge will have profound 
effects on the diagnosis of psychological disease subtypes, prevention, and treatment 
of these diseases. In agreement with Palfreyman et al. 31,  in chapter five, we suggested 
the comparison of the disease and treatment gene signatures (e.g. antidepressants, ECT, 
depression) to identify genes or their potential biologically relevant functional pathways 
which are common between phenotypes of interest. The comparison of the spotted genes 
could identify a set of targets whose alteration might be a better predictor of disease and 
the effect of treatment, either by procedure or drug. This approach also provides the 
opportunity of simultaneously studying the disease, medication used for its treatment and 
the effective procedural treatment when those medications are not effective.  Ultimately, 
such overlapping genes could be used to identify drug compounds that show similarity in 
inducing the gene expressions, which consequently mimic the therapeutic response of ECT. 
As our investigation demonstrates, most of the ECT studies on efficacy of ECT are pre-
clinical and further well-designed longitudinal clinical studies are required to increase our 
knowledge of the mechanisms underlying the efficacy of ECT.  
The variability in drug response is highly complex however, and genetic factors has been 
recognized as one the factors that might influence both the efficacy of a drug and the likelihood 
of adverse reactions. Applications of pharmacogenetics include the identification of new drug 
targets, prediction of efficacy and toxicity for new drug therapy, testing for the direct influence 
of an agent on a specific pathway, and identification of drug responders, nonresponders, 
and toxic responders within a population. With the advent of pharmacogenetics ‘the melding 
of sciences, including genetics, biochemistry, and molecular pharmacology’ has come the 
hope of personalized medicine in the future. Although medicine may be far from realizing 
that goal, there has been much scientific progress leading to the hope of one day attaining 
personalized medicine.
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Owing to its importance, CYP2D6 is the most extensively studied P-450 isoenzyme 
in psychiatry. CYP2D6 enzyme, in part, executes the oxidative metabolism of most of 
antidepressants (ADs), depending on the metabolizing categories and type of drug. The 
presence of allelic variants in CYP enzymes with varying degrees of functional significance 
may result in three main phenotypes, poor metabolizers (PMs), normal metabolizers (NMs), 
and extensive metabolizers (EMs). The PMs lack an active form of the expressed enzyme 
due to an inactivating allelic variant; NMs have at least one copy of an active gene; and EMs 
contain duplicated or amplified gene copies, thus leading to either increased (maybe toxic) 
or decreased (maybe ineffective) concentrations of the drug. 32 Hence, in chapter six we 
investigated the CYP2D6 enzyme phenotype in prediction of patients underwent ECT. In this 
study, frequency of CYP2D6 phenotypes was not associated with failure of antidepressant 
treatment response. CYP2D6 enzyme, in part, executes the oxidative metabolism of most of 
SSRIs, depending on the metabolizing categories and drug-by-drug basis. The observed 
frequency of UM phenotype was 0 as opposed to the previously reported prevalence of 3% 
o in the Dutch population. 33 The prevalence of PMs in ECT patients and patients with single
episode of depression were 5.3% and 6.4%, consistent with previous reports (5.5%-9%) in 
healthy Dutch volunteers. 34-36 The frequencies of IMs in both ECT patients and those with 
single episode disorders of depression were higher than healthy subjects. 36 Consistently, 
Haber et al. demonstrated that Hungarian patients with difficult-to-treat depression did not 
exhibit an increased frequency of aberrant CYP2D6 phenotypes. 37
Several studies have demonstrated that poor, intermediate and ultra-rapid CYP2D6 
metabolizers might have a higher incidence of adverse effects when taking CYP2D6-
dependent AD and more risk of TRD. 38 However, an almost equal number of studies did 
not find significant evidence to support these findings. 38 In line with these evidences, our 
study does not support the routine application of CYP2D6 genotyping prior to treatment 
to reduce the risk of non-responsiveness to the CYP2D6-dependent ADs. Our study has 
the advantage that the unipolar and bipolar depressive patients in each of the study 
groups represent extreme clinical outcomes of depression, i.e., one group of patients with 
severe and recurrent episodes who had received several prior trial treatments, eventually 
indicated for ECT, and the other with only a single episode of depression. However, this 
fact should also be considered that lack of the CYP2D6 phenotype correlation with failure 
of AD treatment response might be due to unreported smaller effect size affecting the study 
power. Accordingly, a large sample size may be required to capture substantial number of 
CYP2D6 phenotypes and such a presumptive effect size (N≈1000 for df=2 or 3, effect size of 
0.1 at α=0.05 and β=0.20). While our results are suggestive that preemptive genotyping for 
CYP2D6 currently appears to have no clinical implications in depressed patients undergoing 
ECT, further large-scale prospective clinical trials are warranted to validate this suggestion. 
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It is noted that the guidelines of the Nederlandse Vereniging voor Psychiatrie (Richtlijnen 
Nederlandse Vereniging voor Psychiatrie, tweede, herziene versie, 2010) does not currently 
provide any recommendation on the impact of pharmacogenomics (PGx), particularly the 
utility of CYP2D6 genotyping, in patients with treatment-resistant depression undergoing 
ECT. An update on the standpoint according to the current evidences is suggested.
The variability in drug response is highly complex however, and genetic factors has 
been recognized as one the factors that might influence both the efficacy of a drug and 
the likelihood of adverse reactions.  In chapter six no increase in prevalence of aberrant 
genotype-predicted CYP2D6 phenotypes was observed among patients who received ECT 
for continuation of depression treatment as compared to patients with single episode of 
depression. However, we found that some clinical characteristics of patients are associated 
with the indication of ECT for treatment resistant depression. The failure of gender to be 
associated with the depression recurrence and preferential response to SSRI medication in 
our results are consistent with previous studies. 39  Older adults might have higher likelihood 
of receiving ECT for treatment of depression. 40 Similarly, Our data show that patients who 
received ECT for the treatment of resistant and recurrent depression were older than patients 
with single episode of depression. Our data also suggest that patients with bipolar depression 
have a higher risk of receiving ECT than those with unipolar depression. Relevantly, Ghaemi 
and colleagues studied the outcomes of antidepressant trials for 41 patients with bipolar 
depression and 37 with unipolar depression matched by age and sex distribution. They 
found that short-term nonresponse was more frequent in bipolar (51.3%) than unipolar 
(31.6%) depression. 41 While our results are suggestive that preemptive genotyping for 
CYP2D6 currently appears to have no clinical implications in depressed patients undergoing 
ECT, further large-scale prospective clinical trials are warranted to validate this suggestion. 
Advancement of safety of anesthetics for ambulatory procedures
After the introduction of propofol (2,6-di-isopropylphenol), this anesthetic became widely 
used for induction of general anesthesia and for sedation in intensive-care patients. In recent 
years, propofol has increasingly been administered for sedation during short diagnostic or 
treatment procedures such as gastrointestinal endoscopy ECT procedures. In comparison 
with conventional sedation using short acting central nervous system sedatives such 
as midazolam, propofol has attractive characteristics to be applied for short procedural 
sedations; namely a considerably more rapid onset of minimum residual sedation after the 
procedure. 42 
Although propofol results in a rapid recovery time and widely used in ECT and other medical 
procedures, adverse hemodynamic and respiratory effects are observed. 43 Sedation with 
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propofol is often associated with a significant decrease in arterial blood pressure especially 
in patients with advanced age, higher ASA (American Society of Anesthesiologist) physical 
status class>II and prior hypotension. 44 Adverse effects on hemodynamic function may 
occur whenever sedative and analgesic agents are administered.
ECT plays an important role in the treatment of late life depression and other psychiatric 
conditions in the elderly. Compared to pharmacologic treatments, ECT is administered in 
high proportion of elderly patients. 45 Therefore, any potential drug-drug interaction that might 
exacerbate the propofol-induced hypotension during induction of anesthesia could be of 
high importance for clinicians and should be assessed. Practitioners providing procedural 
sedation should have a thorough knowledge of the pharmacology of the applied agents 
and always be cautious on observation of anesthetic adverse effect exacerbation. Potential 
adverse effects of these agents on airway patency, respiratory function, and hemodynamic 
balance should be fully appreciated. As an example of such exacerbated adverse events, 
in chapter seven, we introduced a new drug-drug interaction, i.e. propofol induced profound 
hypotension during induction of anesthesia in patients with rifampin pre-treatment.  We 
demonstrated that the risk of a prolonged hypotensive episode increased almost three-fold 
when propofol was used for induction in patients who received rifampin.  In 40% of subjects, 
this exaggerated hemodynamic response required vigorous treatment with vasopressors 
and fluids as well as repeated doses of vasopressors. In our appropriately designed study 
with control groups, we also considered several other factors such as the duration of fluid 
abstinence among subjects 46, the dose or type of pre-induction anxiolytic agent, and applied 
fentanyl doses that might affect the investigation. However, the observed hemodynamic 
response was significantly greater in the propofol-rifampin group, suggesting a drug-drug 
interaction as the cause. Hemodynamic instability was not seen when rifampin was given with 
thiopental, indicating that the interaction is unique to propofol.  The potential mechanisms 
to explain this observation needs to be further investigated. Intravenous administration of 
rifampin alone can induce hypotension by a direct, dose-dependent reduction of vascular 
tone and SVR, 47 and propofol-induced hypotension is largely due to venodilation. 48 One 
potential mechanism might be rifampin augmentation of the venodilating effect of propofol 
through an increased endothelial production and release of nitric oxide (NO). 49 This may 
occur as a result of increased NO production by upregulating iNOS mRNA transcription. 50 
Rifampin is commonly used for treatment of tuberculosis and less often for prophylaxis of 
staphylococcal infections and nisseria meningitidis infections. Clinicians should be aware 
of this potentially dangerous interaction and if patient who is taking rifampin is necessary 
to undergo medical procedures and consider using alternative agents for induction of 
anesthesia. A prospective study is desirable to investigate the mechanism of this drug-drug 
interaction.
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Procedural sedation, which includes medications and monitoring, aims to facilitate 
the performance of the procedures that might cause discomfort such as pain, anxiety, 
unpleasant memories associated with such procedures. In the ambulatory setting, the 
optimal anesthetic techniques would provide ideal procedural conditions and rapid recovery 
with minimizing the side effects of anesthetics. An optimal ambulatory anesthesia will 
increase the efficiency and reduce the preoperative complications as well as the healthcare 
costs. Several clinical factors causes delays in post anesthesia care unit (PACU) discharge 
that significantly increase the cost of ambulatory procedure. 51 In the purview of ambulatory 
anesthesia efficiency, in chapter eight, we investigated the postoperative hemodynamic 
adverse events and potential contributors to the prolonged PACU discharge after spinal 
anesthesia. While recovery from the residual motor and sympathetic blockade is primary 
factor for discharge delay after spinal anesthesia, back pain, post-dural ponctural headache 
and radicular irritation have been other concerns. 52 Hypotension has been reported to be 
present after spinal anesthesia in almost in 5.4% patients. 53 The incidence of bradycardia 
has been shown to be associated with position that the spinal anesthesia was inserted. 
In one study the incidence of severe bradycardia in the PACU was significantly higher in 
patients in the Trendelenburg position (60%) than in the horizontal (20%) or hammock 
(10%) position. 54 The combination of bradycardia and hypotension could cause potential 
life-threatening hemodynamic instability after spinal anesthesia. Therefor in chapter eight, 
we attempted to determine the coincidence of hypotension and baradycardia after spinal 
anesthesia as well as to identify factors associated with these hemodynamic changes. We 
further examined the association of potential dependent variables with increased PACU 
length of stay and its duration. The coincidence of bardycardia and hypotension was 5% of 
the patients recovering from spinal anesthesia and was associated with a prolonged PACU 
length of stay. Among the potential associated factors, the patient’s position during spinal 
placement and the postoperative opioid dose were correlated with the events.
Discharge criteria for patients after spinal anesthesia should minimize the risk of central 
nervous system or cardio-respiratory depression after discharge. After spinal anesthesia 
patients are often discharged from the PACU after recovery for motor and sensory function. 
In this study the severe hemodynamic events occurred even in the absence of profound 
motor block. Accordingly, this observation on late occurrence of severe hemodynamic 
instability is suggestive of considering the addition of the orthostatic stability discharge 
criteria 55, 56 to recovery of sensory and motor function. Modifications of procedural sedation 
guidelines for patients with high risk of developing such events after spinal anesthesia are 
also recommended as a preventive measure. Further studies are required to define and test 
optimal clinical criteria for safe transfer of patients after spinal anesthesia.    
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FUTURE DIRECTIONS
Safety
In this dissertation we investigated several safety aspects of ECT as a procedural treatment. 
We defined the minimal effective doses (MEDs) of two NMBA, i.e. succinylcholine and 
rocuronium for ECT. Accordingly, we suggested a guideline for clinicians how to use 
ED50ECT (50% effect dose for ECT) of these two NMBA to attain the optimal effective dose 
(OED) for each patient resulting in an acceptable induced seizure during his/her ECT. We 
also provided the 90th and 95th percentiles of MEDs for succinylcholine and rocuronium in 
our results. In our study ED50s were calculated with averaging the mid-point doses of all 
independent pairs of patients involving a crossover as per methodology of up-and-down 
adjustment. When using the up-and-down methodology the starting dose should ideally be 
the minimum dose expected to result in a positive response, i.e., close to the expected 
ED50, what we considered in our study. This approach results in a obtaining a more precise 
estimation of ED50ECT, however, any estimated ED95ECT by probit regression using the obtained 
data from this approach could be inaccurate. A future clinical study could address this issue 
by applying some fix doses (e.g. ED25ECT, ED50ECT, 90th and 95th percentiles of MEDECTs) using 
the obtained knowledge from our study to precisely define the ED95ECT of succinylcholine 
and rocuromium. Furthermore, the observed faster recovery time after using rocuronium 
during ECT and higher estimated Ce50 for rocuronium in our PK-PD analysis is a matter of 
further investigation to understand the potential involved mechanisms and other potential 
factors such as longer duration of seizure or different effect of increased CO during ECT on 
rocuronium Ce50.
To Advance the safety of anesthetics for ambulatory procedure such as ECT, we investigated 
severe hemodynamic changes resulted from a newly introduced drug-drug interaction 
(rifampin-propofol) and factors related to the type of procedures. While clinicians should be 
aware of these potential drug-drug or periprocedural side effects, the findings require more 
rigorous future investigation for the validity and mechanisms involved. 
Efficacy
To investigate the role of pharmacogenetics in the efficacy of ECT, we searched for the 
studies used either gene polymorphism to predict the therapeutic outcome of ECT or altered 
transcriptional expression of genes of interest to infer the potentially involved neurobiological 
pathway. We identified several genes in association with response to ECT treatment. 
These genes include BDNF, COMT, DDR2, DDR3, CREB, VEGF, COX-2, TRKB and NMDA 
receptor. Using the network analysis, we showed that the potential co-expressions of these 
genes in specific regions of brain might contribute to treatment response through building 
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the functional regulatory network. We also consistent with prior studies found that AP-1 
transcriptional complex could play an important role in the identified regulatory networks 
associated with ECT therapeutic responses.  All these genes and their potential co-regulation 
by common transcriptional factors should be further investigated in future preclinical and 
clinical studies. There is no doubt that by improvement of the growing technology of functional 
genomics, large-scale gene and protein expression could provide new insights in how 
ECT might differently help in treatment psychiatric disorders and which neurotransmitters 
are more related to the efficacy of treatments. We also studied the application of CYP2D6 
genotyping prior to treatment and its potential role to reduce the risk of non-responsiveness 
to the CYP2D6-dependent medications. Our study does not support the routine application 
of this test prior to treatment.  However, this observation should be further investigated in a 
larger prospective randomized trial to satisfy the possibility of unmeasured confounders as 
well as the potentially smaller effect size of aberrancy of CYP2D6. Such a study also provides 
the opportunity of validating the effect of clinical characteristics such as age and type of 
depression in prediction of the treatment outcome. 
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Electroconvulsive therapy (ECT) is the transcutaneous application of small electrical stimuli to 
the brain to produce generalized seizure for the treatment of selected psychiatric disorders, 
mostly treatment resistant depression, acute mania, and schizophrenic syndromes. ECT has 
evolved into a widely recognized treatment modality in the practice of psychiatry such that 
today, ECT is worldwidely administered to an estimated one million patients a year. Safety of 
ECT increases the efficacy of therapy and provides fulfillment of a series of required treatments 
resulting in longer treatment effect of ECT. During the last few decades, researchers have 
been attempting to identify and improve the effectiveness of ECT, to learn how and why it 
works, to understand its risks and adverse side effects, and to determine the best treatment 
technique. As a result, the safety and efficacy of ECT has been improved and its indications 
have been relatively defined to increase the efficiency of outcome of therapy. While there 
has been considerable improvement in safety features, further investigation have been done 
to promote both the safety and efficacy of the treatment. Such efforts could also increase 
our knowledge on the biological mechanisms involved in effectiveness of ECT that might 
result in discovery of new treatments. In this dissertation, we investigate how preprocedural 
medications could improve the safety and efficacy of ECT and further investigated the 
potential role of pharmacogenetics in the efficacy of ECT and procedural side effects such 
as cognitive disorders.
Chapter one contains a general introduction and describes the current concept of 
electroconvulsive therapy (ECT) and its aim to induce a therapeutic tonic seizure with the 
minimum required energy, tailored to the condition of each patient. This chapter provides an 
overview of the safety and efficacy of ECT depicts the general schema of this dissertation in 
investigation of the role of clincial pharmacology and pharmacogenetics in improvement of 
the safety and efficacy of ECT.
Chapter two reviewes the current concepts of neuromuscular blocking agents (NMBA) 
application for ECT. Anaesthesia and neuromuscular blocking agents (NMBAs) are required 
to ensure patients’ safety during ECT. The optimal dose of muscle relaxant for ECT reduces 
muscle contractions without inducing complete paralysis. Slight residual motor convulsive 
activity is helpful in ascertaining that a seizure has occurred, while total paralysis prolongs 
the procedure unnecessarily. This chapter reviews the current NMBAs and their applied 
doses for ECT and the potential gap in knowledge for an ideal NMBA during ECT.
Chapter three describes a conducted crossover, assessor-blinded, prospective randomized 
study to  study the optimal effective dose of succinylcholine and rocuronium for ECT. 
A
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Succinylcholine or rocuronium  were randomly administered in 227 ECT sessions to 45 
patients. The initial dose was incrementally increased or decreased by 10% based on two 
psychiatrists’ (blinded to treatment) assessment of ‘acceptable’ or ‘not acceptable’ control 
of evoked muscle contractions (sufficient vs. insufficient or excessive paralysis). The optimal 
effective doses of succinylcholine and rocuronium in 50% of patients (OED50) were 0.85 
mg.kg-1 (95% CI: 0.77-0.94) and 0.41 mg.kg-1 (95% CI: 0.36-0.46), and the 90th percentile of 
the applied optimal doses (OED90) 1.06 mg.kg-1 (95% CI: 1.0-1.27) and 0.57 mg.kg-1 (95% 
CI: 0.51-0.62), respectively. The inter-individual variability of the OED50 (coefficient variation) 
was 1.24-fold greater for succinylcholine than rocuronium.
Chapter four presents a follow-up study on chapter three to analyze the pharmacokinetics-
pharmacodynamics (PK-PD) relationship of succinylcholine and rocuronium during ECT. In 
this study the data on the first twitch height (T1) of 31 patients who underwent ECT as well 
as the corresponding intravenously applied doses of succinylcholine and rocuronium were 
used for the analyses in the study using NONMEM. The PD model parameter estimates for 
succinlcholine and rocuronium during ECT were ke0= 0.04 min−1 (SEE=0.004) and ke0= 0.17 
min-1 (SEE=0.19), respectively. The Ce50 estimations for these two NMBAs were amounted 
to 0.7 μg/ml (SEE=0.06) and 1.6 (SEE=0.1), respectively. The Ce50 of neostigmine was 
measured to be 0.412 (SEE=0.06). The results showed that the estimated PK-PD parameters 
for succinylcholine and rocuronium during ECT are almost comparable to previous PK-PD 
estimates for these two NMBA. According to the observed higher Ce50 for rocuronium in this 
analysis, we suggested this observation might explain faster recovery after ECT from NMB 
and proposed further investigation. 
Chapter five discusses the clinical insights into pharmacogenetics of ECT and adjunctive 
medications and how the acquired knowledge could improve safety and efficacy of ECT in 
the indicated patients. This chapter also describes the role of pharmacogenetics in leading 
to the identification of novel treatments in psychiatric disorders through understanding of 
potential molecular and biological mechanisms involved. Our review demonstrates that the 
knowledge for safe application of ECT has been improved, at least partly due to the role of 
pharmacogenetics in application of anesthetic agents. Some genes such as CACNA2D1 
and CACNA1S, BCHE and RYR1 are associated with safe practice of anesthesia in ECT. We 
identified several genes (i.e. BDNF, COMT, DDR2, DDR3, CREB, VEGF, COX-2, TRKB and 
NMDA receptor) that might interactively play important roles in treatment response to ECT. 
These genes are co-expressed as part of transcriptionally regulatory sub-networks in the 
brain. In these sub-regulatory networks, 
AP-1 transcription including CREB demonstrated the most regulatory effects on the network 
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objects.
Chapter six reports an investigation on the accumulation of aberrant CYP2D6 genotypes 
and predicted metabolizer phenotypes (UM, IM, and PM) in depressive patients indicated for 
ECT compared to patients with single episode of depression. 76 Dutch Caucasian subjects 
with unipolar or bipolar treatment resistant depression who underwent ECT were genotyped 
using Amplichip® CYP450 Test for CYP2D6 and 208 patients with single episode of unipolar 
or bipolar depression were used as controls. The result showed that there was no difference 
in prevalence of CYP2D6 phenotypes (PM, IM, EM and UM) between the ECT and control 
patients (5.3%, 38.7%, 56.0% and 0.0% vs. 6.4%, 51.0%, 42.6% and 0.0%, respectively). 
The types of depression (OR=0.33, p=0.018) and age (OR=1.55 for a-10-year increase, 
p<0.001), but not CYP2D6 phenotype or activity score were associated with the response 
to antidepressant treatment. In conclusion, preemptive genotyping for CYP2D6 currently 
appears to have no clinical implications in treatment resistant depressive patients indicated 
for ECT.
Chapter seven describes a case report on occurrence of profound hypertension during the 
induction of general anesthesia with propofol, potentially due to interaction with rifampin. 
The conducted  retrospective data analysis on series of  similar cases demonstrated that the 
risk of a prolonged hypotensive episode increased almost three-fold when propofol rather 
than thiopental was used for induction in patients who had received rifampin. Almost 40% 
of cases showed exaggerated hemodynamic responses that required vigorous treatment 
with vasopressors and fluids. The applied dose of phenylephrine was significantly greater 
in the propofol-rifampin group vs. control groups, i.e. propofol alone and thiopental and 
rifampin (p=0.039). The mechanism for this interaction was not investigated and is unknown. 
Intravenous administration of rifampin alone can induce hypotension by a direct, dose-
dependent reduction of vascular tone and systemtic vascular resistance (SVR). Propofol-
induced hypotension is largely due to venodilation and rifampin might augment this effect 
as a result of increased NO production by upregulating iNOS mRNA transcription. While this 
study reemphasizes that clinicians should be vigilant for the reported drug-drug interaction 
during procedural treatment, it suggests a prospective study to investigate the mechanism 
of this drug-drug interaction.
Chapter eight describes a prospective observational investigation on hemodynamic clinical 
factors that cause delays in post anesthesia care unit (PACU) discharge. 232 consecutive 
patients were evaluated for postoperative hemodynamic adverse severe events (PHASE, 
simultaneous severe bradycardia and hypotension). Fifteen patients showed severe 
hypotension and twelve patients with severe bradycardia, resulting in PHASE in ten patients 
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(5%). PHASE occurred on average 307 ± 82 min after spinal anesthesia with a mean spinal 
anesthesia level of L1 at the time of PHASE. Insertion of spinal anesthesia in the lateral 
position (PHASE: 80%, no PHASE: 34%, p=0.030) and morphine dose (20±12mg versus 
9±8 mg, respectively p=0.011) were found to be associated with PHASE.  In conclusion, 
PHASE during recovery from spinal anesthesia is associated with significantly increased 
PACU length of stay, a 60-minute increase in median PACU length of stay. 
Chapter nine provides a discussion on several important aspects of safety and efficacy of 
ECT that were investigated in this dissertation and how the study contents contributes to 
the existing literature and clinical principals in application of ECT as well as understanding 
of the role of clinical pharmacology and pharmacogenetics in ECT. Finally, future research 
directions to improve safety and efficacy of ECT based on acquired knowledge are explored.
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SAMENVATTING
Elektroconvulsietherapie (ECT) is het opwekken van een epileptische aanval middels een 
korte pulsstroom onder algehele anesthesie om psychiatrische ziektebeelden te behandelen. 
Het wordt vooral toegepast bij de behandeling van resistente depressie, acute manie en 
schizofrene syndromen. ECT lijkt nog maar weinig op de omstreden therapie van vroeger en 
heeft zich ontwikkeld tot een algemeen geaccepteerde behandelmethode die naar schatting 
wereldwijd bij een miljoen patiënten per jaar wordt toegepast. In de laatste decennia hebben 
onderzoekers geprobeerd het werkingsmechanisme van ECT te ontrafelen teneinde de 
effectiviteit te vergroten en de bijwerkingen te minimaliseren. Hoewel dit onderzoek heeft 
geleid tot een significante verbetering van de veiligheid van de behandeling is een verdere 
verbetering van de veiligheid en werkzaamheid van ECT gewenst. Dit proefschrift beschrijft 
ons onderzoek naar het verbeteren van de veiligheid en effectiviteit van ECT door middel van 
optimale toepassing van ondersteunende geneesmiddelen en de mogelijke toepassing van 
farmacogenetica daarbij.
Hoofdstuk 1 bevat een algemene inleiding en beschrijft de huidige stand van zaken van 
elektroconvulsietherapie waarbij men met minimale energie, afgestemd op de conditie van 
de patient, een convulsie tracht te induceren. Dit hoofdstuk geeft tevens een overzicht van 
de veiligheid en werkzaamheid van ECT en beschrijft de indeling en aanpak van het in dit 
proefschrift beschreven onderzoek. 
Hoofdstuk 2 beschrijft de resultaten van een systematisch literatuur onderzoek naar de 
toepassing van spierrelaxantia (neuromusculaire blokkers (NMBA)) bij ECT. Om de ECT 
procedure veilig te laten verlopen is een hypnoticum en een spierverslapper noodzakelijk. 
De optimale dosering van spierrelaxantia tijdens ECT vermindert spiercontracties maar 
geeft geen volledige verlamming. Een kleine residuele motorische activiteit is nuttig bij het 
vaststellen van het optreden van het motorisch insult. Dit hoofdstuk bevat een overzicht van 
de huidige NMBA’s, hun toegepaste doses voor ECT en het mogelijke hiaat in de kennis voor 
een ideale NMBA tijdens ECT.
Hoofdstuk drie beschrijft de resultaten van een gerandomiseerd, geblindeerd cross-over 
onderzoek naar de optimale dosis van succinylcholine en rocuronium bij ECT. Succinylcholine 
of rocuronium werden toegediend gedurende 227 ECT sessies in 45 patiënten. De initiële 
dosis werd stapsgewijs met 10% verhoogd of verlaagd op basis van de beoordeling 
(wel/niet acceptabel) van de opgewekte spiercontracties door twee voor de behandeling 
geblindeerde psychiaters. De optimale dosis succinylcholine en rocuronium in 50% van de 
patiënten (OED50) was respectievelijk 0.85 mg.kg-1 (95% CI: 0.77-0.94) en 0,41 mg.kg-1 (95% 
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CI: 0.36-0.46). Het 90ste percentiel van de optimale doses (OED90) bedroeg respectievelijk 
1.06 mg.kg-1 (95% CI: 1.0-1.27) en 0,57 mg.kg-1 (95% CI: 0.51-0,62). De inter-individuele 
variatie van de OED50 was 1.24 maal groter voor succinylcholine dan voor rocuronium.
Hoofdstuk 4 beschrijft de resultaten van een vervolgonderzoek op het in hoofdstuk 3 
beschreven onderzoek. In hoofdstuk 4 wordt de relatie tussen de farmacokinetiek en 
farmacodynamiek (PK-PD) van succinylcholine en rocuronium tijdens ECT onderzocht. In 
deze studie werden de gegevens over de eerste spierrespons (T1) en de bijbehorende 
doses succinylcholine en rocuronium van 31 patiënten die ECT ondergingen geanalyseerd 
met NONMEM. De PD parameterschattingen voor succinlcholine en rocuronium tijdens ECT 
bedroegen respectievelijk ke0=0.04 min-1 (ZIE=0.004) en ke0=0.17 min-1 (ZIE=0.19). De 
Ce50 schattingen voor deze twee NMBA bedroegen respectievelijk 0.7 ug/ml (SEE=0.06) 
en 1.6 (SEE=0.1). De Ce50 van neostigmine bleek 0,412 (ZIE=0.06). De gevonden 
schattingen voor de PK-PD parameters voor succinylcholine en rocuronium tijdens ECT zijn 
vergelijkbaar met eerdere schattingen van de PK-PD parameters voor deze twee NMBA. 
Mogelijk kan het snelle herstel van neuromusculaire blokkade bij ECT worden verklaard door 
de waargenomen hogere Ce50 voor rocuronium. Verder onderzoek hiernaar is wenselijk. 
Hoofdstuk 5 beschrijft een literatuuronderzoek naar de toepassing van farmacogenetica in de 
behandeling met ECT en de daarbij toegepaste geneesmiddelen om effectiviteit en veiligheid 
van de behandeling te verbeteren. Dit hoofdstuk beschrijft ook hoe farmacogenetisch 
onderzoek kan leiden tot nieuwe inzichten in de moleculaire en biologische mechanismen 
die ten grondslag liggen aan psychiatrische ziekten en daardoor mogelijk kan leiden tot 
nieuwe behandelstrategieën. 
Het literatuuronderzoek laat zien dat de veilige toepassing van ECT mede mogelijk is gemaakt 
door de toepassing van farmacogenetica bij het gebruik van anesthetica. 
Genen zoals CACNA2D1, CACNA1S, BCHE en RYR1 worden in verband gebracht met 
veilige toepassing van anesthesie bij ECT. Uit de literatuur blijkt dat transcripties van de 
genen BDNF, COMT, DDR2, DDR3, CREB, VEGF, COX-2, TrkB en NMDA receptor een 
belangrijke rol zouden kunnen spelen bij reactie op ECT behandeling. 
Hoofdstuk 6 beschrijft de resultaten van een onderzoek naar de mogelijk accumulatie van 
afwijkende CYP2D6 genotypen en afgeleide fenotypen (UM, IM, en PM) bij depressieve 
patiënten geïndiceerd voor ECT. Hiervoor werden gegevens verzameld van 76 Nederlandse 
blanke patiënten met unipolaire of bipolaire behandeling resistente depressie die ECT 
ondergingen en waren gegentoypeerd voor CYP2D6 met de Amplichip® CYP450 Test. Deze 
werden vergeleken met 208 controle patiënten met een enkele episode van unipolaire of 
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bipolaire depressie. Er bestond geen verschil in prevalentie van CYP2D6 fenotypen (PM, IM, 
EM en UM) tussen ECT en controle patiënten (5.3%, 38.7%, 56.0% en 0.0% tegenover 6.4%, 
51.0%, 42.6% en 0.0%, respectievelijk). Het type depressie (OR = 0.33, p = 0.018) en de 
leeftijd (OR = 1.55 voor een verhoging van 10-jaar, p <0.001), maar niet het CYP2D6 fenotype 
of de activiteitsscore bleken geassocieerd met de respons op antidepressiva. Op basis 
van de deze resultaten werd geconcludeerd dat preventieve genotypering voor CYP2D6 
momenteel geen rol lijkt te hebben in de behandeling van therapieresistente depressieve 
patiënten geïndiceerd voor ECT.
Hoofdstuk 7 beschrijft een casus van langdurige hypotensie na toediening van propofol 
in een patient die tevens behandeld werd met rifampicine. Patiënt-controleonderzoek 
onder 75 patienten bevestigde dat het risico op langdurige hypotensie met een factor van 
bijna drie toenam indien propofol in plaats van thiopental werd gebruikt bij patiënten die 
tevens rifampicine kregen. De toegepaste dosis van fenylefrine bleek niet normaal verdeeld 
en significant hoger in de propofol-rifampicine groep vergeleken met de controles (p = 
0.039). Deze studie laat zien dat het belangrijk is alert te zijn op niet eerder beschreven 
geneesmiddelinteracties.
Hoofdstuk 8 beschrijft een prospectief observationeel onderzoek naar het mogelijk 
vertragende effect van hemodynamische klinische factoren op het ontslag van de post 
anesthesie care unit (PACU). In totaal werden 232 opeenvolgende patiënten onderzocht 
op Postoperative Hemodynamic Adverse Severe Events (PHASE, gelijktijdige ernstige 
bradycardie en hypotensie). Vijftien patiënten vertoonden ernstige hypotensie en twaalf 
patiënten vertoonden ernstige bradycardie, resulterend in tien patienten met PHASE (5%). 
PHASE trad gemiddeld 307 ± 82 min na spinale anesthesie op met een gemiddeld niveau 
van spinale anesthesie L1 op het moment van PHASE. Toepassing van spinale anesthesie 
in de laterale positie (PHASE: 80%, geen PHASE: 34%, p = 0.030) en morfine dosis (20 ± 
12 mg versus 9 ± 8 mg, respectievelijk p = 0.011) waren geassocieerd met het optreden 
van PHASE. Er werd geconcludeerd dat het optreden van PHASE tijdens het herstel van 
spinale anesthesie geassocieerd is met een verlenging van 60-minuten van de mediane 
verblijfsduur op de PACU.
Tot slot worden in hoofdstuk 9 de resultaten van het uitgevoerde onderzoek bediscussieerd 
en toekomstperspectieven voor de toepassing van klinische farmacologie en farmacogenetica 
bij de behandeling met ECT geschetst.
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